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ABSTRACT 
 
 
Polycystic ovary syndrome (PCOS) is the commonest endocrine disorder in women 
being characterized by reproductive and metabolic abnormalities. Our hypothesis is 
that overproduction of ovarian androgens during early development  is a key factor in 
the development of PCOS. 
The objective of the work in this thesis was to explore, using both an animal model of 
PCOS and human ovarian tissue, the role of androgens in the development of the 
ovarian abnormalities in PCOS and how these relate to disorders in fat metabolism. 
The expression of the key steroidogenic enzymes in androgen biosynthesis was 
determined in histological sections of polycystic and normal ovaries. Results supported 
the concept of intrinsic up-regulation of P450c17 enzyme in theca cells. In ovaries from 
ewes exposed prenatally to excess androgen, a similar disruption of P450c17 was 
observed along with increased androgen receptor expression and increased granulosa 
cell proliferation in preantral follicles. 
The interaction of adipokines and ovarian function was studied using both human 
ovarian tissue and bovine theca cells in culture. A significant decrease in the 
expression of the protein for adiponectin receptor 1 and 2 was detected in theca cells 
from polycystic ovaries in comparison with ovaries from normal women. In bovine theca 
cells, the administration of adiponectin, but not other adipokines (leptin, visfatin, 
resistin) resulted in a decrease in androstenedione production, accompanied by 
significant reduction of gene expression of key steroidogenic enzymes. In addition, the 
 7 
 knockdown of genes for ADIPOR1 and ADIPOR2 was associated with higher rates of 
androstenedione secretion by theca cells. 
In summary, these results support the hypothesis that dysregulation of ovarian follicle 
development and androgen production can be induced by prenatal androgenisation. 
The results also provide evidence of a link between fat cell metabolism and 
steroidogenesis which is important in understanding the development of metabolic 
abnormalities in PCOS. 
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 CHAPTER 1 
NORMAL AND POLYCYSTIC OVARIES  
 
 
 
1.1  THE NORMAL OVARY  
1.1.1   Anatomy and function 
The ovary is a steroid-producing organ that is responsible for the growth, nutrition, and 
release of fertilisable eggs in women (Oktem & Oktay, 2008). Those functions, as well 
as preparation of the endometrium for implantation, require an interconnected series of 
repetitive events involving egg maturation, ovulation, and regression to the corpus 
luteum (Marshal, 2006; Johnson, 2007a; Bulun  & Adashi, 2008).  In general, each 
adult human ovary weighs 7–10 g, is 2–5 cm long, and 1.5–3 cm wide, and it is 
localised in the pelvic area called the mesovarium (Erickson, 2006; Bulun  & Adashi, 
2008). 
The structural organization of the ovary involves the presence of 3 distinct regions: the 
cortex (containing the surface germinal epithelia and follicles), central medulla (formed 
mainly by the stroma), and hilum (the area of connection between the ovary and other 
tissues)(Fig. 1.1) (Erickson, 2006; Bulun  & Adashi, 2008). The follicle, the basic unit in 
the ovary, is composed of a spherical aggregation of granulosa cells (GCs) and theca 
cells (TCs) and an inner oocyte (Erickson, 1978a; Gougeon, 1996; Johnson, 2007a).   
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Fig 1.1: The normal ovary. 
The ovary consists of three specific zones: the cortex, where the most of preantral follicles are 
localized; the central medulla, represented by stromal tissue; and the hilum, which connects 
the ovary to the mesovarium. Different follicular stages (primordial, transitional, primary, 
secondary and antral) generally in the cortical area are represented in their respective boxes. 
(sections stained in  HE).(bars = 20 µm). 
 
1.1.2. Follicle development (from fetal to adult age) 
Development of the germ cell lineage begins early in gestational life (around 4 –6 
weeks’ post-fertilization) when colonisation of the genital ridge by primordial germ cells 
is established (Baker, 1963; Gougeon, 1996). These primordial germ cells, referred to 
as oogonia, after reaching the future fetal ovary, proliferate by mitosis and develop 
important connections with somatic cells, forming structures called ovigerous cords 
(Gougeon, 1996; Rajkovic 2006). The oogonia population expands to 600,000 at 6–8 
weeks of fetal life and peaks at 6–7 million at 20 weeks’ gestation. At 8–13 weeks, 
 25 
some oogonia enter prophase I of the first meiotic division and change into oocytes 
(Baker, 1963; Gougeon, 1996).  A similar process of follicle development occurs in 
other mammals as shown in sheep ovaries in Fig 1.2 1.  
Follicles are formed as the oocytes become surrounded by a single layer of flattened 
somatic cells (previously called pre-GCs) to form the primordial follicles (Bowles, 2007). 
Primordial follicles constituted between the 6th and 9th months of pregnancy represent 
the total pool of oocytes present at birth in a female over her entire life (about 400,000). 
During gestation, some primordial follicles are recruited, and they develop into other 
follicular stages (primary, secondary, and even antral) as detailed in Fig. 1.3 (Rajkovic 
2006; Johnson, 2007a). After birth, depletion of the pool of follicles occurs so that by 
puberty, the estimated number of follicles has fallen to approximately 150,000. This 
process of follicle reduction is continuous and progressive, and women have an 
average of 25,000 follicles by 37 years of age and only 1,000 by 50 years of age 
(Gougeon, 1996; Bulun  & Adashi, 2008). Just a small fraction (<1%) of this stock of 
follicles in the female ovary will reach maturity and will be ovulated during a woman’s 
reproductive years (Faddy & Gosden, 1996; Oktem & Oktay, 2008). 
  Folliculogenesis  
Follicle development, known as folliculogenesis, refers to the sequential stages of germ 
cell and somatic cell development on the way to producing a mature fertilisable egg 
(Bulun  & Adashi, 2008). Follicular growth starts with the recruitment of primordial 
follicles into the growth phase and is marked by GC shape modification (from flattened 
to cuboidal), an increase in oocyte diameter, and formation of the zona pellucida 
(Gougeon, 1996; Bulun  & Adashi, 2008). To achieve full development, a primordial 
                                                
1 For its particular resemblance with human folliculogenesis, ovaries from sheep treated 
with androgens in utero are employed for the study of polycystic ovary syndrome 
(PCOS), the main subject of interest of this thesis. 
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follicle must first enter a transitional stage, followed by formation of the primary stage, 
secondary stage, and finally, small antral and large antral stages, as shown in Figs. 1.1 
and 1.3 (Erickson, 1978a; Gougeon, 1986; Bulun  & Adashi, 2008).  
The mechanisms involved in follicle assembly from resting (primordial) to growing 
preantral (transitional or primary) follicles are not well understood. Early preantral 
follicle development is less influenced by extra-ovarian factors (e.g. gonadotropins) and 
more by intra-ovarian cytokines and growth factors (e.g. growth differentiation factor-9 
[GDF-9], anti-Müllerian hormone [AMH], etc) (Skinner, 2005; Rajkovic 2006; Krysko et 
al., 2008). While the gonadotropin-dependent stages of antral follicles occur over just a 
few weeks, the preantral follicular stages require several months in the human ovary 
(Gougeon, 1996).  
 
 27 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1.2: Events in folliculogenesis in fetal  ovary (sheep).  
Chronology of events during the development of fetal ovary in sheep. A schematic view of the morphology changes is shown below. Note 
that the capacity to synthesize androgens (D30) and conversion to oestrogens by aromatase  (D32) occurs early and precedes the 
formation of ovigerous cords. (Adapted from Juengel JL et al, 2002 ).  
GESTATION 
(DAYS) 
 28 
 
Fig 1.3: Stages of follicular development.  
This schematic model presents the main classification of the stages of development from a 
primordial to Grafiaan follicle (Bulun  & Adashi, 2008) 
1.1.3. The ovarian cycle 
The term ovarian cycle corresponds to the interval of time between two consecutive 
ovulations (Fig. 1.4). It is divided in a period preceding ovulation called the follicular 
phase and a stage after ovulation called the luteal phase (Gougeon, 1996; Johnson, 
2007a). The follicular and luteal phases vary among species (Fig. 1.5), but they are 
extraordinarily dependent on the modifications in the steroids and hormones produced. 
One critical step to enabling ovulation is dominant follicle selection, which starts earlier 
among pre-existing small Graafian follicles (4.7 ± 0.7 mm) in humans at the end of the 
luteal phase (Marshal, 2006; Bulun  & Adashi, 2008; Oktem, 2008). This process is 
characterised by the persistence of a high mitotic rate of the GCs in the dominant 
follicle under the influence of the follicle-stimulating hormone (FSH) in the last days of 
the luteal phase, while the remaining follicles undergo atresia by mechanisms that are 
not clearly understood.  
As a consequence of FSH stimulation, the dominant follicle grows rapidly and develops 
an increased capacity to secrete oestrogen. This happens because FSH induces 
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aromatase (P450arom) activity in GCs to allow the conversion of androstenedione to 
estradiol (E2) (Richards 1976; Erickson, 1978a; Bulun  & Adashi, 2008). Concomitant to 
increasing oestrogen production, FSH induces expression of the luteinizing hormone 
(LH) receptors in GCs (Knight & Glister, 2006). The presence of LH receptors (seen 
only in the dominant follicle) allows the GCs to respond to the mid-cycle LH surge 
(around the 15th day of a 28-day ovarian cycle) that is required for the resumption of 
meiosis in the oocyte (Bauminger & Lindner, 1975; Erickson, 1978b; Erickson et al., 
1985). LH, of course, also has an effect on TCs and is responsible for androgen 
secretion throughout the cycle but enhancing androgen production in the dominant 
follicle. Furthermore, LH stimulates the production of local prostaglandins that are 
responsible for the induction of proteases (members of the metalloproteinase and 
tissue inhibitors) that will degrade a small area of the follicular wall called the stigma or 
macula pellucida leading to ovulation (Bauminger & Lindner, 1975; Erickson, 1978b; 
Erickson, 2006) 
After the follicle wall undergoes focal degradation, ovulation (extrusion of the egg-
cumulus complex) occurs. Subsequent to ovulation, the follicle forms the corpus luteum 
(CL), a high-vascularised structure that produces significant amounts of steroids 
(particularly progesterone). The process of  luteinisation,  is therefore characterised by 
a rapid increase in steroidogenic activity and a greater secretion of progesterone (P) 
and estradiol (E2) . The persistence of the CL in the presence of the early embryo 
occurs because of the actions of human chorionic gonadotropin [hCG]). However, in 
the absence of pregnancy the CL undergoes regression or luteolysis, an apoptotic 
event that drastically reduces the production of these hormones (Erickson, 1978b; 
Gougeon, 1996; Stocco et al., 2007). 
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Fig 1.4: The ovarian cycle.  
The ovarian cycle is divided in two parts: the follicular phase and, following ovulation, the 
luteal phase. In the follicular phase, FSH stimulates the growth of antral follicles that produce 
the dominant follicle while the others become atretic. As the midcycle approaches, a sharp rise 
in circulating estradiol is observed due increase in the enzyme aromatase in granulosa cells. A 
transitory peak of LH will increase even more the production of oestrogens as a result of more 
conversion of thecal androgens by the aromatase enzyme in granulosa cells. The ovulation or 
extrusion of egg-cumulus complex into the peritoneal cavity is usually observed at day 14 in a 
28-day cycle. The post-ovulatory follicle will be reorganized in the corpus luteum, an endocrine 
gland responsible for the secretion of progesterone and driven essentially by LH. After 
approximately 14 days, the corpus luteum regresses spontaneously in the absence of 
gestation, The endometrium, represented in the bottom of the figure is affected by these 
hormonal changes. During the first part of cycle (endometrial proliferative phase), it 
proliferates rapidly stimulated by estradiol, while in the second part (endometrial secretory 
phase) the endometrial cells suffer differentiation by the action of progesterone and start the 
secretion of glycogen-rich substances to prepare the endometrium for implantantion. In the 
absence of pregnancy, the decline of oestrogens and progestogens will lead to menstruation 
and the lack of steroid feedback will result in a rise in FSH, initiating the next cycle. 
(Adapted from Hall J et al, 2004) 
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Fig 1.5: Follicular and luteal phases in different species (human, 
monkeys, cows, sheep, rats and mice). 
Note the shorter follicular phases in cows and sheep in comparison to humans. In these 
species, a significant antral expansion occurs during the luteal phase of the previous cycle. 
(adapted from Johnson, 2007) 
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1.1.4. Androgen synthesis in women 
 Overview 
Steroid hormones are cholesterol-derived lipids that possess a common 
cyclopentanoperhydrophenanthrene backbone (Strauss III, 2004). Steroids are 
identified and named according the number of carbon molecules attached to this 
common structure. For example, the hormones presenting with one carbon molecule 
fused to 17 carbon cyclopentanoperhydrophenanthrene backbone (18-carbon steroid) 
are called oestranes; those with 19 carbons, androstanes; and those with 21 carbons, 
pregnanes (Strauss III, 2004). In the ovary, E2 (C-18), P (C-21), and androstenedione 
(C-19) are the main steroids produced from GCs, granulosa lutein cells, and TCs, 
respectively (Burger, 2002; Johnson, 2007a; Bulun  & Adashi, 2008). P (C-21) 
production from GCs in the ovary is observed after the LH peak or later in the 
granulosa lutein cells from the corpus luteum (Burger, 2002; Erickson, 2006; Stocco et 
al., 2007). 
Androstenedione (A), the major C-19 steroid, originates in the ovaries (50%) and 
adrenal glands (50%) (Longope C, 1986) (Fig 1.6). Despite weak activity, 
androstenedione can be converted into a potent androgen, testosterone (T), or into 
oestrogens (Longcope, 1986; Simpson et al., 1994; Penning, 1997).  The conversion of 
androstenedione to testosterone occurs in the ovary and in the peripheral tissues, and 
is catalysed by the enzymes 17βHSD type 5 while oestrone is produced from 
androstenedione by the actions of P450arom in the antral GCs or in the skin (Burger, 
2002; Auchus, 2005). 
Testosterone circulates in the blood predominantly bound to sex hormone-binding 
globulin (SHBG) and albumin, and this reduces its free (active) levels to as low as 0.5-
3% of the total pool of testosterone in circulation (Burger, 2002; Davis & Burger, 2003; 
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Miller et al., 2004). Testosterone can be converted into estradiol in the ovary.  In cells 
of the adipose tissue and skin that express the enzyme 5α-reductase, testosterone can 
be converted into a stronger androgen, dihydrotestosterone (DHT; Table 1.1) (Strauss 
III, 2004). Given the fact that conversion of testosterone to DHT occurs intracellularly in 
target tissues, serum levels of DHT are extremely low (Burguer, 2002; Bulun  & Adashi, 
2008). Testosterone and DHT are considered true androgens because their actions are 
directly mediated by an androgen receptor (AR) in target tissues (Fig. 1.7). Inside the 
cell, testosterone and DHT bind to the AR and elicit a conformational change involving 
phosphorylation and release of heat-shock proteins. AR translocates to the nucleus, 
undergoes dimerisation, and starts a process of recruiting co-activators and co-
repressor factors. It simultaneously binds to DNA, leading to translational modification 
of target genes (Simental et al., 1992; Zhou et al., 1995). 
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Table 1.1: Androgens in women (potency versus concentration in 
serum). 
Weak androgens such as androstenedione, DHEAS and DHEA are present in higher 
concentrations in blood in comparison with potent androgens like T and DHT.  (Adapted and 
modified from Davis, S et al 2003; Burger et al, 2002; Bulun et al, 2008) 
 
 
 
 
 
 
 
 
 
 
 
 
Potency 
(arbitrary 
scale) 
Serum levels Observations 
Testosterone  
(T) 
100 0.6 –2.8 nmol/l 1% free 
biologically active 
(unbound to 
SHBG) 
Dihydrotestosterone  
(DHT) 
300 Not reliable 
measurement 
DHT metabolites 
(3α- and 3β-
androstenediol 
glucuronide are 
detected in the 
serum) 
Androstenedione  
(A) 
 
10 2 – 8 nmol/l only androgen 
directly converted 
into T 
Dehydroepiandrosterone  
(DHEA) 
5 3 – 35 nmol/l weak androgen 
Dehydroepiandrosterone 
sulphate  
(DHEAS) 
5 3 –12 µmol/l no  androgen 
activity 
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Fig 1.6: Androgen synthesis in women. 
Testosterone, one of the most important androgens in women, is derived in normal women 
50% from the conversion from androstenedione and 50% from direct secretion (25% 
originated from the ovary and 25% from the adrenals). Androstenedione levels in the blood 
results equally from the ovarian and adrenal production (50% each), but can be re-converted 
in testosterone in gonads and in extra-gonadal tissues (specially the skin). The adrenals are 
responsible for practically all DHEAS secretion and 50% of DHEA; only 20% of converted 
DHEA is synthesised by ovaries.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1.7: Schematic model of androgen receptor activation. 
In cells expressing the enzyme 5α-reductase, testosterone (T) is converted into 
dihydrotestosterone (DHT) which binds to the androgen receptor (AR) and disrupt interactions 
with molecular chaperones (HSP) important to kept the receptor inactive. Additionally, there is 
a phosphorylation of AR which migrates to the nucleus and suffers dimerization.  Inside the 
nucleus, the complex formed by the dimerized AR and DHT recruits co-activactors and co-
repressors that will  determine stimulation or repression of specific genes. 
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Ovarian steroidogenic enzymes and protein. 
Many enzymatic steps are necessary to produce androgens from cholesterol (Fig. 1.8). 
The process of steroid synthesis is dynamic and involves sequential modification of the 
cholesterol molecule (precursor) by enzymes (oxidases, hydroxysteroid 
dehydrogenases, and reductases) (Strauss III, 2004). The steroidogenic machinery is 
located at different intracellular compartments such as the cellular membrane, 
mitochondria, and endoplasmic reticulum (ER). Cholesterol efflux in the cell is 
stimulated by actions of trophic hormones (e.g. LH, insulin, and insulin-like growth 
factor-I [IGF-I]) that lead to increased cholesterol acquisition from low-density 
lipoprotein receptors (LDLR) in the extracellular membrane and de novo synthesis in 
the smooth ER (Carr et al., 1982; Strauss III, 2004). Some key events in 
steroidogenesis (represented in Fig. 1.8) are controlled by specific protein and 
enzymes as described below: 
a) Steroidogenic acute regulator (StAR) protein: StAR is the protein responsible for the 
translocation of cholesterol from outside to inside the mitochondrial membranes which 
is the essential substrate for the actions of P450 cholesterol side chain cleavage 
enzyme (P450scc). In general, tissues expressing StAR are regulated by cyclic 
adenosine monophosphate (cAMP) (Strauss et al., 1999; Strauss III, 2004; Miller, 
2007). StAR synthesis is associated with the transcript rate of the StAR gene, which is 
located on chromosome 8p11.2 (Strauss III, 2004; Miller, 2007). 
 b) The cholesterol side-chain cleavage enzyme (P450scc): P450scc is involved in the 
cleavage of the side-chain of cholesterol that occurs in a 3-step sequence, including 
acquisition of the hydroxyl groups at carbons 20 and 22 and a posterior slit of the side 
chain. This is a rate-limiting step for chronic steroid production and is dependent on the 
delivery of cholesterol to the mitochondria, access to the inner membranes, available 
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amount of P450scc and its co-factors (flavoprotein and iron-sulphur electron transport 
chain), and catalytic characteristics of P450scc (Miller, 1988; Strauss III, 2004; Bremer 
& Miller, 2008). CYP11A1, the gene responsible for P450scc transcription, is found on 
chromosome 15q23-q24 (Miller, 1988; Strauss III, 2004).  
c) 17α-Hydroxylase/17,20 Lyase (P450c17): P450c17 is considered the ‘qualitative’ 
regulator of steroidogenesis since it catalyses reactions that can produce androgens 
(17,20 Lyase) or progestogens (17α-hydroxylase) (Bremer & Miller, 2008). Increased 
17,20 Lyase activity is observed when 1) Δ5 substrates are used instead of others, 2) 
allosteric modification of P450c17 occurs by influence of the presence of cytochrome 
b5, 3) post-translational modification of P450c17 occurs, and 4) increased 
phosphorylation of P450c17 at the serine and threonine residues occurs (Miller et al., 
1997; Strauss III, 2004). Despite its dual function, a single gene located on band 
10q24.3 is responsible for P450c17 (CYP17A1)(Chung et al., 1987; Miller et al., 1997).  
d) 3β-Hydroxysteroid dehydrogenase (3BHSD): Two different 3β-HSD genes, HSD3B1 
and HSD3B2, are located on band 1p13.1. In contrast, 3βHSDII (HSD3B2), which is 
located in ER and in subcellular areas close to mitochondrial membranes, is not a rate-
limiting enzyme, but it is necessary in the intermediate steps of steroidogenesis 
(Strauss III, 2004).  
e) 17β-Hydroxysteroid dehydrogenase type 5 (17βHSD): A large family of 17βHSD 
corresponding to more than 12 subtypes that display a wide variety of actions. Type 5 
17β-Hydroxysteroid dehydrogenase is responsible for the production of testsoterone 
from androstenedione in the ovary (Luu-The et al., 2001; Luu-The, 2001; Qing 2005). 
The type 5 17β-hydroxysteroid dehydrogenase gene is located on bands 10p15-14 
(Strauss III, 2004). 
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According to a theoretical model of ‘two-cell, two-gonadotropin concept of follicle 
oestrogen biosynthesis’, oestrogen is produced in GCs from the conversion of 
androstenedione or testosterone in TCs  which  diffuses through the basal lamina (Fig 
1.9)(Erickson, 1978b). In this simplified model, TC steroidogenesis is dependent on the 
stimulation of LH while steroidogenesis in GCs is primarily under FSH stimulatory 
control (Johnson, 2007a; Bulun  & Adashi, 2008). Evidence from the literature suggests 
that maximal oestrogen production during the follicular phase is dependent on TC 
androstenedione delivery (Suzuki et al., 1994).  
A role for other hormones and cytokines as additional regulators of steroid production 
in the ovary remains to be better understood. In vitro studies on TC cultures suggest 
that transforming growth factor (TGF)-β, TGF-α, basic fibroblast growth factor (bFGF), 
activin, hepatocyte growth factor (HGF), and keratinocyte growth factor (KGF) in media 
can suppress the production of androstenedione, while administration of IGF-I, insulin, 
inhibin, nerve growth factor-1, and GDF-9 produces the opposite effect, increasing 
androgen production (Magoffin, 2005; Rajkovic 2006; Wickenheisser et al., 2006; 
Lagaly et al., 2008). …………………………………………………………………………                                                                                                                                                                  
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Fig 1.8: Biosynthetic pathways for sex steroid hormones. 
The  main  steroidogenic enzymes ( superscript) and their products are represented in Δ5 and Δ4 pathways. 
Δ5 pathway 
Δ4 pathway 
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Fig 1.9: Scheme of ovarian steroidogenesis in a preovulatory follicle 
(two-cell two-gonadotropin model). 
In theca cells, the activation of LHR by LH produces a modification in the cAMP intracellular 
mediating  an increase in the transcription of steroidogenic enzymes (P450scc, 3βHSDII, 
P450c17 )  controlled by  SF-1. As a consequence of the activation of these enzymes, higher 
amounts of androstenedione are produced  and  move out the TCs  reaching  the circulation 
and/or  the granulosa cell compartment. In granulosa cells, the nuclear receptor liver 
homologue receptor-1 (LHR-1) stimulated by FSH promotes the increased expression of 
P450arom which is a critical step in the conversion of androstenedione to estrone, posteriorly 
transformed in estradiol by the 17βHSD-1 and released in circulation and/or follicular fluid. 
(Adapted from Bulun et al, 2008). 
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1.2. POLYCYSTIC OVARY SYNDROME 
1.2.1  General aspects of PCOS 
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women, 
affecting approximately 6–8% of females in the reproductive age (Franks, 1995; 
Diamanti-Kandarakis, 1999). The first clear description of PCOS was reported in 1935 
when the association of polycystic ovaries, hyperandrogenism, obesity, and infertility 
was described by Stein and Leventhal  (Stein & Leventhal, 1935). Since then, many 
different classifications of PCOS have been created. The first standardised PCOS 
diagnosis came in 1990 when an international conference sponsored by the National 
Institutes of Health (NIH) defined PCOS as a condition determined by the presence of 
clinical or biochemical hyperandrogenism, oligomenorrhaea / anovulation after 
exclusion of other disorders such as Cushing syndrome, hyperprolactinaemia, late-
onset congenital adrenal hyperplasia (CAH), and virilising tumours (Zawadski, 1992). 
According to some authors, the main utility of the NIH criteria was to identify an uniform 
phenotype to aid the study of its pathogenesis (Yildiz, 2008). However, PCOS is 
recognized as a clinically and biochemically heterogeneous disorder: in 2003, the 
Rotterdam Consensus expanded the diagnosis of PCOS, stating it required the 
presence of 2 of the following 3 criteria: clinical or biochemical signs of 
hyperandrogenism, chronic anovulation, or polycystic ovaries after the exclusion of 
related pathologies (2004). As a consequence of these new criteria, patients 
presenting with polycystic ovaries and oligoanovulation (without hyperandrogenism) 
and those exhibiting hyperandrogenism and polycystic ovaries (in the absence of 
anovulation) were as a part of the spectrum of presentation of the PCOS. The new 
definition of PCOS did not affect the diagnosis of PCOS according to the NIH criteria in 
1990 (hyperandrogenism plus anovulation). One substantial justification for the new 
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criteria is based on the fact that the status of women with PCOS (anovulatory vs 
ovulatory) frequently changes with slight changes in body weight. 
1.2.2  Reproductive features 
 Main reproductive abnormalities 
The presence of reproductive abnormalities is the basis of the diagnostic criteria for 
PCOS according to the Rotterdam Consensus (2004). In fact, the association of 
hyperandrogenism, chronic anovulation, and polycystic ovaries is present in around 
61% of patients with PCOS, a phenotype that is much more prevalent than the other 
phenotypes of PCOS (Table 1.2).  
Hyperandrogenism is the most prevalent biochemical abnormality observed in women 
with PCOS (Franks, 1995; Azziz, 2005). It may be manifested clinically via the 
dermatological manifestation of alopecia, hirsutism, or acne, or biochemically as 
elevated levels of serum androgens (testosterone and DHEA) or of free androgen 
index, calculated by the following formula: Testosterone/SHBG × 100 (Franks, 1995; 
Azziz, 2005; Norman 2007).  
Chronic anovulation, another diagnostic criterion of PCOS, is usually ascertained by 
the identification of oligomenorrhoea (8 periods per year or period length >35 days) or 
amenorrhea (continued absence of menses for more than three months in the absence 
of pregnancy). However, evaluation of the blood levels of progesterone in the second 
phase of the menstrual cycle is necessary to establish the absence of ovulation in 
some patients who report regular menses but long cycles (equal or longer than 35 
days) (2004). 
 
 43 
 Severe 
PCOS 
Ovulatory 
PCOS 
Mild 
PCOS 
Androgen  
excess 
and chronic 
anovulation 
Menstrual Cycles irregular normal irregular Irregular 
Ultrasonography  
(ovaries) 
polycystic polycystic polycystic normal 
Androgen 
concentrations 
high high mildly 
raised 
high 
Insulin  
concentrations 
increased increased increased normal 
Prevalence of 
affected women 
61% 16% 16% 7% 
Table 1.2: Phenotypes for polycystic ovary syndrome (The Rotterdam 
Consensus, 2003).  
The new diagnosis based in the presence the two of the three criteria for PCOS 
(oligoanovulation, polycystic ovaries and/or hyperandrogenism) expanded the possible  
phenotypes as exposed in this table. Note that the presence of three features (severe PCOS) 
is the most prevalent phenotype and is associated with hyperinsulinemia. (see section 2.3). 
 
A polycystic ovary (PCO) as defined by ultrasonography (US) should include at least 
one of these features: an increase in ovarian volume (>10 mL) or the presence of ≥12 
follicles measuring 2–9 mm in diameter (2004). As a standard, a transvaginal approach 
of US assessment should be performed; however, for virgins, a transabdominal US 
approach is acceptable (Norman 2007; Bulun  & Adashi, 2008; Barter, 2009).   
 Folliculogenesis in PCOS 
Folliculogenesis is disrupted in PCOS. Considering its morphology, polycystic ovaries 
exhibit 2–5 times more preantral and small antral follicles than do normal ovaries 
(Hughesdon, 1982; Webber et al., 2003; Maciel, 2004). Preantral follicles in a PCO 
manifest greater GC proliferation and androgen receptor expression, and disrupted 
AMH expression (Webber L, 2005; Stubbs et al., 2007). Antral follicles are also 
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abnormal, typically  demonstrating thecal hypertrophy and early GC atrophy, resulting 
in an increased production of androgens and a decreased capacity to convert 
oestrogens (Chang, 2008). In fact, hyperandrogenism in PCOS results from a complex 
interaction of different disruptors, as described below (Fig. 1.10): 
a) Hypothalamus and pituitary gland: Increased LH pulsatility has been described in 
PCOS, and it can stimulate steroidogenic enzymes in the thecal compartment and 
possibly in the adrenals to shift androgen production (Morales et al., 1996). As a 
consequence, persistent high androgen concentrations in the blood could desensitise 
the hypothalamus to the negative feedback from progesterone (Patton et al., 1975; 
Norman et al., 2007). 
b) Adrenal glands: At least 30% of women with PCOS exhibit an increased co-
secretion of adrenal androgens (Kumar et al., 2005; Carmina & Lobo, 2007). No 
differences were reported in terms of ACTH levels or pulsatile rhythms between women 
with and without PCOS, but increased P450c17 activity, possibly due the positive 
effects of insulin and/or IGF-1, have been suggested (Chang, 2008). 
c) Ovary: A PCO presents with multiple follicles and consequently a larger pool of TCs 
secreting persistently higher amounts of androgens. Basal androgen secretion in TCs 
is disrupted, possibly due to defective feedback mechanisms and/or increased over-
expression of mRNA for steroidogenic enzymes (P450scc and P450c17)(Nelson et al., 
1999; Wickenheisser et al., 2004; Escobar-Morreale et al., 2005)  
d) ‘Metabolic disorder’: Metabolic disarrangement characterised by insulin resistance 
(IR)/ hyperinsulinemia is also implicated in the pathogenesis of hyperandrogenism in 
PCOS (Franks, 1995; Sam & Dunaif, 2003). Similar to LH, insulin has been shown to 
have positive effects on androgen synthesis in studies on TCs; additionally, it can 
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reduce the hepatic production of SHBG, increasing the free fraction of circulating 
testosterone (Singh et al., 1990). 
e) Peripheral tissues (skin): The subcutaneous fat in women with PCOS contains 
increased expression of 17βHSD type 5, an enzyme responsible for the conversion of 
androstenedione to testosterone, which contributes to the higher levels of androgens in 
the serum (Bulun  & Adashi, 2008). 
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Fig 1.10: Hyperandrogenism and PCOS. 
Androgen excess in PCOS is considered to be originated mainly from the ovaries, but other factors also contribute to the increased 
levels of androgens in PCOS as a result of oligoanovulation  and/or persistent   production of androgens.  
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 1.2.3 Metabolic disarrangement  
 Insulin resistance (IR)  
Although reproductive abnormalities are prominent features of women with PCOS, the 
occurrence of metabolic disorders is also common. About 44–70% of women with 
PCOS present evidence of IR compared to only 10-25% in matched body mass index 
young controls (Legro, 1998b; Carmina & Lobo, 2004; Palomba et al., 2007; Diamanti-
Kandarakis & Chritskou, 2009). IR in PCOS is characterised by impaired insulin-
stimulated glucose transport that occurs independent of body weight and can boost the 
development of other metabolic disorders such as diabetes, obesity, dyslipidaemia, 
and atherosclerosis (Dunaif & Graf, 1989; Dunaif, 1997; Diamanti-Kandarakis et al., 
2008; Franks, 2008). As both a cause and, possibly, a consequence of higher IR, the 
prevalence of overweightness (38–88%), obesity (30–50%), impaired glucose 
tolerance (35–40%), and diabetes (6.9–10%) is higher in women with PCOS than in 
normal women (Morales et al., 1996; Ehrmann, 1999; Diamanti-Kandarakis & 
Chritskou, 2009). Obese women with PCOS exhibit an additional mechanism of IR 
based on increased hepatic glucose production (Dunaif et al., 1989). Evidence in the 
literature indicates a close association among IR, oligomenorrhaea, and 
hyperandrogenism, suggesting that hyperinsulinaemia can contribute to androgen 
production disarrangement and anovulation (Kiddy et al., 1990; Norman et al., 2007). 
Fat distribution  
Fat distribution in PCOS remains a controversial issue. Initial studies employing 
biometrical methods (e.g. waist-to-hip determination) or other limited techniques 
(lipometer, ultrasonography, dual-energy X-ray absorptiometry, etc) have identified an 
increased accumulation of visceral fat in women with PCOS compared with controls 
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with similar body mass index (BMI)(Gambineri, 2002; Cascella et al., 2008). 
Nevertheless, recent evidence obtained by magnetic resonance imaging (MRI) has not 
found any dissimilarity in the distribution of fat deposits in women with or without PCOS 
despite significant differences in IR (Barber et al., 2008) 
Adipokines and PCOS 
Adipokines are active biological proteins produced almost exclusively by fat tissue that 
mediates inflammatory, immune, and metabolic functions (Scherer, 2006; Campos et 
al., 2008; Diamanti-Kandarakis, 2008). Currently, diverse adipokines have been 
isolated (leptin, adiponectin, visfatin, resistin, RBP4, apelin, vaspin, omentin, hepcidin, 
etc), many of which are associated with obesity, IR, and predisposition to the 
development of type 2 diabetes mellitus (DM2) (Rabe, 2008; Geer & Shen, 2009) 
(Table 1.3). The possible role of adipokines in the development of PCOS has been 
proposed, considering the fact that obesity and IR are frequently expressed in PCOS 
and adiponectin have been shown to have effects on ovarian steroidogenesis (Lagaly 
et al., 2008). Adipokines could, therefore, represent a link between metabolic 
disarrangement and reproductive features seen in PCOS (Barber et al., 2008; Carmina 
et al., 2009).  
Adiponectin, which is produced by fat tissue in 32-kDA monomer (Das et al., 2001), 
circulates in more than one molecular form, as monomers, trimers or in the most active 
forms, high-molecular weight (HMW) multimers (Trujillo & Scherer, 2005). There exists 
sexual dimorphism for adiponectin, as men have lower total levels of adiponectin than 
women do. Studies of adiponectin concentrations in women with PCOS have shown 
conflicting results indicating no difference (Barber et al., 2008) or decreased (Aroda et 
al., 2009) (Wickham III, 2011) total and HMW adiponectin levels independent of 
obesity, although a recent meta-analysis suggests a decrease in total levels of 
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adiponectin in PCOS (Toulis et al., 2009). Adiponectin levels in the blood seem to be 
further reduced in anovulatory women compared to women with ovulatory PCOS and 
women with normal ovulation (Carmina et al., 2009; Karkanaki et al., 2009). An in vitro 
study using bovine TC culture demonstrated that adiponectin could act as a 
suppressive agent in thecal steroidogenesis (Lagaly et al., 2008). The impact of other 
adipokines in the development of PCOS remains similarly undetermined.  
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Table 1.3: Serum level of adipokines in PCOS compared to normal 
women. 
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1.2.4  Origins of PCOS 
 Despite its high prevalence and extensive characterisation, the aetiology of PCOS 
remains elusive. It is possible that genetic, environmental (postnatal), or gestational 
(prenatal) factors may all contribute to the development of reproductive and metabolic 
abnormalities in PCOS (2004; Diamanti-Kandarakis, 2008; Franks, 2008). Although 
genetic studies have demonstrated a clustering of reproductive and metabolic 
abnormalities in the families of women with PCOS, the mode of inheritance remains 
unclear and no definitive locus has been identified (Legro, 1998a; Urbanek, 2007b). 
There is some promising work that associates abnormalities in the D19S884 locus at 
chromosome 19p13.2 with a predisposition to PCOS, and this may implicate the action 
of TGF-β (Urbanek, 2007a). However, further studies are required to elucidate the 
mechanisms associated with D19S884 in the pathogenesis of PCOS. Data from a 
recent clinical study that included probands of PCOS and their sisters observed a high 
concordance of PCOS morphology and biochemical abnormalities between the 2 
groups, supporting the concept of genetic transmission of these characteristics (Franks 
et al., 2008b). 
Clinical studies suggest that ‘environmental’ modifications in lifestyle, especially the 
presence of obesity, could negatively influence the progression and severity of some of 
the abnormalities seen in PCOS, such as hyperandrogenaemia, IR, menstrual 
irregularity, and infertility(Kiddy et al., 1990; Gambineri, 2002). Conversely, these 
endocrine alterations can be partially reversed by weight loss (Barker et al., 2002; 
Rosenfield, 2007). Nevertheless, overweightness as an isolated factor is not sufficient 
to explain the origin of PCOS, although obesity itself has been shown to have an 
adverse effect on human reproduction (Wang et al., 2000).  
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Developmental programming and PCOS 
Barker et al established the hypothesis that maternal adaptations to unfavourable 
conditions during gestation could result in events that are beneficial to an individual in 
early existence but may predispose them to the development of diseases in later life, 
such as cardiovascular disease (Barker et al., 2002). Some of the inferences used to 
support this theory came from the first descriptions of the co-occurrence of high 
mortality of coronary artery disease in the same areas of the highest indices of infant 
mortality registered decades earlier in the UK. According to Barker’s hypothesis, many 
metabolic and cardiovascular diseases such as obesity, type 2 diabetes, and 
hypertension could be associated with low birth weight (Barker & Clark, 1997). 
The connections between low birth weight and the development of PCOS are 
controversial. Ibanez et al demonstrated a positive link between low birth weight and 
PCOS development in girls from a specific region of Spain (Ibanez et al., 1998). 
However, these findings were not confirmed by similar studies in other areas in the 
world (Mikola et al., 2001; Haakova et al., 2003; Laitinen et al., 2003; Sadrzadeh et al., 
2003; Anderson et al., 2010; Legro et al., 2010). Criticisms of the study from Ibanez et 
al (1998) were based on the origin of the children studied (northern Spain), where 
abnormally high rates of premature menarche and hyperandrogenism were observed, 
limiting the results to a genetically distinct population. Overall, and particularly in light of 
the evidence regarding genetic factors, doubt exists whether Barker’s hypothesis can 
wholly explain the development of PCOS.   
1.2.5  Treatment of PCOS 
The treatment of PCOS attempts to solve reproductive and metabolic issues employing 
non-pharmacological and pharmacological measures (Franks, 1995). Lifestyle 
modification, represented by adoption of a balanced diet and exercise inducing weight 
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loss, can result in clinical and laboratorial improvements in women with PCOS (Norman 
et al., 2002; Pasquali & Gambineri, 2004). Additionally, the use of drugs (insulin 
sensitisers such as metformin or thiazolidinediones) has proven useful to reduce IR 
and hyperandrogenaemia (Pasquali et al., 2000; Azziz et al., 2001). Anti-androgen 
treatment (e.g. cyproterone accetate) is considered for the treatment of hirsutism, and 
oral contraceptives (OC) are employed to regulate menstrual cycles, inhibit ovarian 
steroidogenesis, and avoid undesirable endometrial hyperplasia (Swiglo et al., 2008; 
Benvenga, 2009). However, some concerns about the adverse effects of OC (insulin 
resistance, hypertriglyceridemia, increased risk to venous trombosis) in certain groups 
of women with PCOS have been raised (Benvevega, 2009). New treatments (e.g. 
statins) have shown promising results for antagonising hyperandrogenism, but further 
studies are required before they may be incorporated into PCOS therapy regimens 
(Kodaman & Duleba, 2008). 
1.3. ANIMAL MODELS OF PCOS  
1.3.1 Origins of androgens in pregnancy 
Studies carried out in mammals indicated that both male and female foetuses have the 
ability to produce androgens that interact with the placenta and then with the maternal 
environment, creating a unique fetal-maternal unit (Fig. 1.11). The placenta converts 
any testosterone in estradiol by the action of the aromatase enzyme. Any other 
substrates (e.g  pregnenolone)  are driven in fetal adrenals to DHEAS production, an 
inactive androgen, which is subsequently transformed into estradiol in the placenta.  
Similarly, maternal and fetal androstenedione are both transformed by the placenta to 
estrone or are converted to testosterone, and later transformed into E2 (Johnson, 
2007b). Therefore, the foetus appears to be protected from direct contact with potent 
maternal androgens during pregnancy. Some authors consider the fetal production of 
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androgens as being irrelevant in terms of maternal levels of androgens and in 
consideration to the action of the aromatase enzyme. One argument supporting this 
premise is the absence of disturbances in females in a twin gestation comprising a 
male and female foetus (Rosenfield, 2007).  
1.3.2  PCOS and developmental programming  
Evidence in the literature have shown that the exposure of female foetuses of sheep, 
monkeys, and other animals to high androgen levels in utero induces the appearance 
of metabolic and reproductive disturbances resembling many features of human PCOS 
(Abbott et al., 2002; Dumesic et al., 2007). Those observations suggest the possibility 
of ‘programming’ the development of PCOS, exposing foetuses to excessive amounts 
of androgen during the early gestational period (2004; Dumesic et al., 2007; 
Rosenfield, 2007).   
In humans, a few situations involving high doses of androgens resemble the ’fetal 
programming’ model of PCOS. One of these situations, namely the presence of 
virilising tumours during pregnancy, has not been associated with virilisation of female 
foetuses, probably, because the actions of the enzyme aromatase in the placenta that 
converts testosterone to E2 (McClamrock & Adashi, 1992). Another example in humans 
where high levels of androgens occur in utero is CAH, in which fetal hyperandrogenism 
is observed due to an enzymatic defect in fetal adrenal steroidogenesis that can be 
intense (classical CAH) or mild (late-onset CAH). This disruption by androgens in early 
life predisposes patients with CAH to the development of some of the characteristics of 
PCOS (e.g. increased LH secretion) in later life. About 50% of patients with classical 
CAH and only 20% of patients with late-onset CAH will exhibit PCOS characteristics in 
adulthood (Azziz et al., 2004; Rosenfield, 2007; Pall et al., 2010).  
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Information depicted in a few studies that analysed gestation in women with PCOS 
indicated that pregnant women with PCOS have significantly elevated levels of serum 
testosterone, DHEAS, and androstenedione at 22–28 weeks’ gestation compared with 
normal subjects. Androstenedione levels persistently increased after delivery during 
lactational amenorrhoea (Sir-Petermann et al., 2001; Sir-Petermann et al., 2002).  
 
 
Fig 1.11: Summary of materno-fetal interaction in steroid production 
during pregnancy.  
During gestation, any precursor of androgen in circulation is transformed in DHEAS, an 
inactive androgen, in fetal adrenals, or converted to oestrogen by placental aromatase.  
Therefore, the fetus appears to be protected from direct contact with androgens during 
pregnancy. Maternal routes = pink; fetal routes = blue; placental routes = green (weak green 
as a minor synthetic route). Dashed lines indicate a possible contribution of fetal ovarian 
androgens to the total steroid pool. (Adapted and modified from Johnson MH. Essential 
Reproduction – 6th edition, Blackwell Publishing).  
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1.3.3  Animal Models of PCOS 
Animal models are useful for the understanding of the intricate mechanisms 
surrounding PCOS pathophysiology, fetal hyperandrogenism, steroid action, and IR 
through the study of ‘development programming’ (Abbott et al., 2002; Dumesic et al., 
2007). In the past decade, many different protocols for ‘programming’ PCOS employing 
androgens (aromatisable and non-aromatisable), aromatase inhibitors, and oestrogens 
have been employed in primates, sheep, rats, and mice (Tables 1.4 and 1.5). The 
principal objective of these treatments was to create a disruption in the endocrine 
system in early life in a way that the animal could manifest key PCOS-like features at 
adulthood such as hyperandrogenism, PCOS morphology, excessive LH, or 
oligoanovulation. As shown in Fig 1.12, the process of androgenisation in different 
species coincides with the progression of folliculogenesis, steroidogenesis, and 
development of the neuroendocrine axis. Post-natal administration of androgens has 
been proposed for rats and mice, which complete folliculogenesis after birth, but they 
generally fail to express the full features of PCOS.  
Supra-physiological amounts of androgens during gestation can virilise not only 
foetuses but also their mothers. One exception occurs in species such as the rhesus 
monkeys, which may develop many endocrine traits of PCOS without virilised genitalia 
when treated with androgens late in gestation (Abbott et al., 2005).   
One relevant aspect regarding the different protocols is whether the real mechanisms 
operating the ‘developmental programming’ are consequences of androgenic and/or 
oestrogenic actions (Fig 1.13). The best comparisons of androgenic versus oestrogenic 
effects on PA come from studies in sheep in which the 2 treatments were run in 
parallel. After analysis, the following were identified as oestrogenic actions: the 
presence of hyperandrogenism, oligoanovulation, PCOS morphology, follicular 
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persistence, and disruption of positive E2 feedback in the hypothalamus (Sarma et al., 
2005; Steckler et al., 2005; Manikkam et al., 2006; Forsdike et al., 2007; Smith et al., 
2009). Consequently, other features observed (LH excess, increased follicular 
recruitment, increased GnRH sensitivity, decreased negative feedback to E2, and 
reduced insulin sensitivity) resulted from androgenic actions in target tissues (Masek et 
al., 1999). However, these observed features in sheep were not necessarily the same 
identified in other species. For example, in PA mice, PCO morphology and 
oligoanovulation are associated with androgenic (and not oestrogenic) actions. 
Possible reasons for these contradictory results are attributed to differences in species, 
dose, and timing of treatment (Padmanabhan & Veiga-Lopez, 2011). 
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Tables 1.4: Prenatal protocols for androgenisation of different species. 
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Table 1.5:  Postnatal  protocols for androgenisation of different species. 
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Fig 1.12:  Intervals for androgenisation and follicle development in different species (monkeys, sheep, 
and rodents). 
Human gestation was used as a parameter and each trimester is represented in a different colour. Vertical lines indicate the period of 
androgen treatment. In practically all animals (exception to monkeys late-treated with testosterone) the androgen administration occurs 
before the formation of primordial follicles.  
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Fig 1.13: Androgenic versus oestrogenic effects in prenatal treatment in 
sheep and rodents.  
There are some discrepancies between the androgenic effects (mediated by DHT) or 
oestrogenic effects (mediated directly by oestrogens or indirectly by T) in sheep (S) and 
rodents( R). To date, only LH hypersecretion could be linked to androgen administration in 
both species. Development of specific features such as oligoanovulation, polycystic ovary 
morphology and abnormal estradiol positive feedback have been totally discordant. 
 
Monkeys 
Prenatally androgenised primates have the highest resemblance to humans with 
PCOS, taking into account the presence of a number of endocrine alterations 
mimicking PCOS and the physiological similarities with primates (Abbott et al., 2009). 
Monkeys prenatally treated with testosterone propionate at 40–80 days’ gestation 
demonstrate the following PCOS features at adulthood: hyperandrogenism, excess LH, 
anovulation, infertility, PCOS morphology, increased follicular recruitment, reduced 
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progesterone-related negative feedback, increased sensitivity of the gonadotropin-
releasing hormone (GnRH) system, IR, intrauterine growth restriction (IUGR), and 
increased visceral fat and dyslipidaemia (Abbott et al., 1998; Eisner et al., 2002; Eisner 
et al., 2003; Zhou et al., 2005; Abbott et al., 2008).   
The adrenal hyperandrogenism described in these animals is in many aspects similar 
to that observed in women with PCOS. Only primates have an adrenal area known as 
the fetal zone and, after birth, the zona reticularis, which is responsible for C19 steroid 
synthesis (Conley et al., 2004; Abbott, 2007). PA monkeys demonstrate enhanced 
basal and stimulated androgen responses to adrenocorticotropin (ACTH), suggesting 
upregulation of P450c17 (Eisner et al., 2002; Zhou et al., 2005). Moreover, equivalents 
to the 4 adult phenotypes of women with PCOS (according the Rotterdam Consensus, 
2003) have been described in adult PA female rhesus monkeys (Abbott et al., 
2009).The same group also characterised the fetal, infant, and adolescent phenotype 
of PA monkeys, demonstrating excess LH, hyperinsulinaemia, hyperandrogenism, and 
increased body weight in these animals after birth. Nevertheless, there are some 
disadvantages of the use of monkeys as animal models: they have longer lifecycles, 
reaching sexual maturity after 3 years of age, and this increases costs and makes it 
difficult to assess treatment effects across successive generations (Franks, 2009).  
Sheep  
Prenatal androgenisation in sheep is characterised by many pathological symptoms 
similar to those in women with PCOS. In female adult sheep, abnormalities that are 
usually observed in the reproductive system consist of upregulation of androgen 
receptor in the ovary associated with anovulation, excess LH, PCO morphology, 
increased follicular recruitment, disruption of the hypothalamic dynamics with increased 
GnRH sensitivity, LH hypersecretion, and reduced steroid feedback to E2 (positive and 
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negative) and progesterone (negative) (Kosut et al., 1997; Masek et al., 1999; Forsdike 
et al., 2007; Veiga-Lopez et al., 2008; Ortega et al., 2009). In addition, there is a 
progression to metabolic alterations leading to hyperlipidaemia, hypertension, and IR. 
IUGR and catch-up growth have also been reported in sheep androgenised during 
gestation (Recabarren et al., 2005; Savabieasfahani et al., 2005; Forsdike et al., 2007; 
Steckler et al., 2007; Padmanabhan & Veiga-Lopez, 2011).  
Important contributions to the understanding of abnormalities in folliculogenesis in fetal 
ovaries subjected to androgenisation and the differences between androgenic and 
oestrogenic actions in fetal tissues came from studies in sheep as described above. As 
a rule, exposure to testosterone or DHT (both 100 mg i.m. biweekly) at 30–90 days’ 
gestation is the most common protocol for prenatal androgenisation (Padmanabhan & 
Veiga-Lopez, 2011). Like the human, the sheep is a monovulatory species whose 
follicle formation occurs entirely during gestation. Relative restrictions for the use of 
sheep include their characteristics as seasonal breeders, their decreased capacity to 
secrete adrenal androgens, and the absence of the zona reticularis (Abbott, 2007). 
 Rats 
Prenatally androgenised rats are emerging as an alternative model for PCOS 
programming. Studies in female rats whose mothers were treated with free 
testosterone 5 mg/day s.c. in utero during days 16–19 showed that at adulthood, the 
offspring exhibited excess LH, anovulation, PCO morphology, reduced positive 
feedback to E2, increased visceral fat, and dyslipidaemia (Demissie et al.,2008). 
Curiously, features not observed in these animals were IR, and the increased GnRH 
sensitivity that was absent in animals treated with DHT (5 mg/day s.c., days 16–19). 
Other protocols in rats involve the use of inhibitors of aromatase (letrozole) or 
androgens (DHT) ranging from 3 hours to 42 days after birth at different doses (Table 
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1.5). Overall, in all post-natal protocols, the best results in terms of similarity with 
human PCOS are obtained with rats treated with letrozole for 21 days starting at post-
natal day 42. Letrozole blocks conversion of testosterone to E2 and androstenedione to 
oestrone in the placenta and increases androgen levels within the ovary. These 
animals exhibit the main reproductive characteristics of PCOS including 
hyperandrogenism, anovulation, and increased ovary size with PCO morphology 
(Kafali et al., 2004; Manneras et al., 2007). Apart from obesity, letrozole-treated 
animals do not have other metabolic abnormalities characteristic of PCOS such as 
abdominal obesity, enlarged adipocytes, and decreased insulin sensitivity (Kafali et al., 
2004; Manneras et al., 2007).  
Rats can be considered less satisfactory models of human ovary function than sheep 
and monkeys because their follicle formation ends after birth and because they are 
polyovulatory animals. Many other metabolic and reproductive changes characteristic 
of human PCOS can be reproduced in rats, which are faster and cheaper breeders 
than are sheep and monkeys, allowing multiple experiments along several generations. 
Rats reach sexual maturity after 5 weeks and their median lifespan is 2.5 years. 
 Mice 
Prenatally androgenised mice (16–18-day-old) with DHT manifest some features that 
mimic human PCOS such as hyperandrogenism, excess LH, and anovulation (Sullivan 
& Moenter, 2004; Roland et al., 2010). Curiously, pancreatic β-cell dysfunction has 
been reported, but it was not associated with impaired insulin sensitivity or increased 
visceral fat as seen in women with PCOS (Roland et al., 2010). 
Similar to rats, mice have the relative drawbacks of exhibiting polyovulatory cycles and 
concluding their folliculogenesis after birth. Mice (and rats) do not express P450c17 in 
the adrenal glands, limiting their potential abnormalities to the gonadal axis (Abbott et 
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al., 2005). However, mice do have the advantages of being faster breeders and 
requiring less money and time to obtain results along generations. Additionally, mice 
offer vast potential for investigation considering the inestimable genetic knowledge of 
this species. 
1.4   DISCUSSION   
PCOS is a complex disorder manifesting metabolic and reproductive abnormalities 
whose origins and mechanisms of development are not well understood. The clinical 
spectrum of PCOS is wide, as defined by the Rotterdam Consensus criteria (2004) and 
involves possibly more than one aetiology causing the syndrome, that are not fully 
explained by genetic, developmental, or environmental factors.  
Part of the difficulties in comprehending PCOS is based on the lack of knowledge of 
key regulatory machinery of the  ‘normal’ ovarian physiology. For example, up to the 
present time, physiological phenomena such as normal follicle recruitment or theca cell 
differentiation and function are still under investigation. The same applies to metabolic 
abnormalities where is not completely clear how insulin or adipokines interact in 
adipose tissue or ovary. 
Therefore, other methods to investigate the possible source of PCOS by the 
employment of animals that share a close physiologic relationship with humans are 
acceptable and can add some valuable knowledge to the pathogenesis of PCOS. 
Animal models employing primates, sheep and rodents are based on the premise of a 
high androgen environment at critical moments in fetal development which can drive 
endocrine modifications that last for the whole life. Primates, of course, are closer to 
human physiology although are more difficult to work because they have long life 
cycles, limiting the study in successive generations. Sheep are monovulatory species 
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that complete ovarian follicle formation in utero like humans, but lack similarities in 
terms of adrenal production of androgens reported to affect approximately 30% of 
women with PCOS. Despite this limitation, important information about the impact of 
androgens in ovarian and extra-ovarian endocrine environment has been provided by 
diverse studies employing PA sheep. More recently, new research has optimized 
protocols for the employment of PA rodents (rats and mice), polyovulatory animals that 
are easy to breed and to follow by generations and, for those reasons, seem to be 
useful to answer other questions about the origins of PCOS. 
As stated before, gonadal and extra-gonadal abnormalities are seen in PCOS women 
and in its animal models. Among these disturbances, a disruption in secretion of 
adipokines (especially, adiponectin which appears to interfere with theca cells 
androgenic secretion) claims attention to the existence of possible links between 
metabolic and reproductive features in PCOS. Thus, the exploration of the role of 
adipokines in the pathogenesis of PCOS would potentially add new evidence in the 
attempt to comprehend of this enigmatic disorder. 
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1.5   AIMS AND HYPOTHESIS 
 
I - To determine the expression of steroidogenic enzymes and 
luteinizing hormone receptor (LHR) in normal ovaries and in polycystic 
ovaries in women.  
- Hypothesis: the expression of key steroidogenic enzymes and LHR, both relevant 
to androgen secretion, is increased in polycystic ovaries and is an intrinsic feature of 
ovarian dysfunction in PCOS. 
 
II  - To study the effects of prenatal androgenisation on folliculogenesis 
and steroidogenesis in prenatally androgenised fetal and adult sheep, 
an animal model of PCOS. 
-Hypothesis: prenatal androgenisation in sheep disrupts ovarian follicle formation and 
steroidogenic enzyme expression. This process starts at early stages of follicle 
development in utero and is also manifest in adult life. 
 
III  - To investigate the role of adipokines on androgen production by the 
ovary. 
-Adipokines modulate with secretion of androgens by theca cells and may be a key 
link between adipose tissue function and androgen excess.  
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CHAPTER 2 
EXPRESSION OF STEROIDOGENIC ENZYMES 
AND LHR IN NORMAL AND POLYCYSTIC 
OVARIES 
 
 
 
 
   INTRODUCTION 
Androgen excess is the hallmark of polycystic ovary syndrome. It is estimated that 
about 60% of women with PCOS have clinical manifestations of hyperandrogenism 
(acne, alopecia, hirsutism) and 60-80% biochemical evidence of increased 
testosterone in the serum (Conway et al., 1989; Balen et al., 1995; Diamanti-
Kandarakis, 1999; Chang et al., 2005). The high abundance of androgens in PCOS 
is derived mainly from ovarian theca cell compartment, although in approximately 
one quarter of women with PCOS an adrenal source for androgen excess co-exists 
(Kumar et al., 2005; Carmina & Lobo, 2007). 
Ovarian hyperandrogenism in PCOS occurs for multiple reasons. Firstly, these 
ovaries exhibit an elevated number of follicles and hypertrophy of the internal theca 
providing a significant bulk of steroidogenic cells (Mahajan, 1988). Secondly, in 
anovulatory patients with PCOS, there is a persistent secretion of androgens 
(Chetkowski et al., 1984). Differently from fluctuating levels of steroids observed in 
women with regular cycles, anovulation favours the accumulation of testosterone, 
androstenedione and DHEA in the blood. Thirdly, theca cells from PCOS ovaries 
demonstrate a defective negative feedback to steroids in relation to a normal 
LH/steroid dose-response curve (Gilling-Smith et al., 1994; Gilling-Smith et al., 
1997b; Wickenheisser et al., 2004). Finally, an increased capacity to synthesize 
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androgens has been reported in theca cells in PCOS. These cells have higher 
expression of mRNA for LH receptor and steroidogenic enzymes (STAR, CYP11A1, 
CYP17A1A1) (Gilling-Smith et al., 1997b; Jakimiuk et al., 2001; Wickenheisser et al., 
2005). In particular, CYP17A1A1 (P450c17), responsible for the qualitative control of 
steroidogenesis, has longer stability and extended half-life due a post-transcriptional 
modification (Nelson et al., 1999).  
It is not clear whether thecal hyperfunction in PCOS is entirely intrinsic, or 
consequent to paracrine or endocrine modulation, as detailed in Table 2.1. Studies in 
vitro employing primary human theca cells (Bergh et al., 1993b; Stewart et al., 1995; 
Gilling-Smith et al., 1997b), and primary bovine theca cells (Stewart et al., 1995; 
Spicer et al., 1997; Spicer et al., 2008) have shown that LH administration can 
increase gene expression of luteinizing hormone receptor (LHR) and key 
steroidogenic enzymes (StAR, P450scc, P450c17, 3βHSDII). Similarly, insulin raised 
levels of StAR, P450scc and P450c17 enzymes resulting in higher androgen 
production by theca cells. Therefore, in PCOS, hyperinsulinemia and disruption of 
frequency and amplitude pulse of LH interact to boost androgen synthesis in theca 
cells by actions in multiple sites. In addition to this, an elevation of inhibin-B (possibly 
secondary to a higher proportion of small developing follicles and/or intrinsic 
abnormalities in FSH stimulation) (Tsigkou et al., 2008), contribute to higher 
androgen secretion in theca cells (Nahum et al., 1995; Sawetawan et al., 1996). 
Other abnormalities associated with ovarian hyperandrogenism in PCOS are related 
to disruption of granulosa cell function, in particular involving a decrease in 
aromatase mRNA (Jakimiuk et al., 1998) and consequent accumulation of 
androstenedione . 
Nevertheless, other factors play a role in this scenario and should not be ignored. 
The list of stimulators of theca cell steroidogenesis includes stem cell factor/kit ligand 
(SCF) (Parrot et al., 1994; Parrot et al., 2000), insulin-like growth factor I (IGF-I) 
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(Magoffin & Weitsman, 1993b; Nahum et al., 1995), growth differentiation factor 9 
(GDF-9) (Nilsson & Skinner, 2002; Chu et al., 2004; Spicer et al., 2008), and 
members of transforming growth factor β superfamily (TGFβ) such as activins (Hillier 
et al., 1991b; Shukovski et al., 1993)  and inhibins (Hillier et al., 1991a; Hillier et al., 
1991c; Sawetawan et al., 1996). 
Surprisingly, few studies in the literature have analysed (and none have quantified) 
the protein expression of steroidogenic enzymes in polycystic ovaries (PCOS) and in 
ovaries from normal women. Tamura et al (1993) firstly described the localization of 
P450c17 enzyme in five polycystic human ovaries from patients with irregular 
menstrual cycles who had undergone therapy for infertility (Tamura et al., 1992). 
Positive immuno-specificity for P450c17 was found in theca interna cells from 
follicles greater than 8 mm in diameter. 
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Enzyme or  protein 
(gene) 
Increased in 
PCO 
ovaries? 
Stimulated 
by 
Inhibited 
by 
StAR (STAR) Yes Insulin 
LH 
hCG 
SCF 
IGF-I+SCF 
 
TGFB1 
BMP4/6/7 
 
P450scc (CYP11A1) Yes Insulin 
LH 
IGF-I 
TGFB1 
 
GDF-9 
BMP4/6/7 
P450c17 (CYP17A1) Yes Insulin 
LH 
TGFB1 
Inhibin 
GDF-9 
IGF-I+SCF 
 
BMP4/6/7 
SCF 
TGFB1 
HGF 
Androgen 
Estradiol 
3βHSD (HSD3B) 
 
Yes LH 
IGF-I 
TGFB1 
hCG 
 
BMP4/6/7 
LHR (LHR/LHCGR) 
 
Yes LH,IGF-I GDF-9 
 
Table 2.1: Modulators of steroidogenic enzymes, protein and LHR in 
theca cells   (modified from Young & McNeilly, 2010). 
LH, luteinizing hormone ; hCG, human chorionic gonadotropin; IGF-I, insulin-like growth 
factor I; SCF,stem cell factor; TGFB1 , transforming growth factor β; GDF-9, growth 
differentiation factor 9; BMP, bone morphogenetic protein; HGF, hepatocyte growth factor. 
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Following this work, Takayama et al (1996), evaluated the expression of P450c17 
and other steroidogenic enzymes (P450scc, 3βHSDII, P450arom), in ovaries from 
five patients with PCOS with history of anovulation and infertility and 32 ovaries from 
normal cycling women (Takayama et al., 1996). In Takayama’s study, healthy 
follicles (type A) demonstrated a positive staining in theca cells for P450scc, 
3βHSDII, P450c17 and AR while GCs expressed AR but not P450arom or ER 
(Takayama et al., 1996).  Finally, Kaaijk et al (2000) identified the 
immunohistochemical localization of P450scc, 3βHSDII, P450c17 and Ad4BP in 13 
ovaries from patients who had undergone unilateral oophorectomy (Kaaijk et al., 
2000). This population included 7 patients with history of anovulation (no response to 
clomiphene) and 6 patients with severe hirsutism and irregular cycles. P450c17 was 
identified clearly in TCs and some stromal luteinized cells and not in GCs. Staining 
for 3βHSDII was present similarly in these groups plus non-luteinized stromal cells. 
Cell labelling for P450scc was observed in different kinds of cells described above, 
including a small proportion of GCs (Kaaijk et al., 2000) 
The 17βHSD type 5 is the enzyme responsible for the direct conversion of 
androstenedione into testosterone in the ovary. Preliminary data have not confirmed 
an increase in mRNA levels of 17βHSD type 5 enzyme in PCO (Nelson et al., 2001) 
ovaries, but no systematic study evaluating the 17βHSD type 5 enzyme protein  
expression has been performed.  
Androgens are produced by ovarian theca cells mainly under direct action of LH 
amplified by insulin, IGFs and local growth factors. To date, no information about the 
luteinizing receptor (LHR) expression in human ovaries by immunohistochemistry is 
available, although this technique had been successfully employed in other species 
(rat, dog, ferret, cow, etc) (Teerds & Dorrington, 1995; Peters et al., 2001; 
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Schoemaker et al., 2002). Hypersecretion of androgens and the presence of multiple 
follicles have been described as key characteristics in polycystic ovaries in PCOS 
(Franks, 1995, 2008). One way to analyse these features is through the study of 
expression of target proteins in follicles at different stages of development. Although 
the sites of steroidogenic enzymes have been identified in PCO follicles in the past, 
no study has systematically compared or quantified the expression of proteins of key 
steroidogenic enzymes or LHR in polycystic ovary syndrome 
2.2    AIMS 
The aims of this study were using a quantitative and/or semi-quantitative 
immunohistochemistry: 
1) To examine the protein expression of key enzymes in the androgen biosynthetic 
pathway (P450c17, 3βHSDII, 17βHSD type 5) in polycystic ovaries compared with 
ovaries of normal women.  
2) To investigate the expression of LH receptor (LHR) protein in polycystic ovaries 
and ovaries from normal women. 
2.3 MATERIALS AND METHODS  
2.3.1. Samples 
Sections of archived human ovaries (formalin-fixed paraffin-embedded) removed 
from non-malignant reasons from patients aging less than 50 years between 1993-
2000 were obtained from the histopathology bank of St. Mary’s Hospital (Imperial 
College Healthcare NHS Trust) in London. Overall, excluding the specimens 
considered unclassified or having a concomitant pathology (e.g. endometriosis), 26 
ovaries from 26 patients were obtained. All specimens were anonymised and 
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collected with previous patient informed consent and in conformity with the local 
Research Ethics Committee. Details about the patients and the preparation of 
samples are given in Chapter 7 (Materials and Methods). Sections were divided in 
groups of normal women (control), ovulatory PCOS (ovpcos) and anovulatory PCOS 
(anov). Table 2.2 a and b  show a summary of follicles analysed in the experiments. 
 
Table 2.2a: Proportion of theca cells expressing LHR. 
 Normal  ovaries 
(n = 7) 
Ovulatory PCO 
(n = 9)  
Anovulatory PCO 
(n = 3) 
Follicles 25 58 13 
Total n of theca cells 1092 2850 655 
Proportion of 
positive cells  
Median (IQ range) 
0.09 
(0.01; 0.46) 
0.40  
(0.21; 0.51) 
0.65  
(0.45; 0.88) 
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Table 2.2b: Proportion of theca cells staining for P450c17, 3βHSD II, and 17βHSD type 5 in human ovaries.  
Data show the proportion of staining expressed in its median, interquartile ranges, number of sections (n), and number of follicles analysed.
P450c17   3βHSD II 17βHSD type 5 
Normal PCO Normal PCO Normal PCO 
Total 
staining 
Strong 
staining 
Total 
staining 
Strong 
staining 
Total 
staining 
Strong 
staining 
Total 
staining 
Strong 
staining 
Total 
staining 
Total 
staining 
0.59 
(0.45-0.78) 
(n=9) 
(26 follicles) 
0.13 
(0.04-0.25) 
(n= 9) 
(26 folllicles) 
0.79 
(0.58-0.87) 
(n=14 ) 
(58 follicles) 
 
0.34 
(0.19-0.50) 
(n=14 ) 
(58 follicles) 
0.43 
(0.22-0.66) 
(n=6 ) 
(9 follicles) 
0.047 
(0-0.05) 
(n= 6) 
(9 follicles) 
0.52 
(0.41-0.62) 
(n= 14) 
(60 follicles) 
0.11 
(0.11-0.16) 
(n= 14) 
(60 follicles) 
0.47 
(0.24-0.71) 
(n=8 ) 
(23 follicles) 
0.53 
(0.42 -0.63) 
(n=13 ) 
(68 follicles) 
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2.3.2  Immunohistochemistry (P450c17, 3βHSDII, 17βHSD type 5) 
To verify the expression of proteins of P450c17, 3βHSDII and 17βHSD type 5 an 
immunohistochemistry study was performed in paraffin sections as described in detail 
in Chapter 7.  Primary antibodies employed included: mouse monoclonal antibody 
against P450c17 (generously donated by Dr R Parker, University of Alabama at 
Birmingham, USA), rabbit polyclonal antibody against human 3βHSDII (a gift from Prof 
JI Mason, University of Edinburgh), and rabbit polyclonal antibody to human AKR1C3 
(17βHSD type 5) obtained from Abcam (Abcam, Cambridge, UK). Immunoreactivity 
was detected by incubation of sections in HRP-conjugated 3,3’- diaminobenzidine 
tetrahydrochloride (DAB) as the chromogen (Dako, UK). To reduce bias in analysis, 
follicles were divided in 8 zones and one zone chosen for quantitative or semi-
quantitative evaluation employing a random number sequence.  
2.3.3  Immunohistochemistry for LH receptor (LHR) 
A modified immunohistochemistry protocol was employed to the study of the luteinizing 
receptor (LHR) expression in sections of human ovary sections as detailed in Chapter 
7.  Sections were incubated overnight at 40C with the primary antibody P1B4 LHR  (a 
gift from Professor K Teerds, Wageningen University, Netherlands). Immunoreactivity 
was detected by incubation of the tissue sections in HRP-conjugated 3,3’- 
diaminobenzidine tetrahydrochloride (DAB) as the chromogen (Vector Lab, 
Peterborough,UK ). Analysis utilized a random number sequence to define the follicular 
area to be studied.  
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2.3.4   Semi-quantitative and quantitative measurement 
The labelling  for a specific protein was analyzed in follicles and classified as present 
(positive) or absent (negative).  In 3βHSDII, P450c17 and 17βHSD type 5 
immunohistochemistry experiments, a semi-quantitative determination was performed 
establishing categories for weak (+) or strong (++) staining based on the intensity of 
staining for each antibody. An alternative approach to compare the expression of 
P450c17 and 3βHSDII enzymes involved the quantification of labelling with auxiliary of 
the software NIS-Elements Ar (Nikkon, Japan) connected to a digital camera and 
microscope. This system allows the measurement of absorbance, assessed by optical 
density values  (in arbitrary units). All images used for these analyses were obtained 
using the same microscope settings as described in Chapter 7. 
2.3.5  Statistic analysis 
Differences between groups of sections were tested using Student t-test (if normal 
distribution assumed) or Mann-Whitney test (if asymmetric distributed). For the 
comparison of more than two groups normally distributed, an one-way analysis of 
variance (ANOVA) and additional post-test (Tukey’s or Dunnet’s test) was chosen; for 
data asymmetrically distributed, the Kruskal–Wallis test and additional (Dunn’s multiple 
comparison test) were performed.  In all cases, a probability (P )  inferior to 0.05 was 
considered as statistically significant.  Normal distributed data was represented by 
mean plus SEM or SD. Clearly assimetric data was represented by median plus 
interquartile range. For data with a normal trend but small n, the mean plus 95% of 
confidence interval was selected.(Gougeon, 1996; Webber et al., 2003) 
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2.4  RESULTS  
2.4.1   P450c17 protein expression in the human ovary. 
General considerations 
Immunoreactivity for P450c17 protein was identified exclusively in the cytoplasm of 
theca cells (internal and external layer), theca-lutein and granulosa lutein cells (corpus 
luteum), and some dispersed interstitial cells in the parenchyma (Fig 2.1). No labelling 
was identified in TCs or in preantral follicles before the secondary stage. Overall, 26 
follicles (1206 theca cells) in normal ovaries, and 58 follicles (3052 theca cells) were 
analysed (Table 2.2). 
Semi-quantitative analysis of theca cell staining for P450c17 
P450c17 expression was observed in TCs in all antral follicles in ovaries from normal 
women and PCOS. The proportion of theca cells exhibiting positive staining for 
P450c17 was similar between controls and PCOS (mean + SD) 0.56 + 0.08 vs 0.72 + 
0.05 (P =0.11 Student t test). However, in PCOS there was   a clear increase in the 
strong staining (++) for P450c17 in TCs. Considering the total number of follicles 
(healthy + atretic), a significant increase in the strong labelling was observed in PCO 
group (mean + SD) 0.34 + 0.04 in comparison with normal ovaries 0.14 + 0.04 (P = 
0.01 Student t test). This remarkable difference in labelling persisted in a subgroup of 
healthy follicles, PCOS 0.40 (0.27-0.68) and controls 0.17(0.07-0.37) (median 
[interquartile range]) P =0.04 (Mann-Whitney test) (Fig. 2.2). A stronger staining for 
P450c17 was also observed in atretic follicles from PCO ovaries (mean + SD) 0.28 + 
0.05 vs controls 0.13 + 0.04, although it did not reach statistical significance  (P =0.1 
Student t test).  
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Quantitative immunohistochemistry  
The density of expression measured in optical density arbitrary units was also 
significantly increased in PCOS theca cell layers in comparison to ovaries from normal 
women. The value in PCOS group was 0.82 (0.52-1.2) and in controls 0.37 (0.28- 0.57) 
P =0.04 (Mann-Whitney test) (Fig. 2.2). 
 
 
Fig 2.1: P450c17 expression in human ovaries. 
A specific staining was observed in theca cells in early antral follicles (A), as well in healthy 
(D), luteal (E) and atretic (F) antral follicles. Labelling for P450c17 was present in internal 
theca layer (D-black arrow) and external theca layer (D- white arrow). Some theca cells did not 
labelled for P450c17(G- small arrows). With  rare exceptions, such as a secondary follicle 
showing theca cell positivity for P450c17 (B), labeling for P450c17 was  not found in preantral 
follicles(C). Theca-lutein cells identified by a black arrow in the corpus luteum (H) showed 
strong labeling for this antibody  and were used as an internal positive control.  Negative 
control (I). 
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Fig 2.2: Comparison of P450c17 expression in PCO and normal ovaries. 
Proportion  of theca  cells  (mean + SEM) showing   positive  immunostaining  for P450c17: 
(A),(C),(E) =  any staining(+ and ++) ; (B),(D),(F) = strong staining (++). The  proportion of 
strong staining TCs in PCO was significantly greater than in follicles of ovaries of normal 
women. This was confirmed by quantitative immunohistochemistry (G).  
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2.4.2  3βHSDII protein expression in the human ovary  
General considerations 
The labelling for 3βHSDII protein was mainly observed in cytoplasm of theca cells, 
granulosa-lutein, theca-lutein cells and in minor intensity in antral granulosa cells (Fig. 
2.3).  For this study, 9 antral follicles (274 theca cells) in normal ovaries and 60 antral 
follicles (1506 theca cells) in PCO ovaries were examined. 
Proportion of theca cells staining for 3βHSDII protein  
Equal proportions of theca cells in normal and PCO ovaries expressing 3βHSDII 
protein (Fig 2.4A). The proportion of theca cells staining for  3βHSDII in normal ovaries 
was 0.43 (0.22-0.66) and in PCO ovaries 0.52 (0.41-0.62). Similarly, no statistical 
significance was observed in the fraction of theca cells demonstrating strong staining in 
PCO ovaries (about 10% of theca cells)( Fig 2.4B). Quantification of 3βHSDII protein 
staining performed as described for P450c17 was also performed and did not show 
differences between the groups (0.13 + 0.01 for controls and 0.16 + 0.01 for PCO) (Fig. 
2.4C). 
2.4.3. 17βHSD type 5 expression in the human ovary 
General considerations 
Labelling for 17βHSD was observed in the cytoplasm. Cells showing positive labelling 
for this protein were identified in granulosa cells in preantral follicles, theca and 
granulosa cells in antral follicles and theca-lutein and granulosa-lutein cells in the 
corpus luteum (Fig. 2.3).   
Altogether, 23 follicles (1948 theca cells) in ovaries from normal women and    68 
follicles (4860 theca cells) in PCO ovaries were analysed in this study. 
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Proportion of theca cells staining for 17βHSD type 5 protein 
Similar expression of 17βHSD protein was detected in theca cells from PCO and 
normal ovaries; the mean + SD for cells staining in normal ovaries was  (0.39 + 0.14) 
and in PCO ovaries (0.39 + 0.07) (Fig 2.4D). No differences were observed in healthy 
follicles (0.51 + 0.10) in controls versus  (0.54 + 0.05) in PCO.  Staining density was 
very uniform so was not possible distinguish differences in intensity of staining between 
groups. 
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Fig 2.3: 3βHSDII and 17βHSD type 5  expression in human ovaries.  
Labelling for 3βHSDII was identified in theca cells from antral follicles (A)(B) and in granulosa- 
lutein cells (white arrow) and theca-lutein cells (black arrow) from the corpus luteum (D).  
Minimal staining was noted in praeantral follicles (C). Staining for 17βHSD type 5 protein was 
identified in the corpus luteum (G) in granulosa lutein cells (white arrow) and theca lutein cells 
(black arrow) as well in theca cells and in granulosa cells at antral stage (F). Granulosa cells 
from preantral follicles were also positive for 17βHSD type 5. Negative control for 3βHSDII and 
for 17βHSD type 5 are respectively represented by antral follicle section shown in (E) and (I). 
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Fig 2.4: Comparison of 3βHSDII and 17βHSD type 5 expression  in   
PCO and normal  ovaries. 
The overall proportion of TCs in follicles staining for 3βHSD II and  17βHSD type 5 was 
similar between PCO and normal ovaries (A),(D). No differences were observed for strong 
labelling (B) or mean density (C) in 3βHSD II immunostaining. Data shown mean + SD. 
 A
B
C
 D
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2.4.4. Luteinizing hormone receptor (LHR) expression in the human 
ovary 
General considerations  
The staining for LHR was confined in cytoplasm and identified in theca cells, theca-
lutein cells (corpus luteum), epithelial cells from the oviduct and, less frequently in 
luteinized   granulosa cells (Fig 2.5). Overall, 96 follicles (25 from normal ovaries, 58 
from ovulatory PCO and 13 from anovulatory PCO) were analysed as shown in Table 
2.2a. 
Proportion of theca cells expressing LHR. 
No differences were observed in terms of proportion of staining for LH in follicles 
from normal women -median (IQ range) 0.09 (0.01-0.46) compared with follicles from 
ovulatory PCO 0.40 (0.22-0.63) (Fig. 2.6A). However, theca cells from anovulatory 
polycystic ovaries expressed a higher proportion of positive staining for LHR when 
compared to controls; median (IQ range) 0.65 (0.59-0.76) (P = 0.04, Kruskal Wallis 
test; Dunn's multiple comparison test P <0.05 (anovPCOS vs control) (Fig. 2.6A). 
These differences persisted in the analysis of atretic follicles (P =0.02, Kruskal Wallis 
test; Dunn's multiple comparison test P <0.05 control vs anovPCOS) (Fig 2.6B and C). 
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Fig 2.5: Luteinizing hormone receptor (LHR) expression in human 
ovaries.  
A positive labelling was demonstrated in rat ovaries (positive control) (F), cells from the 
Fallopian tube  (C), theca-lutein cells in corpus albicans (I) theca cells in antral follicles (D) 
(G). With exception of luteinized cells (E), no staining in granulosa cells was observed in 
preantral (A)(B) or antral stages(D). (H) negative control. 
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Healthy                                                          B 
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Fig 2.6: Comparison of luteinizing hormone receptor (LHR) expression 
in PCO and in normal ovaries.  
A significant increase in the proportion of theca cells expressing strong labelling for LHR 
was identified in total follicles (A), and atretic follicles (C), but not in healthy follicles from 
PCO group. Graphs represent median and interquartile range.  
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2.5 DISCUSSION 
In this chapter, immunolabelling for P450c17, 3βHSDII, 17βHSD type5 and LHR was 
performed employing sections of human ovaries (n=26) (formalin-fixed, paraffin-
embedded) previously characterized as normal (ovulatory) ovaries, ovulatory PCO, 
or anovulatory PCO.  A significant increase in the staining for P450c17 as defined by 
quantitative immunohistochemistry was identified in antral follicles from PCO 
sections in comparison to ovaries from normal women. The proportion of theca cells 
expressing LHR was also higher in anovulatory PCO group while no differences were 
detected between the proportion of theca cells staining for 3βHSDII or 17βHSD 
type5. 
The microsomal enzyme P450c17 is the main regulatory step in androgen production 
in gonads and adrenal.  In this study, about one third of theca cells of PCO which 
was twice the proportion that in normal ovaries, showed strong labelling for P450c17. 
This substantial difference was also evident when labelling was quantified by 
measurement of optical density. Optical density  (arbitrary units) in PCO ovaries was 
more than twice that observed in normal ovaries. These data indicate that the level of 
protein expression of P450c17 is increased in TCs of women with PCO supports the 
findings of hypersecretion of androstenedione by cultured TCs, and augmented 
transcription, greater mRNA content and stability of CYP17A1 gene. It is therefore 
reasonable to suggest that overexpression and enhanced activities of P450c17 is a 
key feature in the  development of hyperandrogenism in PCOS.  Nevertheless, it is 
not clear from such studies whether increased expression of P450c17 is a primary 
abnormality or whether it occurs as a result of abnormal regulation by endocrine 
and/or paracrine factors. An obvious candidate in this patterns is LH and this 
interaction with LHR. 
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 The expression of luteinizing hormone receptor (LHR) was evaluated by 
immunohistochemistry. To date, no other studies have used this technique to 
address the role of LHR in the pathogenesis of PCOS, due, in fact, to the lack of a 
suitable specific LHR antibody. We were fortunate to obtain a high-specific LHR 
antibody from Professor Katja Teerds (Wageningen University, The Netherlands) 
who tested successfully this antibody in many other species.   In normal ovaries LHR 
was identified in theca-lutein cells and theca internal and external. Luteinized 
granulosa cells, as would be expected, also demonstrated the presence of LHR. 
Remarkably, a significant increase in the proportion of LHR labelling in theca cells 
was observed in anovulatory PCOS when compared with theca cells in follicles from 
normal women.  An increase in mRNA content of LH receptor in theca cells from 
PCOS ovaries has been described previously (Nelson et al, 1999) and may 
represent a mechanism to enhance androgen synthesis in PCO.  
Other steroidogenic enzymes evaluated in this study were 3βHSDII and 17βHSD 
type 5. Both participate in androgen synthesis cascades. The first one  (3βHSDII) is 
essential for the conversion of DHEA into androstenedione; the second, (17βHSD 
type 5) can catalyse the conversion of androstenedione to testosterone. However, in 
these studies, we found no differences in expression of either 3βHSDII or 17βHSD 
type.  
To sum up, this study provides new evidence for an increased expression of 
P450c17 and LHR protein in polycystic ovaries consistent with the main features of 
PCOS (hyperandrogenism and anovulation). The results above also agree with 
previous results in the literature showing increased mRNA expression for CYP17A1 
and LHR in theca cells from PCO ovaries and support the hypothesis that increased 
presence of P450c17 may, at least, is proven in anovulatory PCO to related 
enhanced LHR expression. This, in turn, could be an intrinsic abnormality of the 
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theca cells but may also reflect the abnormal endocrine environment in anovulatory 
women with PCOS, including hyperinsulinism.  
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CHAPTER 3 
ABNORMALITIES IN STEROIDOGENESIS AND 
FOLLICULOGENESIS IN PRENATALLY 
ANDROGENISED SHEEP: (1) STUDIES IN THE 
ADULT EWE 
 
 
3.1  INTRODUCTION 
Prenatally androgenised (PA) sheep are increasingly being recognised as an 
informative model of PCOS. These animals have been shown to reproduce many 
PCOS-like abnormalities such a multifollicular ovarian phenotype, anovulation, 
increased expression of AR, reduced estradiol / progesterone negative feedback, 
insulin resistance, hyperlipidaemia, LH excess and increased body weight (Abbott, 
2007; Dumesic et al., 2007; Forsdike et al., 2007; King et al., 2007; Veiga-Lopez et al., 
2008; Padmanabhan & Veiga-Lopez, 2011).  In addition, sheep are monovulatory 
animals and, like humans and other primates, ovarian, follicle formation is completed 
during gestation. These characteristics make PA sheep suitable for investigating the 
mechanisms of ovarian disruption by androgen in utero.  
Recent studies in PA sheep have provided important insights into the effect of 
androgen on ovarian function, which is relevant to the understanding of PCOS. For 
example, previous studies have described the polycystic appearance and the 
disruption of normal follicle development and function in ovaries of PA sheep (West et 
al., 2001; Forsdike et al., 2007; Smith et al., 2009).  
Nevertheless, other questions with translational relevance to PCOS remain. In the 
human polycystic ovary, an important finding is the remarkably higher proliferation of 
granulosa cell in PCO ovaries, which is linked to the ‘stockpilling’ of follicles, 
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premature luteinisation and cell death (Webber et al., 2003; Maciel et al., 2004; 
Stubbs et al., 2007). To the best of our knowledge, this information has not been 
extensively investigated in PA animals.  
Another key feature of PCOS is hyperandrogenism. Androgen excess has been 
reported in monkeys and sheep treated with testosterone during gestation (Eisner et 
al., 2002); however, the mechanisms that drive  increased ovarian ‘functional’ 
hyperandrogenism in sheep have not been very much explored in detail.  
Therefore, the objective of this study was to assess the consequences of prenatal 
androgenisation in sheep ovaries at adulthood. 
3.2  AIMS 
The aims of this study were: 
1) To assess the expression of steroidogenic enzymes (P450c17, 3βHSDII, and 
17BHSD type 5), and androgen receptor (AR) by immunohistochemistry in PA adult 
sheep ovaries compared to its normal controls; 
 
2) To study the granulosa cell proliferation in the same groups  analyzing   the 
expression of  the  minichromosome maintenance protein 2 (MCM-2) in the adult 
sheep ovary. 
3.3 MATERIALS AND METHODS  
3.3.1 Samples 
Sections of adult sheep ovaries at 20 months and foetal sheep ovaries at d90 of 
gestational life were obtained from a previous study undertaken at the Babraham 
Institute as detailed in Materials and Methods (Chapter 7). Overall, twelve of twenty-
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five female sheep received injections of testosterone propionate (100 mg i.m bi-
weekly) from day 30 to 90 of gestation. The first breeding season generated 20 ewes 
(11 androgenised and  9 controls), from which ovaries were collected at 20 months.  
3.3.2  Immunohistochemistry  
immunohistochemical detection involved incubation with a peroxidase-conjugated 
avidin-biotin complex (RTU-ABC Kit, Vector, Peterborough, UK) and the HRP-
conjugated 3,3’- diaminobenzidine tetrahydrochloride (DAB) protocol described in 
Chapter 7. The primary antibodies used included monoclonal mouse anti-human 
P450c17 Ab, (a gift from Dr Richard Parker Jr., University of Alabama at Birmingham, 
USA) at 1:40 dilution (v/v PBS); polyclonal rabbit anti-3βHSDII Ab (generously 
provided by Prof JI Mason, University of Edinburgh) at 1:200 (v/v PBS); polyclonal 
rabbit anti-human 17βHSD type 5 (Abcam, UK) at  2.5 µg/mL; polyclonal rabbit anti-
human androgen receptor (RDI-ANDRECPTabr, Fitzgerald Industries, USA) at 1.6 
µg/ml; and, monoclonal anti-human minichromosome maintenance 2 (MCM-2) (a gift 
from Prof Stephen Dilworth, Imperial College London, UK) at 15 µg/mL. All sections 
were incubated with the primary antibody overnight at 40 C. The complete  protocol is 
described in Chapter 7 (Materials and Methods). In briefly, after a rinsing in PBS, the 
sections were incubated with the secondary antibody at 1:200 dilution (goat anti-
rabbit, for primary antibodies made in rabbit, and goat anti-mouse for those raised in 
mice) for one hour. After washing, the sections were put through an ABC reaction for 
30 minutes and in PBS, incubated with 3,3’-diaminobenzidine tetrahydrochloride 
(DAB)( Zymed, UK) for 3-10 min in the dark, and counterstained with haematoxylin. 
Slides were covered with glass cover slips sealed with DPX mountant (VWR, Poole, 
UK). 
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3.4  RESULTS  
EFFECTS OF PRENATAL ANDROGENISATION ON THE EXPRESSION OF 
STEROIDOGENIC ENZYMES IN THECA CELLS FROM THE OVARY OF 
ADULT EWES 
 
3.4.1  P450c17 expression in adult sheep ovaries. 
General features 
Positive staining for P450c17 was identified in the cytoplasm of theca cells, theca-
lutein cells (corpus luteum) and in stromal cells in the parenchyma (Fig. 3.1). Overall, 
44 follicles at antral stage were analysed: 19 follicles in the controls, accounting for 
1302 theca cells, and 25 follicles in androgenised group, accounting  1440 theca cells. 
No staining was observed in the granulosa or theca cells of preantral follicles. 
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Table 3.1: Adult sheep ovaries: numbers of follicles analysed in each study.  
P=primordial follicles; T= transitional follicles; 1ary =primary follicles; 2ary  =secondary follicles; A= antral follicles. 
 
 
 
 Androgen Receptor MCM-2 P450c17 3βHSDII 17βHSD 
type 5 
 P T 1ary 2ary A P T 1ary 2ary A A A A 
Control 
(n=9) 
46 98 21 4 17 67 66 15 11 17 19 13 25 
              
Androgenised 
(n=11) 
29 71 12 7 25 42 61 14 2 20 25 34 44 
              
Total 75 169 33 11 42 109 127 29 13 37 44 47 69 
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Proportion of theca cells staining for P450c17 
A remarkable increase in the P450c17 labelling in theca cells of antral follicles from 
PA sheep was observed as illustrated in Fig 3.2A. The proportion of theca cell 
staining in PA sheep [mean (95%CI)] was 0.46 (0.28; 0.63), more than three times 
that observed in controls 0.12 (0;0.29), (P = 0.008 Student t test). A higher 
proportion of theca cells expressing P450c17 protein were also found in a subgroup 
of healthy antral follicles from PA sheep (Fig. 3.2C) wherein the proportion of 
positive-staining theca cells [mean (95%CI)] was 0.46 (0.21; 0.71) versus 0.15 
(0;0.33) in the controls (P =0.03 Mann Whitney test). However, in atretic antral 
follicles, disparities in P450c17 labelling [mean (95%CI)] 0.35 (0.17;0.53) in PA 
sheep and controls (0.13 -1;1.8) did not reach significance due to the reduced 
number of controls (Fig 3.2E).  
The intensity of P450c17 expression was also analysed. The amount of theca cells 
staining strongly for P450c17 was consistently increased  in total follicles in PA 
sheep [mean (95%CI) 0.1 (0.01;0.17)] versus control sheep [0.01(0;0.02)] (P = 0.008 
Mann Whitney test)(Fig. 3.2B). Strong labelling for P450c17 protein was greater in 
the subgroups (Fig. 3.2D and 3.2F) although this did not reach statistical 
significance.  
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Fig 3.1: P450c17 protein expression in adult sheep ovaries. 
Staining for P450c17 was classified as weak (black arrow, C) or strong (white arrow, D) and 
identified only in theca cells at antral stage (C,D). Minimal expression was identified in the 
corpus luteum (E). There was no P450c17 staining in granulosa cells at any stage 
(A,B,C,D) or in theca cells  from  growing preantral follicles (B). (F) = negative control.  
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Fig 3.2: Comparison of P450c17 expression in PA and control adult
sheep ovaries.
(TOTAL STAINING) A significant increase in P450c17 protein was detected in theca cells
from the total pool of antral follicles (healthy and atretic) (A) (P= 0.008 Student’s t test) and
in the subgroup of healthy antral follicles(C) (P= 0.03 Mann-Whitney test). No differences
were observed in terms of atretic follicles (E).
(STRONG STAINING). A higher proportion of theca cells in PA sheep ovaries presented
strong staining for P450c17 in the total pool of antral follicles (B)(P= 0.008 Mann-Whitney
test), but not in the subgroups of healthy (D) or atretic follicles(F).
98
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3.4.2  3βHSDII expression in adult sheep ovaries 
General features 
The staining for 3βHSDII was clearly observed in the cytoplasmic portion of theca 
cells and in theca-lutein and granulosa-lutein cells (Fig. 3.3A-C). Faint labelling was 
noted in the cytoplasm of granulosa cells (Fig. 3.3C). For this study, 13 follicles (152 
theca cells) in the control group, and 34 follicles in the androgenised group (635 
theca cells) were examined.  
Proportion of theca cells stained for 3βHSDII. 
PA sheep exhibited increased 3βHSDII staining in theca cells (Fig. 3.4). In the total 
follicle population (healthy and atretic follicles) the proportion of positively stained 
theca cells [mean (95%CI)] did not differ between groups: 0.33 (0.08; 0.58) in 
controls and 0.59(0.32;0.86) in the follicles of PA sheep (P >0.05 Mann-Whitney test) 
(Fig. 3.4A). Importantly, however, the relative amount of 3βHSDII protein expression 
in healthy theca cells was 0.34 (-0.01; 0.7) in controls and more than double in PA 
sheep 0.73 (0.55; 0.91) (P =0.04 Mann Whitney test) (Fig. 3.4C). Expression in 
atretic follicles did not differ between groups; the proportion of staining was 0. 42 (-
0.26; 11) in controls versus 0.73 (0.43;1.0) in PA sheep (Fig. 3.4E).  
3.4.3 17βHSD type 5 expression in adult sheep ovaries 
General features 
Immunohistochemistry revealed 17βHSD type 5 protein in the cytoplasm  of theca 
and granulosa cells (Fig. 3.3).  Overall, 25 follicles in controls and 44 in 
androgenised sheep, and  respectively, 1226  and  2123 theca cells in each group 
was analysed. 
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Proportion of theca cells with positive staining for 17βHSD type 5 
Similar labelling was observed in control and androgenised ovaries. The proportion 
of theca cells among the total number of follicles positively stained for 17βHSD type 
5 protein  [mean (95%CI)] was 0.31 (0.24;0.38) in controls and 0.31 (0.21;0.40) in 
PA sheep (P >0.05 Mann-Whitney test) (Fig. 3.4B). Likewise, similar results were 
detected in healthy follicles in controls [0.35 (0.25;0.45)] and in PA sheep follicles 
[0.25 (0.14; 0.36)] (Fig. 3.4D). No differences were noted in atretic follicles: 0.30 
(0.17;0.43) in controls and 0.31(0.22;0.40) in PA sheep (Fig. 3.4F). 
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Fig 3.3: 3βHSDII and 17βHSD type 5 expression in adult sheep ovaries.  
Positive staining for 3βHSDII was noted in granulosa-lutein (black arrow) and theca-lutein 
cells (white arrow) in the corpus luteum (F) and theca cells in antral follicles (C)(D) and (E). 
Labelling for 3βHSDII was weak in granulosa cells in antral (C)(E) and preantral follicles 
(A)(B). A similar pattern was observed with staining for 17βHSD type 5 in granulosa-lutein 
(black arrow) and theca-lutein (white arrow) in the corpus luteum (K) as well in theca cells 
(J). Granulosa cells from all stages of follicular development expressed some degree of 
positivity for 17βHSD type 5 antibody. Negative controls for 3βHSDII and 17βHSD type 5 
are shown, respectively, in (G) and (L). 
 
 
 
 
Fig 3.4: Comparison of 3βHSDII and for 17βHSD type 5 expression in
PA and control adult sheep ovaries.
A significant increase in the proportion of cells stained for 3βHSDII was observed in
healthy follicles from PA sheep (C), and a trend towards increased  expression of this
protein was  found in total follicles (A), but less substantially in atretic follicles (E).  The
presence of 17βHSD type 5 was similar in all groups of follicles:  total (B), healthy (D),
and atretic (F).
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 healthy                C          D
  atretic                  E           F
NS
NS
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Mann-Whitney
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EFFECTS OF PRENATAL ANDROGENISATION ON EXPRESSION OF THE 
ANDROGEN RECEPTOR AND PROLIFERATION OF GRANULOSA CELLS 
IN THE OVARIES OF ADULT EWES. 
 
 
3.4.4 Androgen receptor (AR) expression in adult sheep ovaries 
General considerations 
Labelling of androgen receptor (AR) was identified mainly in the nucleus with faint 
staining in the cytoplasm (Fig. 3.5).  All tissues (granulosa, theca and stroma) 
expressed this protein as expected, but with different degrees of intensity (Fig. 3.5C-
F). The number of follicles in the control group was186 (4322 granulosa cells) and in 
the androgenised group 144 (5369  granulosa cells).  
Proportion of granulosa cells staining for AR 
An association between follicular GC morphology (flat, intermediate and  cuboidal) 
and AR expression was observed in controls and androgenised ovaries (Fig. 3.6A). 
However PA sheep ovaries exhibited a significantly higher proportion of GCs positive 
labelled GCs at all morphologies when compared to controls (P <0.001, Fisher’s 
exact test) (Fig. 3.6A).  
Enhanced AR immunostaining  was also demonstrated with the progression of 
follicular stage such that at the antral stage, all follicles in both groups expressed AR 
(Fig. 3.6B).  In PA sheep, primordial and transitional follicles had a significantly 
higher proportion [mean (95%CI)] of cells labelling for AR [0.25 (0.18; 0.32)] versus 
controls  [0.10 (0.04; 0.17)] (P <0.0.0001 ANOVA plus Bonferroni test) (Fig. 3.6B). 
No differences in AR labelling were detected in primary, secondary or antral follicles 
between PA and control groups: controls 0.54 (0.15;0.93) and PA sheep: 0.55 
(0.28;0.82);  or in antral follicles: controls: 0.99 (0.99;1) and PA sheep 0.98 
(0.96;0.99) (Fig. 3.6B). 
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Analysis of the proportions of positively  stained  GCs to the total pool of granulosa 
cells stratified by the follicle type and morphology of GCs yeld interesting results. As 
shown in Fig. 3.6C, a substantial proportion of granulosa cells expressed higher 
levels of AR protein at earlier preantral stages in PA sheep. These differences did 
not persist beyond the secondary stage.  
 
 
 
 
 
 
Fig 3.5: Androgen receptor (AR) expression in  adult sheep ovaries. 
Nuclear staining of AR was identified in the granulosa cells at all stages of follicular 
development: primordial (A), secondary (E) and antral stage (F). Cells from the corpus 
luteum (E) and theca cells (C) also expressed AR (A). Negative control, obtained by the 
omission of primary antibody (F).  
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Fig 3.6: Comparison of AR  expression at different stages of follicular 
development in PA adult sheep and its  controls.  
Considering the total pool of follicles, GC staining for AR increased with the progression of 
follicle development, as shown in (B), Regardless of morphology, a higher proportion of 
GCs from PA ovaries expressed AR (P <0.0001, Fisher’s test)(A). Further analysis in which 
follicle developmental stage was taken into account revealed a significant increase in the 
proportion of AR-labelled GCs at early stages of follicular development, particularly at 
transitional phase (P <0.0001; Fisher’s test). (C)-next page. When a per section analysis 
was performed (B), a clear disparity in the ratio of staining in primordial/transitional follicles 
was noted.  Data shown in B refers to mean +SEM. 
 
 
A
B
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Fig 3.6 (cont.) 
C 
P <0.0001 Fisher’s 
exact test 
 
(white bars =control sheep ; 
 black bars = PA sheep)  
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3.4.5  Granulosa cell proliferation (MCM-2) in adult sheep ovaries 
General features 
Staining for minichromosome-2 (MCM-2), a marker for cell proliferation, was 
essentially nuclear and was demonstrated in all cells of the ovary (Fig. 3.7). Overall, 
176 follicles (4626 granulosa cells) in the control group and 139 follicles (4330 
granulosa cells) in the androgenised group were analysed. 
Proportion of GCs stained for MCM-2 
Labelling for MCM-2 increased as follicular stage progressed and the GCs changed 
their morphology (Fig. 3.8A, 3.8B). A remarkable elevation in MCM-2 staining was 
detected with changing   granulosa cell morphology  (from flat to cuboidal). 
Moreover, individual analysis (per section) showed a significant elevation  [mean 
(95%CI)] in MCM-2 positive staining in primordial/transitional follicles of PA sheep 
0.25(0.04; 0.44) versus controls 0.02 (-0.01; 0.06) (P = 0.03, Student’s t test plus 
Welch’s correction). This almost 10-fold difference was also detected at the 
primary/secondary stages where the [mean (95%CI)] was [0.53 (0.22; 0.84)] in PA 
sheep and [0.057 (-0.03;0.14)] in control sheep ovaries (P=0.04 Mann-Whitney test). 
Finally, equal ratios of staining were detected in the antral follicles in both groups 
[0.83(0.64; 1.02)] in PA sheep  compared to [ 0.68 (0.25;1.1)] in control sheep.  
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Fig 3.7: Staining for MCM-2 at different stages of follicular 
development in adult sheep ovaries.  
Nuclear staining for MCM-2 was observed at all stages of follicular development: primordial 
(A),(B), primary(C),(D), secondary (F),(G) and antral stage (H),(I),(J). Presence of positive 
immunolabeling for MCM-2 (black arrow) and its absence (white arrow) in preantral follicles: 
note the  increased proportion of positive cells as follicles progress to the antral stage. Cells 
from mice intestinal mucosa (black arrow) were used as a positive control (K). (L) = 
negative control . 
 
 
 
 
 
 
 
 
 
 
 
 
 I 
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Fig 3.8: Proportion of granulosa cells staining for MCM-2  at different  
stages of follicular development in PA  adult sheep and its controls. 
Considering the total pool of follicles in each group, a significantly greater increase in the 
proportion of MCM-2 staining was observed with the progression of granulosa cell 
morphology (A) and at all preantral stages (C) in PA sheep ovaries (*P<0.0001 Fisher’s 
exact  test). Analysing the staining per section identified a similar trend, statistically 
significant at primary/secondary stages (* P <0.0001 Fisher’s exact test for a single 
morphology – control versus PA sheep).  Data shown in B refers to mean + SEM. 
A 
B 
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Fig 3.8 (Cont.)
C 
P <0.0001 Fisher’s 
exact test 
 
(white bars =control sheep ; 
 black bars = PA sheep) 
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DISCUSSION 
The  findings reported in this chapter indicate  that foetal exposure to androgens is 
associated with disruption of normal steroidogenesis and follicular development at 
adult age. 
In this regard, a marked increase in the proportion of P450c17 in theca cells from 
antral follicles in PA sheep was identified. Theca cells from androgenised sheep 
demonstrated stronger staining than was observed in control sheep, indicating an 
overexpression of this enzyme. The observed results are concordant with the 
upregulation of P450c17 from PCO ovaries described in Chapter 2, and with data in 
the literature showing hypersecretion of androstenedione, augmented transcription, 
greater mRNA content and stability of CYP17A1 in human PCOS. Overall, the 
evidence supports a major role for P450c17 in androgen secretion by the ovary in 
PCOS (Wickenheisser et al., 2006).  The increase in P450c17 in theca cells is  
related to a functional balance of diverse influences, specially hormones and ligands 
such as insulin, LH and  IGF-I; however, constitutive overexpression of this enzyme 
remains a possibility. 
 In addition to P450c17, we did not observe increased expression  of 3βHSDII in the 
total amount of theca cells from all follicles studied, but only in theca cells from 
healthy follicles of androgenised adult sheep. This is partially consistent with the 
study of 3βHSDII in human ovaries wherein no differences were noted between PCO 
and ovaries from normal women. Thus, 3βHSDII is not  rate-limiting, but an enzyme 
necessary to intermediate some steps of androgen synthesis (Chapter 1).   The last 
steroidogenic enzyme evaluated in this chapter was 17βHSDtype 5, an enzyme 
responsible for the direct conversion of androstenedione in testosterone in the ovary. 
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The results reported here show no difference between androgenised and in the 
control sheep.  
Other relevant findings highlighted increased proliferation (represented by MCM-2 
labelling) and AR labelling in granulosa cells from the preantral stage follicles in PA 
sheep. Not surprisingly, comparable results have been reported in PCOS. Increased 
granulosa cell division in preantral follicles as demonstrated by MCM-2 was 
previously described in PCO (Stubbs et al., 2007). It is believed that high proliferation 
of granulosa cells could mediate the disordered dynamics of early follicle growth 
(Stubbs et al., 2007; Franks et al., 2008a). Analogously, the increase in AR 
expression was earlier demonstrated in PCO ovaries at the transitional stage  
(Weber, 2005) (Fig. 3.9). A link between increased granulosa cell proliferation (Ki-67) 
and AR expression has been demonstrated in monkeys (Vendola et al., 1998; 
Vendola et al., 1999), suggesting that a connection on between AR and granulosa 
cell proliferation may also occur in PA sheep.  The results reported in this chapter  
were derived from a different methodology than the work of Ortega et al (2009), 
which analysed the relative expression of AR as determined by the assessment of 
optical density in a streptavidin-biotin immunoperoxidase immunohistochemistry. In 
this report, higher androgen receptor expression was detected only at the antral 
stages (Ortega et al., 2009).  Since the proportions of labelled cells were not 
evaluated, the observed increase in optical density in antral follicles described in 
Ortega’s work does not contradict the  previously reported results. 
In summary, this chapter described the mechanisms by which a normal follicle 
formation and function are disrupted in PA adult sheep. Our results indicate a 
remarkable escalation in granulosa cell proliferation and AR expression at the 
preeantral stages, associated with a significant boost in the presence of microsomal 
enzyme P450c17 in the theca cells from antral follicles.  
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Fig 3.9 Percentage of androgen receptor-positive follicles in 
transitional follicles in cortical biopsies of normal and polycystic 
ovaries. 
Data obtained from Dr. Lisa Webber  (unpublished data)  which included the analysis of AR 
expression in  ovaries from 12 anovulatory women with PCOS and 16 women with normal 
ovarian morphology . 
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CHAPTER 4 
ABNORMALITIES IN STEROIDOGENESIS AND IN 
FOLLICULOGENESIS IN PRENATALLY 
ANDROGENISED SHEEP: (2) STUDIES IN THE 
FETAL SHEEP 
 
 
4.1   INTRODUCTION 
The reasons for, and the mechanisms associated with development of PCOS are still 
unknown.  Despite the fact that PCOS becomes clinically evident at puberty, evidence 
from clinical and experimental studies suggests that higher androgen exposure during 
critical periods of gestation can program the appearance of PCOS traits in adulthood  
(Abbott D, et al 2002).  
To date, at least one recognized situation of developmental programming associated to 
PCOS exists:  the congenital adrenal hyperplasia from 21-hydroxylase deficiency 
(CAH). In this disorder, characterized by high levels of adrenal androgens in utero, the 
prevalence of PCOS in adulthood is considerable high (Rosenfield RL et al, 2007). 
Interestingly, the occurrence of virilizans tumours in women during pregnancy 
practically not affect the conceptus due the strong presence of aromatase enzyme in 
placenta responsible for the conversion of excess of  testosterone in estradiol. 
Prenatal testosterone excess in sheep can lead reproductive and metabolic 
abnormalities at adult age similar to those observed in PCOS. Based on Barker’s 
hypothesis (Chapter 1), it is believed that the ‘developmental programming’ caused by 
androgens can affect diverse traits (neuroendocrine, reproductive, metabolic) which will 
be dysregulated for the entire life of an individual. 
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Therefore, the study of the ‘developmental programming’ of androgens on the 
development of follicles during gestation in animal models seems to provide a good 
translational parallel to explore the mechanisms underlying the pathogenesis of PCOS 
in utero.  Like humans, sheep are monovulatory animals which complete their follicle 
formation during gestation. 
In this chapter, studies were conducted on fetal sheep ovaries at day 90 (d90) of 
gestational life.  At this particular moment, the cortex of the fetal ovary is organized in 
two distinct zones: one containing some germ cells in regressing ovigerous cords, and 
one presenting primordial, transitional  and some primary follicles. For this reason, day 
90 seems to be a critical moment in fetal folliculogenesis and may be affected by 
disruptors as androgens. 
4.2   AIMS 
The aims of this study were: 
1) To investigate the effects of prenatal androgenisation on the follicle formation in fetal 
sheep ovaries at d90 of gestation through the identification of VASA protein  
2) To assess the consequences of androgenisation in utero on expression of androgen 
receptor (AR), P450c17 and 3βHSDII in fetal sheep ovaries.  
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4.3 MATERIALS AND METHODS  
4.3.1  Samples 
Sections of adult sheep ovaries at 20 months and fetal sheep ovaries at d90 of 
gestational life were obtained from a previous study undertaken at the Babraham 
Institute as detailed in Material and Methods (Chapter 7). Overall, twelve of twenty-five 
female sheep received injections of testosterone propionate (100 mg i.m bi-weekly) 
from day 30 to 90 of gestation. The first breeding season generated 20 ewes (11 
androgenised; 9 controls), which were followed and had their ovaries collected at 20 
months. In the second breeding season under the same conditions, the gestation was 
interrupted at day 90 and ovary samples from 12 fetuses (6 androgenised; 6 control) 
were obtained.   
4.3.2. Immunohistochemistry 
Immunohistochemistry protocols employed in this section for other antibodies such as 
androgen receptor antibody, P450c17 antibody and 3βHSDII visualised by HRP-
conjugated 3,3’- diaminobenzidine tetrahydrochloride (DAB) and VASA antibody 
visualised by  AEC are available on Chapter 7.  
4.3.3  Quantitative PCR (qPCR)  
cDNA from day 90 fetal ovaries from 5 controls and 6 PA sheep were employed in a 
series of qPCR  studies. The qPCR reactions were performed using KAPA™SYBR 
FAST Master Mix (2X) ABI Prism (KAPABIOSYSTEMS, USA) and analysed by Applied 
Biosystems ABI-StepONe Plus), as described in details in Chapter 7 (Material and 
Methods). 
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4.4  RESULTS  
EFFECTS OF ANDROGEN TREATMENT ON FETAL FOLLICULOGENESIS 
4.4.1  Follicle formation in PA sheep ovaries at day 90 of gestation (VASA 
Study) 
The objective of this study was to investigate whether androgen treatment affects 
follicle formation in ovaries of PA sheep at day 90 of gestation, just after the end of 
treatment with testosterone. Immunolocalisation of VASA, a specific marker of germ 
cells, was used to distinguish the proportions of germ cells that were enclosed in 
follicles. VASA staining was localized in the cytoplasmic area of germ cells as shown in 
Fig. 4.1.  Overall, 7246 germ cells and 1969 follicles were analysed: 2541 germ cells 
and 897 follicles in ovaries of PA sheep, and 4699 germ cells and 1005 follicles in 
ovaries of control sheep (Table 4.1).  
Remarkably, the proportion of germ cells enclosed in follicles was significantly 
increased in PA sheep fetal ovaries when compared to normal sheep ovaries at day 
90.  As can be seen in Fig. 4.2A, androgenised sheep had almost double the 
proportion of follicles related to germ cells (mean /SD) 0.38  + 0.05 than control sheep 
0.19 + 0.06 (Student’s  t test; P =0.03).  Moreover, when  analysed by follicle stage, PA 
sheep ovaries showed a reduction in the proportion of primordial follicles and an 
increase in growing follicles (transitional and primary) (Fisher’s exact test P < 0.02) 
(Fig. 4.2B).  
4.4.2  Androgen receptor (AR) expression in fetal sheep ovaries 
The presence of AR in granulosa cells was evaluated by qPCR and IHC.  AR positive 
immunolabelling was identified in granulosa cells and stromal cells in the fetal ovary 
sections (Fig. 4.3).  
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No significant differences were detected in the expression of the AR gene in qPCR 
studies (mean of four experiments)(Fig. 4.4A). Nevertheless, a higher proportion of 
primordial and transitional follicles expressed AR protein in PA fetal sheep ovaries in 
IHC (Fig. 4.4B). Similar figures were observed when the proportion of granulosa cells in 
primordial, transitional and primary follicles were taken into account (Fig. 4.4C). In total, 
567 follicles (263 in controls and 304 in androgenised sheep), and 4032 granulosa 
cells (1878 in controls and 2154 in androgenised sheep) were analysed.  
4.4.3   3βHSD type II and  P450c17  expression in fetal sheep ovaries   
The comparison of the expression of HSD3B2 and CYP17A1 between control and PA 
sheep ovaries at day 90 of fetal life was performed through qPCR studies and  
immunohistochemical  studies as  shown in  Figs. 4.5 and 4.6. 
 No differences were seen between controls and androgenised sheep considering the 
gene expression of HSD3B2 in the whole fetal ovaries(mean of four experiments)(Fig. 
4.6A).  However, a significant increase in protein expression in androgenised sheep 
was demonstrated in granulosa cells and in follicles at primordial and transitional 
stages when the proportion of staining for 3βHSDII protein was analysed, as shown in 
Fig. 4.6C and 4.6D.  
Surprisingly, the maternal exposure to androgens was associated a reduction in the 
CYP17A1 gene expression in PA sheep at day 90 (mean of four experiments)(Fig. 
4.6B). The protein presence of P450c17 was very low in the ovary tissue and, 
therefore, not possible to be demonstrated by immunohistochemistry in our studies. 
Two different primary antibodies targeting P450c17 (polyclonal goat antibody against 
human P450c17 and monoclonal mouse antibody against human P450c17) were 
employed unsuccessfully. 
 119 
 
 
 
Table 4.1: Fetal sheep ovaries: numbers of follicles / (germ cells) in the VASA study, and follicles  (positive/total 
GCs) in AR and in 3βHSDII experiments.   
P=primordial follicles; T= transitional follicles; 1ary =primary follicles; 2ary = secondary follicles;  A= antral follicles. 
    
 VASA AR 3βHSDII 
 P T 1ary P T 1ary P T 1ary 
Control 
(n=6) 
383 
(1601) 
537 
(3860) 
76 
(922) 
205 
(140/235) 
169 
(943/1177) 
44 
(416/496) 
 179 
(320/784) 
820 
(861/1424)  
51 
(357/452)  
          
Androgenised 
(n=6) 
243 
(1244) 
562 
(3998) 
91 
(1130) 
71  
(257/315) 
175 
(1026 /1196) 
58 
(595/645)  
94 
(262/419)  
187 
(1116/1372)  
92 
(711/822)  
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Fig. 4.1: Immunolabelling for VASA antibody in fetal sheep ovaries (d90) 
(A) follicle hemisection. (B)(C)(D) areas of positive staining for VASA in germ cells (black 
arrows), not observed in formed follicles (white arrows). (E) = negative control.
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Fig 4.2: Proportion of follicles in PA fetal sheep ovaries and its controls 
(d90). 
Germ cells were imunolabelled with VASA antibody.  A significant increase in the  proportion  
of follicles per amount of germ cells ( mean + SD) was identified  in androgenised sheep 
ovaries at day 90, as shown in (A) and (B). The stratification of follicles according to 
developmental stage (C) showed a significant reduction in primordial, and increase in growing 
follicles (transitional and primary).  
 
 
 
A 
B 
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Fig 4.3: Androgen receptor expression in  fetal sheep ovaries (d90). 
(A) Positive staining was identified mainly in stromal cells (black arrows) and, to a lesser 
extent, in granulosa cells (white arrows). (B) =negative control. 
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Fig 4.4: Comparison of androgen receptor expression at different stages 
of follicular development in PA fetal sheep ovaries and its controls (d90).  
 Gene expression for AR in whole ovaries did not differ between these two groups (A) (mean + 
SD). Nevertheless, small but significant differences were detected in the proportion of follicles 
(B) and granulosa cells (C) staining for AR at non-growing (primordial) and growing stages 
(transitional  and primary stages). Black bars identify prenatally androgenised sheep and white 
bars its controls. 
 A 
C 
B 
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Fig 4.5: 3βHSDII  expression in fetal sheep ovaries (d90). 
A positive staining for 3βHSDII was identified mainly in granulosa cells from growing follicles 
(black arrow) and probably uncertain in germ cells; minimal labeling was demonstrated in the 
stroma. (B)= negative control 
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Fig 4.6: Comparison of 3βHSDII (HSD3B2), P450c17 (CYP17A1) in PA 
and normal sheep ovaries (d90). 
The gene expression for HSD3B2 was similar between PA and control sheep (A); however, a 
significant reduction in CYP17A1  gene expression was identified in androgenised animals 
(B). The labeling for 3βHSDII indicated an increase in the proportion of staining for 3βHSDII in 
follicles (C) and in granulosa cells (C) at primordial, transitional and primary stages. Black 
bars identify prenatally androgenised sheep and white bars its controls.  data shown in A and 
B represents mean /95% CI. 
A 
B 
           C 
 
Chi-Square  
Test 
* P < 0.0001 
         D 
 
Chi-Square  
Test 
* P < 0.0001 
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 4.5  DISCUSSION 
The findings in fetal sheep ovaries were intriguing and rather different from those in 
adult ewes. Nevertheless, they support the idea of disruption of steroidogenesis and 
folliculogenesis being present in the fetal ovary as early as d90 of gestation.  
In our study, a very significant finding was an increase in the proportion of germ cells 
that were enclosed in primordial follicles. This was demonstrable in the ovaries of PA 
sheep after immunolabelling for VASA (a specific marker for germ cells). Moreover, a 
reduction in the proportion (reserve) of primordial follicles and a reciprocal increase 
in the pool of early growing (transitional and primary) follicles was detected in PA 
sheep ovaries, strongly suggesting that androgen treatment accelerates the rate of 
both follicle formation and follicular recruitment in the fetal ovary. These figures 
observed at d90 contrasts with a previous report that employed a stereological 
analysis in HE staining, and which has found similar changes in the pool of 
primordial, transitional and primary follicles in PA only at day 140 of fetal life (and not 
at day 90) (Smith et al., 2009).  
Some reasons for these differences could be listed. First of all, there is good 
evidence that stereological methods are superior to assess number of follicles in 
comparison with the traditional analysis of individual sections. Because of this, it is 
not impossible that errors involving the technique chosen in this study resulted in 
dissimilarities between PA and control sheep. Nevertheless, VASA is recognized as 
a very specific marker for germ cells, resulting in more accurate identification of this 
cells and follicles, as seen Fig. 4.1. Other differences between the studies regards to 
the breed (Dorset versus Suffolk) that might be responsible for variations in 
physiological follicle formation.  
Conflicting results between gene and protein expression observed in fetal sheep 
experiments may be a result of transitional changes in the ovary and/or a product of 
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analysis of unselected genetic material. For instance, an absence of elevation of AR 
gene expression, shown in Fig 4.4A was similarly reported by another  recent paper  
(Hogg et al., 2011). Those results contrasted with the findings of increased 
expression of AR protein in granulosa cells exposed in Fig 4.4 in this thesis and in 
the study of Ortega (Ortega et al, 2009). 
 Pondering that different cells in the same organ express variable levels of AR with 
different responses, in terms of gene expression, to the same insult (e.g stromal cells 
heavily express AR in comparison with germ cells), it is plausible that the direction 
and intensity of gene expression changes differ intrinsically in each type of cell, and 
therefore could not be detected in RNA from whole ovary. Moreover, those 
modifications can be dynamic, and short-lived.   
Another good example of this situation applies to the increased proportion of follicles 
in PA sheep ovaries overexpressing  3βHSDII protein in comparison to control 
sheep, whereas no big differences in gene expression for HSD3B2 were detected. 
The reason to keep high 3βHSDII in some cells would be a shift in the production of 
progesterone (C21), given that other pathways, especially P450c17 are probably 
suppressed by the excess of testosterone.  
In fact, a marked reduction in the gene expression of CYP17A1 observed in our 
samples agreed with a recent report of Hogg et al where CYP17A1 (as well STAR 
and CYP11A1) were downregulated in the fetal ovary (Hogg et al, 2011). 
Unfortunately, the level of P450c17 protein expression was too low to allow analysis 
of the expression of this protein in different types of follicles.  
To sum up, the results in this chapter indicate clearly that multiple abnormalities such 
as disruption of follicle formation and steroidogenesis associated to high AR 
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expression occur during the development of fetal ovaries (d90) in prenatally 
androgenised (PA) sheep.  
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CHAPTER 5 
ADIPOKINES, THEIR RECEPTORS, AND 
ANDROGEN PRODUCTION IN THECA CELLS 
 
5.1   INTRODUCTION  
Evidence from the literature indicates that the ovary is the principal source of 
androgen excess in PCOS (Franks & Mason, 1991; Franks, 1995; Norman et al., 
2007; Chang & Azziz, 2008). Since androgens in the ovary are produced mainly by 
the theca-interstitial layer, the cells in this layer constitute the target for the study of 
hyperandrogenism in PCOS (Burguer, 2002; Young & McNeilly, 2010). 
5.1.1. Theca cells 
Theca cells (TCs) are a group of cells from the heterogeneous interstitial 
compartment in the ovary, which also consists of many other classes of cells 
(Erickson, 1978a; Erickson et al., 1985). TCs are thought to be initially recruited from 
stromal cells via an influence of a signal (or signals) from primary follicles through 
unknown gonadotropin-independent mechanisms (Magoffin & Weitsman, 1993a). By 
the secondary stage of follicle development (i.e., 2 or more layers of granulosa cells), 
the thecal cells have completely encircled the follicle. The close proximity of these 
cells to blood vessels makes them particularly susceptible to short- and long-
feedbacks from hormones in the systemic circulation. Later in their development, TCs 
acquire LH responsiveness and, stimulated by the frequency of the pulses of LH, 
change their form and function, ultimately enhancing their capacity to produce 
androgens (Magoffin & Weitsman, 1993a). As TCs increase in size, their morphology 
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also changes (from flattened to round) and accumulates lipid droplets (Erickson et al., 
1985). Thereafter, TCs become increasingly rich in mitochondria and agranular 
endoplasmic reticula, where key steroidogenic enzymes responsible for the secretion 
of C-19 steroids (P450c17, P450scc, 3βHSDII) are present (Erickson, 1978a). The 
regulation of steroid secretion in TCs is complex and involves an interaction of other 
endocrine and paracrine factors (hormones and related peptides), as summarised in 
Table 2.1 (page 71). Acknowledged stimulators of androgen secretion from TCs are 
LH (principally), insulin, and IGF-1(Magoffin & Weitsman, 1993b; Gilling-Smith et al., 
1994; Spicer et al., 1996; Gilling-Smith et al., 1997a; Spicer & Chamberlain, 1998; 
Magoffin, 2005). 
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5.1.2   Abnormalities in TCs from PCOS 
The principal characteristic of TCs in PCOS is an intrinisic defect of steroidogenesis 
that leads to an increased capacity of androgen biosynthesis. Previous in vitro 
studies have shown a higher secretion of androgens in media from TCs obtained 
from PCO ovaries than those from healthy ovaries (Gilling-Smith et al., 1994; Nelson-
DeGrave et al., 1999), even after several passages in culture (Nelson-DeGrave et al., 
1999). These previous experiments also demonstrated a clear increase in the activity 
of key steroidogenic enzymes or proteins (P450scc, StAR, and P450c17) in TCs from 
PCO ovaries, indicating a substantial up-regulation of these factors in PCOS. 
However, after stimulation with LH, a proportional (%) increase in androgen secretion 
is observed in TCs from PCOS and healthy women (Erickson et al., 1985; Gilling-
Smith et al., 1994). These results suggest that a higher basal concentration of 
androgens is the essential abnormality in hyperandrogenism in PCOS. Additional 
studies have demonstrated that treatment with LH elicits a significant boost of 
androgens in primary culture of TCs isolated from PCOs, and even higher levels of 
androgens have been detected upon co-treatment of these cells with IGF-I (Chang 
2010). Nevertheless, previous reports have failed to identify a synergy between 
insulin and LH in androstenedione secretion by TCs from PCOs (Bergh et al., 1993a; 
Chang, 2010).  
The molecular mechanisms underlying androgen production in PCOS TCs remain 
unclear, and few pathways have been explored to date. Studies from Nelson-
Degrave (2005) demonstrated a reduction in the MAPK signalling pathway 
manifested by an approximately 50% decrease in the phosphorylation of MEK1 and 
Erk, which was associated with higher androgen production by PCO TCs (Nelson-
Degrave et al., 2005; Wickenheisser et al., 2006). The same research group 
demonstrated an increase of CYP17 after treatment of PCO TCs with MEK1/2 
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inhibitor (PD98059), indicating that blocking the MAPK signalling pathway could 
enhance androgens synthesis. Other studies showing independent stimulation of 
androgen synthesis by insulin in TCs through the inositolglycan pathway have also 
been reported (Nestler, 1998; Baillargeon et al., 2004). However, to our knowledge, 
no conclusive results on the underlying mechanisms of androgen production in PCOS 
TCs have been published to date. It seems likely that functional disruption of TCs in 
ovaries affected by PCOS is derived from numerous, simultaneous disarrangements. 
Modifications in the macro endocrine environment leading to changes in the secretory 
patterns of LH, insulin, and IGF-I have been well described in subgroups of PCOS 
patients (Apter DA, 1994; Morales AJ, 1996). Hyperandrogenism is clearly 
accentuated in women with PCOS in the presence of obesity and/or insulin 
resistance, cases in which steroidogenic enzymes and its co-factors are also 
increased (Franks, 1995; Ehrman, 2005; Franks et al., 2006).  
5.1.3   Possible mechanisms of steroidogenesis control: LHR 
LH has critical roles in androgen secretion in TCs. Its biological actions are mediated 
by the LH/human chorionic gonadotropin receptor (LHR), a member of G-protein 
coupled receptors (GPCR) (McFarland et al., 1989). Under stimulation of its ligand for 
extended time, LHR become desensitized by a series of events not fully understood 
(Hoffman et al, 1991; Peltoketo, H et al.,2011). 
Recent studies from Menon et al. suggested that LH can promote LHR down-
regulation through stimulation of an RNA binding protein for LHR (LRBP) via Erk 1/2 
signalling (Menon et al., 2011). According to the same authors, the identified LRBP 
was determined to be mevalonate kinase (MVK), an enzyme involved in the synthesis 
of cholesterol de novo (Nair AK, 2004). Furthermore, recent studies from this group 
have shown that activation and/or inhibition of Erk1/2 stimulates or decreases LHR 
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expression, respectively (Wang et al., 2007; Menon et al., 2011). Nevertheless, there 
continues to be a lack of information about the specificity of MVK, particularly 
concerning the question about whether it is the only mechanism for LHR inhibition, 
and whether MVK repercussions are not a result of secondary disturbances (e.g.  
‘trafficking’ effect).  
 5.1.4   Adipokines, PCOS, and steroidogenesis 
 Adipokines are cytokine products of fat that regulate energy homeostasis and insulin 
sensitivity (Campos et al., 2008). Since hyperandrogenism is accentuated in PCOS in 
the presence of obesity, researchers have begun exploring a possible role for 
adipokines as a linker between reproductive and metabolic abnormalities. In this 
regard, women with PCOS have been found to demonstrate a considerable 
disrturbance in their serum levels of many adipokines: increased leptin (Brzechffa et 
al., 1996; Pusalkar et al., 2010; Yildizhan et al., 2011), increased visfatin (Panidis et 
al., 2008; Carmina et al., 2009; Plati et al., 2010; Yildiz et al., 2010; Cekmez et al., 
2011; Dikmen et al., 2011), increased resistin (Panidis et al., 2004; Escobar-Morreale 
et al., 2006; Yilmaz et al., 2009) increased RBP4 (Yildizhan et al., ; Carmina et al., 
2009), reduced adiponectin (Carmina et al., 2009; Cekmez et al., 2011),  and more 
recently, increased appelin (Cekmez et al., 2011). 
Nevertheless, few studies have addressed the effects of adipokines on reproductive 
tissues. However, in a series of independent studies, Spicer et al. evaluated the 
effects of adiponectin, resistin, and leptin on ovarian steroidogenesis (Spicer & 
Francisco, 1998; Spicer et al., 2000; Lagaly et al., 2008). In one of these studies, a 
primary bovine TC culture was used as a model to investigate the effects of 
adiponectin, an insulin-sensitising adipokine produced mainly by white subcutaneous 
depot, on androgen production. In TCs cultured in the presence of LH and insulin 
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(100 ng/ml of each), treatment with adiponectin (3 µg/ml) caused a decrease in 
associated androstenedione and progesterone production, as well as a significant 
decrease in LHR and CYP17A1 gene expression (Lagaly et al., 2008). However, 
under the same experimental conditions in a separate study, no differences were 
evident upon treatment of TCs with resistin (in the presence of 100 ng/ml LH and 100 
ng/ml insulin)(Spicer et al., 2011). Furthermore, weak inhibitory effects were 
observed upon treatment of TCs with leptin (in the presence of 100 ng/ml LH) (Spicer 
& Francisco, 1998). To date, these findings of Spicer group have been neither 
confirmed nor contradicted. 
5.1.5   Adipokine receptors in PCOS 
Adipokine receptors have been partially characterised in humans. For example, 
adiponectin receptors (adiponectin receptor 1 [AdipoR1], adiponectin receptor 2 
[AdipoR2], and T-cadherin) and leptin receptor (LR isoforms) are reportedly localised 
in diverse human tissues such as muscle, liver, subcutaneous and omental fat, brain, 
lung (Goldstein & Scalia, 2004; Takemura et al., 2006; Li et al., 2007; Petridou et al., 
2007; Carmina et al., 2008; Psilopanagioti et al., 2009; Brochu-Gaudreau et al., 2010; 
Michalakis & Segars, 2010), including those in the ovary (Loffler et al., 2001; 
Chabrolle et al., 2009). However, the receptors for other adipokines (e.g. visfatin, 
resistin, RBP4, vaspin, omentin, chemerin) remain to be identified. Furthermore, the 
expression of adiponectin receptors has never been compared between ovaries 
affected by PCOS and those in healthy women.   
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5.2  AIMS 
The aims of this study were: 
1) To evaluate the effects of adiponectin and other adipokines (leptin, visfatin, 
resistin) on bovine TC androgen production; 
2) To explore the expression of adiponectin receptors in human PCOS ovaries and in 
PA sheep ovaries compared to controls. 
5.3   MATERIALS AND METHODS 
5.3.1  Human ovaries 
Whole ovary tissue samples were obtained from the histopathology tissue bank of St 
Mary’s Hospital (London, UK). The samples were from patients subjected to 
oophorectomy for non-malignant gynaecological disorders from 1993 to 2000 (Stubbs 
et al., 2005), as detailed in Chapter 7 (Material and Methods). Three groups were 
defined: 1) normal women, indicated by normal ovarian morphology and evidence of 
ovulation (corpora lutea and/or corpora albicantia); 2) ovulatory PCO, defined by 
PCOs with evidence of ovulation (same as controls); and 3) anovulatory PCO, 
identified by the presence of PCOs without evidence of ovulation. Overall, 26 
sections from human ovaries were obtained: normal women (n = 10), ovulatory PCO 
(n = 11), and anovulatory PCO (n = 5).  
Fresh granulosa cells for total RNA extraction were obtained from primary culture of 
cells extracted from follicles of women undergoing treatments at the IVF Unit at 
Hammersmith Hospital (London, United Kingdom) between 2008 and 2010. All 
patients whose samples were included in this study signed an informed consent 
document under a protocol approved by the Local Research Ethics Committee.  
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5.3.2  Sheep ovaries 
Sections from 12 fetal sheep ovaries at day 90 of gestational life (6 control; 6 
prenatally androgenised) and from 20 sheep ovaries at 20 months of age (9 control; 
11 prenatally androgenised) were obtained as previously described.  
5.3.3  Immunohistochemistry 
Detailed protocols for immunohistochemistry, analysis, and follicle classification 
employed in the experiments in this chapter are available in the Material and Methods 
section (Chapter 7). 
Immunohistochemistry was carried out using primary antibodies against human 
antigens (rabbit anti-human AdipoR1 and rabbit anti-human AdipoR2; both from 
Phoenix Pharmaceuticals Inc., Burlingame, CA, USA). A peroxidase-conjugated 
avidin-biotin complex and 3,3′-diaminobenzidine tetrahydrochloride were used to 
permit visualisation of labelled complexes, which were counterstained with 
haematoxylin (2 min), rehydrated in alcohol (70%, 95%, and 100%) and then 
mounted in DPX. As a negative control, the primary antibody was omitted from the 
protocol.  
5.3.4  RNA Isolation, and RT-PCR 
Total RNA was extracted from both human and bovine granulosa cells (GCs) in 
culture and frozen isolated human and bovine TCs using Trizol reagent, according to 
the manufacturer’s instructions. AdipoR1 and AdipoR2 expression was measured by 
reverse transcription-polymerase chain reaction (RT-PCR) in duplicate with three 
different samples. Specific primers pairs used for amplification were at follows: 
ADIPOR1 sense, 5′-ACATCTGGACC CATCTGCTT; ADIPOR1 anti-sense, 5′-
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TGAATGACAATAGACGGTGTGA; ADIPOR2 sense, 5′-ACACAGAAACAGG 
CAACATTT; ADIPOR2 anti-sense, 5′- TTTAGAGAAGAGCCGAGAGACC. 
5.3.5   Bovine TC culture 
 As described in Chapter 7, ovaries from adult non-pregnant cattle were obtained 
directly from the abbatoir (Anglo-Dutch farms Ltd., Charing, UK) and transported to 
the laboratory at 38°C in medium.  Briefly, TCs were isolated from large antral 
follicles in bovine ovaries, and, after being digested in collagenase and DNase, were 
plated in 10-cm dishes and allowed to grow in D-MEM/F12 medium containing 10% 
FBS, 1µg/ml Transferrin (Sigma, Gillingham, UK), 1 ng/ml Selenium (Sigma, 
Gillingham, UK), 1 µg/ml Linoleic acid (Sigma, Gillingham, UK), 100 UI/ml Penicilin 
(invitrogen, Paisley, UK), 100 µg/ml Streptomycin (Invitrogen, Paisley, UK), 0.5 µg/ml 
Gentamicin (Sigma, Gillingham, UK), and 2.5 µg/ml Amphotericin (Sigma, Gillingham, 
UK). After 48 hours at 38.5 °C, cells were detached with Accutase (Sigma, 
Gillingham, UK), transferred into the same conditions in new 6-, 12-, 24-, or 96-well 
plates, and maintained for more than 24 h. Before administering treatments, the wells 
were washed twice in medium including all previous components except serum. At 
the end of the experiments, medium was collected and the number of viable cells 
present in each well was estimated using an ATP assay (CellTiter-Glo®, Promega, 
Fitchburg, USA).  
 5.3.6  Adiponectin receptor gene knockdown 
 A knockdown of the genes encoding proteins ADIPOR1 and ADIPOR2 or their 
common effector, an adaptor protein containing a pleckstrin homology domain 
(APPL1), was executed by using small-interfering RNA (siRNA) (Dharmacon Accel® 
siRNA; Dharmacon, Thermo Scientific Inc., Europe). In summary, bovine TCs were 
  
138 
plated at 1.5 x 104 cells per 0.14 cm2, and incubated for 72 h with either 1 nM siRNA 
specific for the respective targets (ADIPOR1, ADIPOR2, or APPl-1), scrambled 
siRNA, or medium only containing 10 ng/ml LH. At this time, images were taken of 
the fluorescent scrambled siRNA to confirm successful transfection had taken place. 
Following this step, medium was removed and replaced with fresh medium (D-
MEM/F12 medium containing 1µg/ml Transferrin, 1 ng/ml Selenium, 1 µg/ml Linoleic 
acid), 100 UI/ml Penicilin, 100 µg/ml Streptomycin, 0.5 µg/ml Gentamicin) with or 
without adiponectin (3 µg/ml), and was incubated at 38.5 °C for an additional 24 h, 
when the experiment was ended. Medium was collected for use in androstenedione 
measurement, which was adjusted for cell viability and mRNA was extracted. 
A comprehensive description of the protocol for primary culture of bovine TCs and 
details about the protocols used for total RNA extraction, small-interfering RNA 
(siRNA), qPCR and immunohistochemistry is part of Chapter 7.  
 5.4  RESULTS 
 BOVINE TC CULTURE   
5.4.1  Characterization of theca cells  
Changes in morphology in TCs in culture (24−72 h) 
TCs exhibited typical changes in their monolayer arrangement after 48−72 h of 
culture at standard culture conditions (38.5 °C, 5% CO2) in medium containing D-
MEM/F12, 1µg/ml Transferrin, 1 ng/ml Selenium, 1 µg/ml Linoleic acid), 100 UI/ml 
Penicilin, 100 µg/ml Streptomycin, 0.5 µg/ml Gentamicin.  After reaching confluence, 
the cells began to present more vesicles in the cytoplasm and to modify their initial 
triangular appearance  into round-shape cells, creating areas of cell agregation with a 
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3-dimensional expansion (Fig 5.1), as previously characterised in the literature 
(Shores, 2000).  
Purity of cells  
The identity and purity of isolated TCs were assessed  in bovine TC samples using 
two different methods (Fig 5.2): 1) demonstration of the presence of P450c17 protein 
(absent in GCs); 2) indication of the presence of LHR and the absence of FSH 
receptors by reverse-transcriptase PCR (RT-PCR).  
Immunofluorescence indicated the presence of P450c17 protein in bovine theca cells. 
As shown in Fig 5.2, a fluorescent labelling was localized in the cytoplasm of theca 
cells (and absent in negative controls). Gene expression for LHR and FSHR were 
also assessed by RT-PCR in samples of bovine granulosa and theca cells 
monolayers. TCs demonstrated a strong expression for LHR and virtually no FSHR, 
suggesting a  minimal presence of GCs in TCs growing in vitro.  
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5.1:  Primary bovine theca cells in culture.  
A) theca cells appearance in 10cm dishes, before transfer to 96 or 24 well plates; (B) theca 
cells after 24 hours of treatment with insulin (100 ng/ml) and LH (100 ng/ml) – note the 
increase in the secretory activity in cells, characterized by the presence of numerous 
vesicles. (C, D, E) After 48 h of treatment, the architecture of the monolayer changes with 
formation of cells conglomerates in 3 dimensions that persists over 72 hours (F,G,H,I).(X 
magnification).  
(X 10) (X 40) 
(X 4) (X 20) (X 60) 
(X 4) (X 20) (X 60) 
(X 20) 
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Fig. 5.2: Characterization of the presence of P450c17 (CYP17A1) in 
monolayers of bovine theca cells after 48 hours of culture. 
Imunofluorescence for P450c17 identified labelling in the cytoplasm (B),(C). Nuclear 
counterstaining with DAPI in the presence (A) or absence of antibody (D). Negative control 
=(E).  Results of RT-PCR demonstrate  CYP17A1 and LHR gene expression and almost 
complete absence of FSHR expression suggested a very low GC presence in cell culture 
monolayers (F). 
 
 F 
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5.4.2  Optimisation of bovine TC culture 
TCs obtained from bovine ovaries were originally cultured in a variety of different 
conditions, as described in the section below, to identify the optimised growth 
conditions to be included in the standard protocol.  
Effect of temperature 
The influence of the temperature of culture on androgen levels in media in primary 
bovine TC culture was evaluated because some experiments in the existing literature 
were performed at 38.5 °C (the corporal temperature in cows) and others at 37 °C. 
Samples obtained from the same original pool of bovine TCs were treated with insulin 
and LH (100 ng/ml each) and allowed to grow for 24 h in incubators adjusted to 
distinct temperatures (38.5 or 37 °C). At the end of the experiment, androstenedione 
levels in the media were measured and adjusted for the number of viable cells 
present. As shown in Fig. 5.3, there was a significant effect of temperature on the 
steroid levels. Cultured bovine TCs treated at 38.5 °C (mean ± SD; 1.3 ± 0.29 ng/ml) 
produced significantly more androstenedione than cells treated at 37 °C (0.82 ± 0.21 
ng/ml) (P = 0.002; Student’s t-test).  
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Fig 5.3: Effects of different temperatures on androstenedione secretion 
by bovine theca cells.  
Theca cells at same plating density were allowed to grow at 38.5 0C or 37.0 0C in media with 
insulin 100ng/ml and LH 100ng/ml. After 24 h, androstenedione levels in media were 
significantly higher in the group of cells set up at 38.5 0C (P =0.002, Student’s t test). Data 
shown mean + SD. 
 
Cell density 
The effects of different cell densities (treated with insulin and LH) on androgen 
production over 24 h were also accessed. As reflected in Fig. 5.4, bovine TCs were 
plated at variable densities (2.0 x 104, 15.0 x 104, 7.5 x 104, 3.75 x 104, and 1.87 x 
104cells per 0.14 cm2) and allowed to grow for 24 h under standard culture conditions 
(38.5 °C, 5% CO2). After this period of time, cells were treated with serum-free media 
(D-MEM/F12 medium containing 1µg/ml Transferrin, 1 ng/ml Selenium, 1 µg/ml 
Linoleic acid, 100 UI/ml Penicilin, 100 µg/ml Streptomycin, 0.5 µg/ml Gentamicin), 
supplemented with insulin and LH (100 ng/ml of each) for an additional 24 h, and the 
androstenedione levels were measured at the end of the experiment. 
Androstenedione levels in the medium were directly proportional to the density of 
cells plated initially; thus, a density of 2.0 x 104 cells per cm2 in 0.14 cm2 resulted in 
the highest androgen production (Fig 5.4). Therefore, this quantity of cells was 
deemed as an ideal plating density for the other experiments in this study. 
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Fig 5.4: Effect of the cell density on the measurement of cell viability 
assay (CellTitter-Glo) and in the levels of androstenedione in medium.  
Primary theca cells were plated at different densities in 96 well plates under standard 
conditions for 24 hours. At the end of the experiment, an assay to estimate the amount of 
viable cells was performed and shown a proportional reduction in the luminescence 
(arbitrary units) with the decline of number of cells (A). The measurement of 
androstenedione levels by ELISA detected a reduction in the amount of steroid produced 
with a decrease in the number of cells plated originally (B). Background refers to values in 
the absence of cells (only medium). Results  represent the mean + SEM. 
A 
B 
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Effects of different treatments on androstenedione production in bovine TC 
culture 
The stimulatory effects of insulin and LH administration on androstenedione  
production were assessed in bovine TCs in dose-response experiments.  
In TCs growing in serum-free media, as described in section 5.4.1. (D-MEM/F12, 
1µg/ml Transferrin, 1 ng/ml Selenium, 1 µg/ml Linoleic acid, 100 UI/ml Penicilln, 100 
µg/ml Streptomycin, 0.5 µg/ml Gentamicin)  the presence of 10-fold increasing 
concentrations of insulin (10, 100, or 1000 ng/ml) enhanced androstenedione levels 
progressively without reaching a plateau (Fig. 5.5A). In contrast, TCs treated with LH 
(10, 100, or 1000 ng/ml) exhibited a different pattern, showing an early peak of 
androstenedione at 10 ng/ml with decreased levels at higher concentrations (Fig. 
5.5B). When TCs were treated with a combination of these two treatments (100 ng/ml 
LH and 100 ng/ml insulin), a small positive effect on androstenedione production was 
observed (Fig. 5.5C). Taking these results into account, the administration of both LH 
and insulin (each at 100 ng/ml) was selected as the optimum treatment for stimulating 
androgen production in bovine TCs. Alternatively, in those specific experiments 
where it was necessary to avoid influence of insulin signalling, incubation of TCs in 
serum-free medium as described before supplemented with LH (10 ng/ml) alone was 
considered the best choice.    
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Fig 5.5: Androstenedione levels in medium in dose-response curves to 
insulin, luteinizing hormone (LH), and variable insulin concentrations 
plus LH (100 ng/ml).  
Individual treatments for 24 hours with insulin (A), LH (B), or insulin plus LH (C) in bovine 
theca cells lead to an increase in the androstenedione  secretion in the medium. Data shown 
mean + SEM.  
B 
  A 
C 
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5.4.3 Effects of different adipokines (adiponectin, resistin, leptin, 
visfatin) on androgen secretion by TCs 
To explore the effects of adipokine properties on TC steroidogenesis, two different 
approaches were used: 1) investigation of a possible stimulatory effect of adipokines 
in the absence of LH and insulin; 2) exploration of a possible suppressive effect of 
adipokines in the presence of recognised stimulators of steroidogenesis (insulin 
and/or LH).  
Effects of adipokines (adiponectin, visfatin, resistin and leptin) on bovine TC 
steroidogenesis in the absence of LH or insulin. 
 TCs extracted from large follicles of bovine ovaries were plated at density of 1.5 × 
105 cells per 1.9 cm2 and allowed to grow in medium (as reported above) for 24 h. 
Subsequently, the wells were washed twice with serum-free medium (same 
composition except by the omission of serum) and the cells were incubated for 24 h  
adding  different concentrations (30, 300, and 600 ng/ml) of resistin, visfatin, leptin, or 
adiponectin (0.3, 1, and 3 µg/ml). After 24 h, the medium in the wells was collected 
and the androstenedione levels measured by ELISA; values were corrected by the 
number of viable cells present in the corresponding wells (each well), which was 
estimated by an ATP assay (CellTiter-Glo®). 
As shown in Fig 5.6 (A and D), a statistically significant increase in androstenedione 
levels in the medium was observed in TCs treated with resistin (300 or 600 ng/ml) or 
adiponectin (3 µg/ml). Androstenedione concentrations (mean ± SD) in medium of 
TCs treated with resistin at 300 or 600 ng/ml were 0.16 ± 0.01 ng/ml and 0.19 ± 0.03 
ng/ml, respectively, whereas levels in control medium were 0.08 ± 0.01 ng/ml (P < 
0.001; Kruskal-Wallis test plus Dunn’s multiple comparison test). Furthermore, 
adiponectin at 3 µg/ml elicited stimulation increasing androstenedione levels in media 
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to 0.19 ± 0.04, which were also significantly greater than the value of the same 
control group (P = 0.01; Kruskal-Wallis test plus Dunn’s multiple comparison test). 
However, no differences were noted upon treatment of cells with visfatin or leptin at 
concentrations up to supraphysiological doses (600 ng/ml), as shown in Fig 5.6 (B 
and C). 
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Fig 5.6: Effects of different adipokines (resistin, visfatin, leptin, and 
adiponectin) on androstenedione levels (medium) in the absence of 
luteinizing hormone and insulin.   
Theca cells were incubated with resistin (A), visfatin (B), leptin (C) and adiponectin (D) at 
three different concentrations representing serum levels within the physiological range (30 
ng/ml), high (300 ng/ml) and supraphysiological (600 ng/ml). Adiponectin (D) concentrations 
were based on a previous study in the literature (Lagally et al 2008). After 24 hours of 
treatment, androstenedione levels in medium were significantly elevated in theca cells 
treated with resistin (A) and adiponectin (D) at higher doses, but not with other adipokines.  
Results are shown as median /IQ range. 
A 
    C 
 
D 
B 
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Effects of adipokines (adiponectin, visfatin, resistin, and leptin) on bovine TC 
steroidogenesis in the presence of LH and insulin 
TCs extracted from large follicles of bovine ovaries were initially plated in 96 and 24 
well plates using the same standard conditions described previously in this chapter 
(in 10% FBS). After this step, the wells were washed twice in media medium without 
serum and the cells were incubated for 24 h in serum-free media as described above 
with both LH and insulin (100 ng/ml each), in addition to one of the following 
treatments: resistin (300 ng/ml), visfatin (600 ng/ml), leptin (600 ng/ml), or 
adiponectin (3 µg/ml). At the end of the experiment, androstenedione levels were 
determined by ELISA and the results corrected  for the amount of viable cells present 
in the corresponding wells (each and every one) as described before (5.3.5).  
 A small but significant increase in the androstenedione levels was observed in the 
TCs treated with leptin and visfatin (but not resistin). In leptin- and visfatin-treated 
cells, the androstenedione levels in the medium were (mean ± SD) 0.63 ± 0.04 and 
0.64 ± 0.08, respectively, which were both significantly higher than the levels found in 
the controls 0.54 ± 0.08 (P = 0.001; Kruskal Wallis test plus Dunn’s multiple 
comparison test). Remarkably, in contrast to these results, incubation of TCs with 
adiponectin in the presence of LH and insulin elicited a marked decrease in 
androstenedione levels in the media (mean ± SD) 0.23 ± 0.09 (Fig. 5.7). 
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Fig 5.7: Effects of different adipokines (resistin, visfatin, leptin, and 
adiponectin) on androstenedione levels in medium in the presence of 
luteinizing hormone (100 ng/ml) and insulin (100 ng/ml). 
Compared to controls, adiponectin treatment elicited a clear decrease in the levels of 
androstenedione in media where bovine theca cells were co-treated with LH (100 ng/ml) and 
insulin (100ng/ml). A significant increase in androstenedione production was noted when 
leptin or visfatin were added to theca cells in similar conditions. Data shown mean + SEM. 
 
Effects of adipokines (adiponectin, visfatin, resistin, and leptin) on bovine TC 
steroidogenesis in the presence of LH alone 
TCs, which were cultured as described above, were rinsed twice in serum-free media 
and allowed to grow for 24 h with resistin (300 ng/ml), visfatin (600 ng/ml), leptin (600 
ng/ml), or adiponectin (3 µg/ml) in the presence of 10 ng/ml LH. After the cells were 
treated in these conditions, medium was collected, and was used to measure the 
androstenedione levels by ELISA. The measured androstenedione levels were 
corrected for the number of viable cells as described previously.  
A persistence of the suppressive effect of adiponectin on androgen secretion was 
noted in LH-treated cells (mean ± SD; 0.77 ± 0.11 ng/ml) compared with control cells 
(1.57 ± 0.26 ng/ml), whereas the increases in leptin-treated (1.84 ± 0.34 ng/ml) and 
visfatin-treated cells (1.64 ± 0.24 ng/ml) did not reach statistical significance (Fig. 
5.8).  
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Fig 5.8: Effects of different adipokines (resistin, visfatin, leptin, and 
adiponectin) on the androstenedione levels in medium in the presence 
of luteinizing hormone (10 ng/ml). 
Differently from the others adipokines evaluated (resistin, visfatin and leptin), adiponectin 
elicited a clear decrease in androstenedione levels in bovine theca cells co-treated with LH 
(10 ng/ml). Data shown mean + SD.  
 
Effects of adiponectin treatment on the gene expression of steroidogenic 
enzymes (CYP11A1, CYP17A1), protein (STAR) and LHR 
The effects of adiponectin on the gene expression relevant to LHR and key 
steroidogenic enzymes and protein in bovine TCs were assessed by qPCR. As 
shown in Fig. 5.9, after 24 h of treatment with adiponectin, there were significant 
decreases in the expression of StAR (STAR; 74%)(P=0.028), P450c17 (CYP17; 
48%)(P=0.02), P450 side-chain cleavage (CYP11A; 72%)(P=0.012), and LHR (LHR; 
70%)(P= 0.02). 
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Fig 5.9: Gene expression of LH receptor (LHR) and key steroidogenic 
enzymes (CYP17A1, CYP11A1) and protein (STAR) after 24 h of 
treatment with adiponectin  in the presence of luteinizing hormone (10 
ng/ml), in the presence of LH (10 ng/ml). 
A marked decrease in gene expression of LHR (A), CYP17A1 (D), STAR (B) and CYP11A1 
(C) was observed in bovine  theca cells  after 24-hour treatment  with  adiponectin  (3µg/ml). 
Results shown  mean/95% CI. 
A 
B 
C 
D 
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5.4.4   Knockdown of ADIPOR1, ADIPOR2, and APPL1 
To address the impact of adiponectin on steroid production in TCs, a knockdown of 
ADIPOR1, ADIPOR2, and their common effector, APPL1, genes was carried out 
using corresponding SiRNA (Dharmacon Accel SiRNA; Dharmacon, Thermo 
Scientific Inc., UK). The full protocol, including the oligo sequences that were used, is 
detailed in Chapter 7 (Material and Methods). Briefly, bovine TCs plated at 1.5 x 104 
cells per 0.14 cm2 were incubated with either 1 nM SiRNA specific to its target 
(ADIPOR1, ADIPOR2, or APPL1), 1 nM scrambled SiRNA, or supplemented medium 
containing LH (10 ng/ml) for 72 h. At the end of 72 h, images of fluorescent 
scrambled SiRNA were taken to confirm successful transfection (Fig. 5.10). Medium 
was removed and replaced with fresh medium either with or without adiponectin (3 
µg/ml), which was allowed to incubate for an additional 24 h, when the experiment 
was finalised. Medium was collected for assessment of androstenedione levels, 
which were adjusted for cell viability as indicated for previous experiments. In 
addition, mRNA was extracted in selected wells.  As expected, TCs treated with 
adiponectin shown a decline in androstenedione production, exhibiting a reduction of 
about 40% compared with their basal level 24 h before treatment  (Fig. 5.11). A 
similar decrease (30% reduction) was observed upon treatment with scrambled 
control SiRNA. In contrast with these results, all knockdown groups exhibited 
increases in androstenedione secretion, reaching above 100%, namely 119% to 
136% for ADIPOR1 SiRNA, 170% to 266% for ADIPOR2 SiRNA, and 177% and 
257% for APPL1 (Fig 5.11). 
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Fig 5.10: Estimation of the efficiency of transfection using a scrambled 
siRNA  sequence with a fluorescent marker attached.  
After 48 hours of culture, theca cells transfected with a fluorescent scramble siRNA exhibited 
a particular labelling at fluorescent microscopy indicating that a significant amount of cells 
(seen in the brightfield microscopy) have been successfully target. On the bottom, a 
negative control not treated with this fluorescent scramble siRNA. 
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Fig 5.11: Androstenedione variation (%) compared to basal values after 
24-h  treatment with adiponectin.  
Numbers 1 and 2 refer to oligo sequences for siRNA knockdown for each target (ADIPOR1, 
ADIPOR2 or APPL1) available in details in Chapter 7.  After 24-h treatment with adiponectin 
(3 µg/ml) a relative decrease in androstenedione secretion was observed in control and in 
the scrambled group while an increase over 100% was detected in all siRNA groups.  
Results are represented by median /IQ range. 
 
MVK and LHR gene expression 
To explore the possible mechanisms underlying LHR down-regulation by adiponectin, 
a time-course experiment was carried out. For these experiments, TCs were divided 
into four groups: siRNA for APPL1 TCs treated with adiponectin (group 1), scrambled 
siRNA TCs treated with adiponectin (group 2), adiponectin-treated control cells 
(group 3), and adiponectin-untreated control cells (group 4). Cells in groups 1 and 2 
were allowed to grow in serum-free medium for 72 h with APPL-1 siRNA or 
scrambled siRNA, respectively; cells in groups 3 and 4 were grown in the absence of 
SiRNA. After 72 h, the medium was removed, the wells were washed twice with 
serum-free medium as described above, and adiponectin (3 µg/ml) and LH (10 ng/ml) 
were both added to TCs in groups 1, 2, and 3. TCs in group 4 were incubated only in 
  
157 
LH (10 ng/ml) until the end of the experiment. Samples of mRNA were extracted for 
gene expression analysis at different intervals in the study (0, 2, 12, and 24 h). 
As shown in Figs 5.12 and 5.13, adiponectin treatment promoted MVK gene 
expression, with an initial increase at 2 h, followed by a plateau between 2 and 12 h, 
and finally a sharp decline by 24 h. In contrast, TCs treated with APPL1 SiRNA 
exhibited time-related progression of MVK expression, which was statistically 
significant from the control TCs and the TCs treated with scrambled SiRNA. MVK 
gene expression in these groups displayed little variation over 24 h.  
LHR expression in response to adiponectin treatment was also intriguing. 
Adiponectin-treated cells exhibited a progressive decline of LHR, reaching the lowest 
level at 24 h. TCs treated with APPL-1 SiRNA demonstrated an initial decrease in 
LHR expression, followed by recuperation, and finally ended with higher levels than in 
the control and scrambled groups.  The knockdown efficiency  for APPL-1 estimated 
by qPCR  was 50%. 
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Fig 5.12: Effect of adiponectin on mevalonate kinase (MVK) gene 
expression (0-24h). 
Theca cells were cultured for 72h in serum-free medium in four different groups: group 1 
(siRNA APPL1- knockdown of APPL1 gene); group 2 (scrambled siRNA); group 3 
(adiponectin) and group 4 (control). All groups were kept in serum-free medium for the initial 
72 hours. After this time, wells were washed twice with serum free medium and groups 1, 2 
and 3 were treated  for 24 hours with adiponectin (3µg/ml). Group 4 (control) was incubated 
for the same time in serum-free medium. Theca cells treated with adiponectin (group 3) 
exhibited an initial rise after 2 hours followed by a plateau (12 hours) and then a consistent 
decline in MVK gene expression over 24 hours. Minimal variation was observed between 
controls and scrambled groups during the same period. Differently from other groups, SiRNA 
APPL-1 theca cells demonstrated a progressive increase in LHR gene expression tending to 
reach a plateau over 24 hours. (results from 2 independent experiments). 
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Fig 5.13:  Effect of adiponectin on LHR gene expression (0-24h). 
Theca cells were cultured for 72h in serum-free medium in four different groups: group 1 
(siRNA APPL1- knockdown APPL-1 gene); group 2 (scrambled siRNA); group 3 
(adiponectin) and group 4 (control). All groups were kept in serum-free medium for the initial 
72 hours. After this time, wells were washed two times with serum free medium and groups 
1, 2 and 3 were treated for 24 hours with adiponectin (3µg/ml). Group 4 (control) was 
incubated for the same time in serum-free medium. 
While theca cells treated with adiponectin (group 1) exhibited a progressive decline in LHR 
gene expression, controls and scramble had a discrete positive variation. siRNA APPL-1 
theca cells demonstrated an initial reduction in LHR gene expression (2 hours) followed by a 
slow recovery over the next 10 hours, and a sharp rise over the controls at the end of 24 
hours.(results from two independent experiments). 
 
 
 
 
 
NS (ANOVA) 
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ADIPONECTIN RECEPTORS (AdipoR1 and AdipoR2) IN HUMAN AND 
SHEEP OVARIES 
5.4.5   Adiponectin receptors in normal and polycystic human ovaries  
Expression of ADIPOR1 and ADIPOR2 in the human ovary 
Total RNA from human GCs and TCs was extracted and RT-PCR was carried out 
using primers that amplified fragments of ADIPOR1 (182 bp) and ADIPOR2 (225 bp). 
As shown in Fig. 5.14 ADIPOR1 and ADIPOR2 expression were detected both in 
GCs and TCs, as well as in cortical biopsies of ovaries from normal women 
(Chabrolle et al., 2009). At least three different samples of each group were 
evaluated in three different experiments. 
Immunohistochemistry  
Immunolabelling of AdipoR1 and AdipoR2 was identified in pre-antral and antral 
follicles at different stages of development (Fig. 5.15 and 5.16). The observed 
staining in GCs and TCs was mostly noted in cytoplasm (Fig. 5.15 and 5.16). These 
results confirm previous findings, which showed strong labelling of AdipoR1 and 
AdipoR2 in muscle and liver tissues, respectively; both were present in the corpus 
luteum (Chabrolle et al., 2007)(Fig. 5.15 and 5.16).  
Overall, 726 follicles were examined for AdipoR1 staining and 920 follicles for 
AdipoR2 staining, corresponding to 85 antral follicles for AdipoR1 and 97 antral 
follicles for AdipoR2.  
In antral follicles, no statistically significant differences in the proportions of GCs 
expressing AdipoR1 or AdipoR2 were identified between PCOs and normal ovaries 
(Fig. 5.17). Specifically, the proportion of GCs staining for AdipoR1 in PCOs (mean 
[95% of confidence interval - CI]) was 0.93 (0.90; 0.96), compared with 0.93 (0.68; 
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1.1) in normal ovaries; for AdipoR2, the observed proportions were 0.77 (0.71; 0.82) 
and 0.85 (0.68; 1), respectively (P > 0.05). However, a marked reduction in AdipoR1 
and AdipoR2 staining was observed in theca cells from polycystic compared with 
normal ovaries (Fig 5.17). The proportion of TCs staining for AdipoR1 was 0.29 (0.20; 
0.38) in PCOs versus 0.52 (0.32; 0.72) in normal controls (P = 0.002, Mann−Whitney 
test); for AdipoR2, the proportions were 0.65 (0.52; 0.78) in PCOs and 0.77 (0.69; 
0.85) in ovaries from normal women (P = 0.049; Mann−Whitney test). 
 
 
 
Fig 5.14: Expression of adiponectin receptor 1 (ADIPOR1) and 
adiponectin receptor 2 (ADIPOR2) in human ovaries.  
Expression of ADIPOR1 and ADIPOR2 in granulosa (G), theca cells (T) and in cortical 
biopsies(C) from human ovaries was demonstrated by RT-PCR. The + or – signal indicate, 
respectively, the presence or absence of cDNA  used for analysis. As shown in this picture, 
ADIPOR1 and ADIPOR2 are present in the human ovary. 
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Fig 5.15: Expression of adiponectin receptor 1 (AdipoR1) in human 
ovary.  
Immunolabelling for AdipoR1 was detected in granulosa cells from preantral stages 
(B)(C)(D). At these stages, positive staining (black arrows), or negative staining (white 
arrow) were better observed in cuboidal cells (C); not infrequently, flat cells in  primordial 
follicles were negative (A).  In antral follicles, staining for AdipoR1 (A)(C) was present in 
granulosa cells and  in theca cells in healthy (E), luteal (F) and atretic follicles (black arrow 
indicate theca cell group)(G). In the corpus luteum, staining was noted in theca-lutein cells 
(black arrow) and less intense in granulosa-lutein cells (H).  A positive control for AdipoR1, 
mouse muscle (E) was run to confirm the specificity of the antibody, but not shown in this 
figure. Negative control, determined by the absence of the primary antibody is shown in (I). 
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Fig 5.16: Expression of adiponectin receptor 2 (AdipoR2) in human 
ovary.  
Similarly to adipoR1, AdipoR2 labelling was detected in preantral granulosa cells at all 
stages (A)(B)(C)(D), and better visualized in cuboidal cells (C) (black arrow-positive cells, 
white arrow –negative cells). Incipient theca cells at secondary stages also stained for 
AdipoR2 (black arrow)(D).  In antral follicles, staining for AdipoR2 was clearly strong in theca 
cell layers as shown in healthy (E),(F) and atretic follicles (G). Theca-lutein (black arrow) and 
granulosa-lutein cells (white arrow) from the corpus luteum also were positive for AdipoR2. 
Another positive control (mouse liver) not shown in this figure was employed to confirm the 
specificity of the antibody. (I) = negative control. 
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Fig 5.17: Comparison of the expression of AdipoR1 and AdipoR2 
protein in GCs and TCs in PCO  and in normal ovaries. 
A significant reduction in the proportion of TCs labeling for AdipoR1 (A) and adipoR2 (B) 
was demonstrated in PCO in comparison with ovaries from normal women. No differences 
were detected in the labeling for AdipoR1 (C), or AdipoR2  (D) in the proportion of staining in 
granulosa cells. Data shown mean + SEM. 
  A 
B 
C 
 D 
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5.4.6  Adiponectin receptors in sheep ovaries.  
The expression of both adiponectin receptors in fetal sheep ovaries was assessed by 
qPCR.  Samples containing cDNA obtained from 11 sheep ovaries (hemi-sectioned) 
at day 90 of gestation (5 control and 6 androgenised) were analysed for expression of 
ADIPOR1 and ADIPOR2 genes. As shown in Fig. 5.18, the expression of  ADIPOR1 
and ADIPOR2 was significantly reduced in androgenised sheep ovaries during 
gestation. The relative gene expression of ADIPOR1 (mean [95% CI]) was 0.77 (0.7; 
0.84) in androgenised ovaries and 1.0 (0.28; 1.2) in control sheep ovaries (P = 0.003; 
Student’s t-test); for ADIPOR2, it was 0.36 (0.15; 0.58) in androgenised ovaries and 
1.2 (0.54; 1.8) in fetal ovaries from controls (P = 0.003 Student’s t-test).  
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Fig 5.18: Comparison of adiponectin receptor 1 (ADIPOR1) and 
adiponectin receptor 2 (ADIPOR2) gene expression in PA fetal sheep 
ovaries and its controls (day 90).  
A significant decrease in the gene expression for ADIPOR1(A) and ADIPOR2(B) analysed 
by qPCR was observed in fetal sheep ovaries (d90) from androgenised sheep versus its 
controls. Data shown mean + SEM. 
 
 
 
 
 
 
 
 
 
 
 
B 
A 
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5.5   DISCUSSION 
This chapter explored the role of adipokines and their receptors in the development of 
hyperandrogenism in PCOS. Based on the results presented herein, four assertions 
can be made: 1) adipokines elicited changes in androstenedione production in bovine 
TCs; 2) adiponectin caused a marked reduction in both androstenedione levels and 
LHR gene expression in bovine TCs co-treated with LH; and 3) the expression of 
adiponectin receptors in TCs from PCOs was reduced compared with the expression 
in TCs from ovaries from normal women; 4) prenatal androgenisation affected the 
expression of adiponectin receptors in the fetal ovary (d90). 
In the presence of LH and insulin, both leptin and visfatin caused a significant 
increase in the androstenedione level in the culture media from bovine TCs, while 
adiponectin treatment resulted in the opposite outcome. The suppressive effect of 
adiponectin on androstenedione secretion in bovine TCs also occurred in the 
presence of LH alone, and it was associated with down-regulation of genes encoding 
LHR and key steroidogenic enzymes (CYP17A1, CYP11A1) and STAR. Remarkably, 
50% knockdown of adiponectin receptors (ADIPOR1, ADIPOR2) and their common 
mediator (APPL1) was sufficient to reverse the repression of LHR and to increase 
(relatively) the secretion of androstenedione over 24 h.  
Downregulation of LHR by adiponectin seemingly played a role in reducing androgen 
secretion. Mechanisms involving LHR down-regulation are still obscure, but may 
involve an LRBP that was later identified as MVK by Menon’s group (Nair & Menon, 
2004; Menon et al., 2009; Wang et al., 2010; Menon et al., 2011). In our present 
study, knocking down APPL1 caused a diverse response in MVK in a time-course 
experiment carried out with TCs, but these results should be interpreted cautiously 
due to the possibility that other non-specific molecular mechanisms (e.g. trafficking) 
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could be associated with this phenomenon. The in vitro results observed in this study 
concur with initial observations by Spicer et al., who treated bovine TCs with 
adiponectin in the presence of LH and insulin and observed a reduction in 
androstenedione levels (Lagaly et al., 2008). Curiously, the suppressive effects of 
adiponectin disappear in the absence of LH, which should be further investigated in 
future studies.  
As shown in Fig. 5.17, PCOs exhibited a significant decrease in the proportion of 
adiponectin receptors (AdipoR1, AdipoR2) in TCs, compared with normal ovaries. 
Changes in the expression of adiponectin receptors have also been described in fat 
tissue in women with PCOS. For instance, Tan et al. identified an increase in 
adiponectin receptors in omental and subcutaneous adipose tissue from obese 
PCOS patients (Tan et al., 2006). Another study (Seow et al., 2009) observed a 
down-regulation of adiponectin receptors in omental fat from lean women with PCOS. 
However, it remains unclear whether these changes in adiponectin receptors 
represent a cause or a consequence of obesity / insulin resistance. Also of note, a 
susceptibility for PCOS given by an association of polymorphisms of ADIPOQ 
(adiponectin gene) remains to be confirmed, although the present studies offer 
contentious results (Heinonen et al., 2005; Zhang et al., 2008; Baba et al., 2009; 
Yoshihara et al., 2009; Demirci et al., 2010).  
A marked disruption in the serum levels of adipokines occurs in women with PCOS. 
Specifically, increases in leptin, visfatin, and resistin, along with a reduction in 
adiponectin, have been reported in different studies (Toulis et al., 2009; KG 
Michalakis, 2010). Moreover, a reduction in adiponectin levels has been correlated 
with androgen levels and with anovulation, or with the classic phenotype in PCOS 
(Carmina et al., 2009; Karkanaki et al., 2009). The observed reduction of expression 
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of adiponectin receptor expression in fetal sheep ovaries supports the concept that 
androgens have a suppressive effect on adiponectin action and emphasises the 
important interaction of androgens and adipose tissue in the manifestation of PCOS 
in women. 
Taking all of this information into account, and extrapolating the results obtained in 
bovine TCs, it is reasonable to speculate that the adipokines that are frequently 
disrupted in PCOS may generate an impact on basal steroid production through 
common pathways influenced by LHR, as shown in Fig. 5.19. Although the molecular 
mechanisms underlying this speculation must be further explored, it is tempting to 
hypothesise that a 70% reduction in MEK1/2 and a 50% reduction in Erk1/2 
phosphorylation, which are accepted as the main factors associated with higher 
androgen production in TCs from PCOs (Nelson-Degrave et al., 2005), could be 
affected by a reduction in adiponectin as a result of reduced levels of adiponectin in 
the serum and/or adiponectin receptors in the ovary (as would be expected in 
obesity). In this regard, insulin signalling could be potentially affected by the reduction 
in adiponectin, as adiponectin has insulin-sensitising actions in many tissues 
(Brochu-Gaudreau K, 2010). Reduced phosphorylation of MEK/Erk would create a 
disruption in MVK production responsible for the down-regulation of LHR, according 
to studies by Menon et al. (Menon et al., 2011). In addition to this, other adipokines, 
including leptin and visfatin, by mechanisms still not identified, can weakly enhance 
basal androgen secretion in bovine TCs. 
In summary, our results revealed a significant effect of leptin and visfatin in increasing 
androstenedione levels in bovine TCs in vitro, whereas a marked reduction was 
noted after administration of adiponectin through the reduction of LHR and 
expression of key steroidogenic enzymes. In addition, a noticeable decrease in the 
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expression of AdipoR1 and AdipoR2 in the TC layer of PCOs was observed. These 
results strongly suggest that disruption of adipokines (especially a decrease in 
adiponectin signalling) can favour an exacerbation of basal androgen secretion, a 
typical feature in PCOS. 
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Fig 5.19: Possible actions of adipokines favouring hyperandrogenism in 
polycystic ovary syndrome. 
A   reduction in MEK/Erk phosphorylation described by McAllister et al  (Wickenheisser et al 2006), 
an important factor associated to higher androgen secretion in theca cells from PCOS in vitro, could 
be mediated  by a reduction in adiponectin signalling  determined  by decreased adiponectin levels 
and/or in adiponectin receptors.  The consequence of the decline in MEK/Erk phosphorylation (in the 
presence of LH) is a defective inhibition of LH receptor (Menon et al, 2011) and perpetuation of high 
LH signaling able to enhance the overexpression of steroidogenic enzymes and increased androgen 
secretion. Another possible mechanism related to adipokine disruption involves the effect of 
increased adipokines  (e.g. leptin and visfatin) that can stimulate androgen production in conditions of 
high LH and insulin. 
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CHAPTER 6: CONCLUSIONS 
 
 
This thesis aimed to investigate the role of androgens in the pathophysiology of PCOS, 
the commonest endocrine disorder in women.  
The understanding  that guided the studies presented here was the hypothesis that the 
development of ovarian hyperandrogenism  and aberrant folliculogenesis observed in 
PCOS are products of the disruption of  androgen secretion and that adipokine action 
has an important part to play in this process.   
In order to perform this investigation, ovaries from prenatally androgenised sheep, a 
recognized animal model of PCOS, and its respective controls were used for exploring 
comparative studies evaluating aspects of follicle formation and steroidogenic enzyme 
expression in fetal (d90) and adult sheep ovaries.  In addition, original work using 
sections from ovaries from normal adult women and from PCOS women was 
performed. The work has generated data about the protein expression of the key 
steroidogenic enzymes (P450c17, 3βHSDII, 17βHSD type 5) and LHR in PCOS. In 
parallel to these studies, experiments to assess the possible impact of adipokines 
(adiponectin, visfatin, resistin, leptin) on androgen production were performed in 
primary theca cells obtained from bovine ovaries.  
Consequences of androgen treatment on ovary development and function 
The results presented in this thesis have demonstrated that the consequences of 
prenatal treatment with testosterone on sheep ovaries during gestation  occur as early 
as day 90 of fetal life.  As shown in chapter 4, PA sheep ovaries at day 90 of fetal life 
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presented a significant increase in the expression of AR and 3βHSD enzyme in 
granulosa cells from primordial, transitional and primary follicles; in contrast to what 
was expected, the same ovaries demonstrated a significant reduction of gene 
expression of CYP17A1.  In addition to these abnormalities in steroidogenic enzymes, 
a marked disruption of folliculogenesis in fetal sheep (d90) was identified by 
immunohistochemistry with VASA, suggesting an increased recruitment of germ cells 
and accelerated follicular development that caused a disproportion between germ cells 
and follicles.  
As shown previously, at adult age, these PA sheep exhibit a polycystic appearance 
and anovulation (Forsdike at al, 2007). The studies presented in this thesis show that 
ovaries of these animals demonstrated enhanced expression for P450c17 in contrast 
with control sheep. P450c17 is considered the ‘qualitative’ regulator of steroidogenesis 
and its increase in PA sheep is a good explanation for the development of 
hyperandrogenism in this species.  The adrenal could also be a source of increased 
androgens but adrenal tissue was not available for these studies.  Other important 
features observed in PA sheep were the intense labelling for AR in granulosa cells 
associated with an increased expression of proliferation marker, MCM-2. The increase 
in MCM-2 labelling is relevant because it demonstrates that accelerated proliferation in 
GC is likely to account for accelerated follicle formation.  
Therefore, the results above indicate that early treatment with testosterone can affect 
follicle development and androgen production in an animal model of PCOS. Once 
testosterone (an aromatisable androgen) was employed, it is not possible to determine 
if all the observed consequences were mediated directly by androgenic or indirectly by 
ooestrogenic actions. In particular, it is not possible to be sure that the increase in 
P450c17 is a result of activation of AR or ER. Considering the weak AR expression in 
theca cells and the data available in the literature linking the existence of 
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hyperandrogenism to ooestrogenic actions in sheep (i.e, not observed in other studies 
where sheep was treated with DHT) it is reasonable to speculate that the increase in 
P450c17 was a result of ER rather than AR activation (although both could be 
involved). Conversely, the strong labelling for MCM-2 and AR in GCs from PA sheep 
may suggest the effect of androgens on GC proliferation.   
The findings in PA adult sheep are consistent with abnormalities seen in PCOS in 
humans. As shown in Chapter 2, an increased expression of P450c17 in theca cells 
was detected in PCO compared to ovaries from normal women.  To our knowledge, 
this is the first confirmation of elevation of protein for P450c17 in PCO and it supports 
the previous findings of increased androgen production and increased CYP17A1 
mRNA in theca cells from PCOS patients (Wickenheisser et al., 2005). Observation of 
increased AR expression and enhanced MCM-2 (a marker of proliferation) in PCO has 
also previously been reported by our group (Webber, 2005 ; Stubbs et al.,2007).  
Effects of adipokines on androgen production 
Chapter 5 addressed the effects of different adipokines on androgen production 
employing a primary theca cells obtained from bovine ovaries. Treatment with 
adiponectin (or resistin) alone elicited a stimulation of androstenedione production by 
bovine theca cells in vitro. Importantly however, in the presence of LH (10 to 100µg/ml) 
adiponectin caused a significant inhibition of androgen production.  Further 
investigation of the mechanisms underlying the reduction in androgen levels indicated 
that the co-administration of LH and adiponectin (3µ g/ml) caused a suppression of 
LHR, of key steroidogenic enzymes (CYP17A1, CYP11A1), and STAR. In an attempt 
to confirm the role of adiponectin in androgen production, a knockdown of adiponectin 
receptors (ADIPOR1 and ADIPOR2) or its common effector (APPL1) was performed by 
the use of specific SiRNA. As a result, an increase (up to 200%) in androstenedione 
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levels in media was demonstrated in theca cells in which ADIPOR2 and APPL1, was 
suppressed, suggesting that, at least in vitro, adiponectin levels may influence basal 
secretion of androgens.  Interestingly, the knockdown of ADIPOR2 and APPL-1 
employing SiRNA in the presence of treatment with LH and adiponectin was 
associated with a relatively higher expression of LHR. Therefore, the results obtained 
in vitro suggest that adiponectin can simultaneously reducing androgen secretion in 
theca cells and reducing LHR expression.  The results presented in this thesis 
regarding the action of adiponectin are in agreement with (but greatly extend) the 
preliminary findings by Lagaly and colleagues (Lagaly et al., 2008). 
The mechanism of adiponectin effects on LHR expression remains unclear. Studies by 
Menon et al. suggested a role for MVK (an enzyme involved in the cholesterol 
synthesis) in the process of LHR downregulation through translational mechanisms. 
However, these results are still preliminary and are not consensually accepted. 
Informed by these concepts, we assessed the gene expression of MVK in theca cells 
exposed to adiponectin (plus LH) and in APPL1 SiRNA theca cells in order to explore 
in more detail the mechanism of adiponectin-induced downregulation of LHR. When 
theca cells were treated for 24 hours with adiponectin (in the presence of LH) gene 
expression of LHR was decreased as well as that of MVK; the opposite results (high 
LHR and high MVK) were observed when SiRNA APPL-1 theca cells where treated in 
the same conditions. It is not clear if these phenomena are related to direct actions of 
adiponectin in LHR control or if they are just consequences of cellular trafficking 
disturbances.  
Adiponectin and adiponectin receptors in PCOS 
Adipokines have been suggested as possible linkers between reproductive and 
metabolic abnormalities in PCOS. These cytokines, mainly produced by fat, can 
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regulate many processes regarding energy homeostasis and insulin sensitivity. Not 
surprisingly, abnormalities in serum adipokine levels have frequently been reported in 
PCOS. Levels of adiponectin (total and HMW) are abnormally decreased where leptin, 
visfatin and resistin have been described as increased or similar (Chapter 1).  
Clinically speaking, adiponectin levels are related to the ovulatory status in PCOS. A 
significant reduction in total adiponectin was found to be a feature of women PCOS 
exhibiting oligomenorrhea/amenorrhea  but not those PCOS women with regular cycles 
(Karkanaki et al., 2009; Katsikis et al., 2009). In addition, reduced serum 
concentrations of adiponectin may also represent a factor in the development of other 
associated features of PCOS such as accelerated atherosclerosis, liver disturbances 
such as non-alcoholic steatohepatitis (NASH), diabetes mellitus and metabolic 
syndrome (Kadowaki & Yamauchi, 2005). Although it remains uncertain whether 
abnormalities in serum adipokine levels are related to PCOS itself or to the obesity that 
often accompanies it, the evidence presented in this thesis suggests that disturbed 
adipokine production contributes significantly to hyperandrogenism in PCOS.  
Results presented in Chapter 5 indicated a significant decrease in the expression of 
AdipoR1 and AdipoR2 in theca cells from PCO compared to those from ovaries from 
normal women.  Although reasons for adiponectin receptor decrease were not clear 
(they might be related to insulin resistance according to some authors), this finding 
suggests an additional factor to reduce even more actions of adiponectin in PCO 
ovaries and consequently may lead to an increase in androgen secretion by theca 
cells. At least during gestation, the treatment with androgens caused a marked 
downregulation of adiponectin receptors (ADIPOR1 and ADIPOR2 genes) in the ovary 
of PA sheep (d90).   
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Androgens and adipokines: looking for an integrated hypothesis  
In PCO, increased expression of LHR, P450c17 and decreased expression for 
adiponectin receptors (AdipoR1 and AdipoR2) were observed in comparison to ovaries 
from normal women.  
Although phosphorylation of MEK/Erk was not assessed in our studies, stimulation of 
MEK/ Erk by adiponectin has been described in the literature in other cells such as 
pancreatic cells (MIN6, C2C12), (Wijesekara et al., 2010) and human adrencortical 
cells (H295R) (Ramanjaneya et al., 2011).  Most importantly, it has been shown that 
APPL1 mediates the activation of ERK1/2 pathway and this downregulation of APPL1 
by RNA interference is associated with a reduction in ERK1/2 activation in human 
embryonic kidney cells (HEK293). 
The reduced phosphorylation of MEK/ Erk is a key molecular characteristic of theca 
cells in PCO (Nelson-Degrave et al., 2005; Wickenheisser et al., 2006). To date, there 
has been no suitable explanation for this abnormality although it has been suggested 
that it is related to disruptions generated by excess of insulin (or IGFs) or androgens 
(Tosca et al., 2008). Nevertheless, its consequences may be directly related to LHR 
expression. According to Menon et al, a reduction in phosphorylation of MEK/ErK could 
create modifications in MVK  that reduce the downregulation of LHR (Wang & Menon, 
2005; Menon et al., 2009; Menon et al., 2011).  LH and its receptor are recognized as 
one of the most important stimulators of thecal steroidogensis. Once activated, LH can 
enhance at once many steroidogenic enzymes such as P450scc, P450c17 and 3 
βHSDII.  
In our working hypothesis adiponectin deficiency, together with reduced adiponectin 
receptors in theca cells, would generate (or be associated with) higher LHR and 
P450c17 expression in theca cells and consequently enhance ovarian 
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hyperandrogenism. A reasonable speculative mechanism in this scenario is the 
upregulation of LHR due to low MEK/Erk signalling caused not only by low adiponectin 
input but also by other mixed defects in insulin signalling or other ligands e.g, IGF-I. 
Although the precise mechanism of adipokine /adiponectin actions still need to be fully 
delineated, it is clear that adipokines provide an important link between adiposity and 
androgen production.  
We can conclude from these studies that increased androgen production may itself be 
exacerbated by prenatal exposure to androgen and that disordered adipokine balance 
further contributes to androgen excess. 
 
 
 
 
 
 
 
 
 
 
 179 
CHAPTER 7 
MATERIALS AND METHODS  
 
 
 
7.1 SAMPLES  
7.1.1  Source of ovarian tissue 
Human ovaries 
Sections of archived human ovaries (formalin-fixed paraffin-embedded) removed from 
patients less than 50 years of age with benign gynaecological disease (collected 
between 1993-2000), were obtained from the Histopathology Bank of St. Mary’s 
Hospital (Imperial College Healthcare NHS Trust) in London. Overall, excluding the 
specimens considered unclassified or having a concomitant pathology (e.g. 
endometriosis), 26 sections were obtained. All specimens were made anonymous and 
collected with previous patient informed consent and in conformity with the local 
Research Ethics Committee. Two different operators (Dr Adrienne Flanagan and Dr 
Lisa Webber) classified the ovaries histologically as normal, ovulatory PCO or 
anovulatory PCO (Table 7.1). The histological definition the ovary as PCO was based 
on the presence of three or more abnormalities: increased ovarian volume (>9 ml), 
identification of 10 or more follicles between 2-8mm in diameter, increased 
volume/density of stroma or a thickened tunica. The existence of corpus luteum or 
corpus albicans identified the ovary as ovulatory. In addition to histological information, 
clinical data including BMI, menstrual history and an ultrasonogram of the ovaries were 
obtained. The conjunction of these data established three different categories disposed 
below that matched the criteria of ESHRE/Rotterdam Consensus 2003 ("Revised 2003 
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Consensus on Diagnostic Criteria and Long-Term Health Risks Related to Polycystic 
Ovary Syndrome, 2003)(2004). 
 
 
Group Age 
(years) 
       
Histology Menstrual history Ultrasonography 
Normal 
(n=11) 
 
32.4 
(26-38) 
normal Regular* Normal** 
Ovulatory 
PCO 
(n=10) 
 
 
 
32.2 
(24-38) 
PCO + 
corpus 
luteum or 
corpus 
albicans 
Regular*** PCO **** 
Anovulatory 
PCO 
(n=5) 
 
 
 
36.2 
(30-44) 
PCO without 
corpus 
luteum or 
corpus 
albicans 
Oligomenorrhea 
(cycle intervals 
longer than six 
weeks) or irregular 
cycles 
PCO 
 
Table 7.1: Classification of human ovary sections  
*7 of 11 women whose ovaries were classified as normal had their menstrual history 
ascertained. In all cases (7/7) the menstrual pattern was identified as normal (regular cycles 
lasting less than 6 weeks). ** 6 of 11 of normal women were submitted to ultrasonography the 
results of which were considered normal. *** 8 of 10 women considered as ovulatory PCOS 
had their menstrual history evaluated. In all cases (8/8) the menstrual pattern was classified as 
regular. **** 6 of 10 women in ovulatory PCO group had performed an ultrasonography  which 
was defined as polycystic in all cases.  
 
Adult and fetal (d90) sheep ovaries 
Sections from adult (n=20) and fetal (n=12) ovaries were obtained at The Babraham 
Institute, Cambridge, UK (52012’N) during the course of a previous   study between 
March 2000 and November 2002 (Forsdike et al., 2007). Briefly, 7 Poll Dorset adult 
female sheep, hereafter referred to as mothers were randomized to receive a treatment 
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with androgens (testosterone propionate 100mg i.m. twice weekly between days 30 
and 90 of gestation) or just vehicle (1ml vegetable oil i.m.). The offspring (11 prenatally 
androgenised and 9 control ewes) had their ovaries collected approximately 12 months 
after the first breeding season.  In a following procreation season, the same “mothers” 
were allowed to mate and treated again with androgens or not. At 90 days of gestation 
the mothers and the fetuses were slaughtered and the ovaries removed.  
7.2   PREPARATION OF SAMPLES AND IMMUNOLABELING TECHNIQUES  
The method for identification of specific proteins by immunohistochemistry is described 
below and it is summarized in the Fig 7.1. 
7.2.1. Preparation of samples 
Ovary samples were previously fixed in formalin and then transferred to 70% ethanol 
(Analar, VWR International, Leicestershire, UK). The tissue was dehydrated by 
bathing in increasing concentrations of ethanol (70%, 90%, 100%) and subsequently, 
in a histological clearing agent, Histo-Clear (National Diagnostics, East Riding, UK). 
Following this stage, the tissue was submerged in paraffin wax. The ovaries were cut at 
5µm and mounted on poly-l-lysine slides. 
7.2.2. Colourimetric immunohistochemistry 
The sections had paraffin removed by two changes (5min) in Histoclear, followed by 
rehydratation through an alcohol sequence. The antigen in the sections was retrieved 
with the use of citrate buffer solution (0.01 M pH 6.0), boiled for 20 min in the 
microwave. After cooling down in ice, the endogenous peroxidase activity was 
quenched with the administration of 0.3% hydrogen peroxidase in 70% methanol for 30 
min at room temperature (Hydrogen Peroxide 30%, Analar, Poole, UK).  In particular 
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cases, when false positive staining was attributed to treatment with citrate, the antigen 
retrieval was intentionally omitted or other buffers (e.g. Tris-HCL pH10 or EDTA 1mM) 
employed in substitution to the previous buffer. The reduction of non-specific antibody 
binding was performed through 20 min incubation of the sections with 10-20% serum 
(different species, according the experiment) at 1:5 dilution in PBS (v/v) and 4%(w/v) in 
bovine serum albumin (BSA, Sigma, Steinheimer, Germany). Sections were incubated 
overnight at 4 0C with the primary antibody. Dilutions of the antibodies employed are 
indicated in Table 7.2. After an overnight, sections were washed three times with PBS 
and incubated for 60 min with a secondary antibody (usually goat anti-rabbit E0432, 
DAKO, Dennmark) at 1:200 dilution. Subsequently, incubation with peroxidase-
conjugated avidin-biotin complex (RTU-ABC Kit, Vector, Peterbourogh, UK) for 1 hour 
was conducted after a 10min bath with PBS.  Sections were washed again (10min) and 
the HRP-conjugated 3,3’- diaminobenzidine tetrahydrochloride (DAB) used in dark to 
permit labeling visualisation. The time required to get an adequate staining varied 
between the antibodies and tissues employed, but in general was not superior to 5min. 
Sections were counterstained for two min with haematoxilin (BDH, Poole, UK), re-
hydrated in alcohol  (70%, 95%, 100%) and mounted in DPX after 2 changes (5 min) in 
Histoclear. The omission of the first antibody was used to produce the negative control. 
The incubation the sections in the presence of non-imune serum and pre-imune serum 
was proceeded to confirm the absence of non-specific binding of the primary antibody 
to the targeted protein. Positive controls were also obtained to ascertain the specificity 
of the antibody. The prior testing of several dilutions of the primary antibody was 
performed in order to optimize and establish the best labelling conditions. 
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Immunohistochemistry for LHR 
A specific immunohistochemistry protocol was employed to the study of the luteinizing 
hormone receptor (LHR) expression in sections of human and sheep ovaries. After 
removal of paraffin with Histoclear, blockage of the endogenous peroxidase was 
performed by the use of 3%H202 in 100% methanol (v/v) for 30 min.  Sections were 
washed in PBS for 10 min and then incubated with 0.75%Glycine (w/v) (Merk, 
Nottingham, UK) for 30 min. A PBS wash (10min) was then performed, and sections 
were treated with 5% normal goat serum in PBS (v/v) for 30 min at RT; sections were 
incubated with the primary antibody clone P1B4 LHR reconstituted at dilution of 1:4000 
overnight at 40C.  Thereafter, sections were washed with PBS (30min) and incubated 
with the secondary antibody goat anti-mouse (Biotynilated anti-rabbit IgG made in goat, 
BA100, Vector, Burlingame, USA) at 1:200 dilution for 1 hour. A wash with PBS 
(30min) was performed, and the ABC antibody employed at dilution of 1:1000 
(Vecstatin ABC KIT, vector, Peterbourogh, UK).  Visualization of the immunolabelling 
by light microsocopy was possible using Impact DAB (Vector, Burlingame, USA) 
diluted at 1:200 (v/v) applied directly to the sections. The presence of staining in the 
positive controls (theca cells in the rat ovary) and in specific targets (usually corpus 
luteum in sheep and human ovaries), were the criteria used to interrupt the other 
imunolabeling running reactions by the immersion of sections in distilled water. 
Sections were counterstained with hematoxyline (Vector, Burlingame, USA), washed in 
water, and covered with aquamont or processed through a sequence of ethanols,  
Histoclear and mounted in DPX. 
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Fig 7.1: Immunohistochemistry: basic protocol. 
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Table 7.2: Antibodies used for immunohistochemistry experiments.  
NA=not available. M= monoclonal antibody; P= polyclonal antibody  
Primary 
 Antibody 
Type 
 
Obtained  
 from 
Code  
(concentration  
undiluted) 
Antigen 
 
Species 
(host) 
Secondary 
Antibody 
(1:200) 
Primary Antibody  
AS=adult sheep 
FS= fetal sheep 
H= human 
Observations. 
MCM-2  
 
M Gift from Dr Stephen 
Dilworth, Imperial 
College London,UK 
Clone DI 12A3 
(15µg/ml) 
NA mouse Goat anti-
mouse  
AS  15  µg/ml 
 FS 15 µg/ml 
 
VASA M Gift from Dr T. Noce 
,Mitsubishi Kagaku 
Institute of Life Sciences, 
Japan 
Anti-mouse Vasa 
homologue 
(NA) 
NA rabbit Goat anti- rabbit FS (1:5000) 
 
Antigen retrieval 
Tris-HCl buffer pH 
10; labeling with 
AEC (Dako,UK) 
3βHSDII 
 
P Gift from  Dr JL Mason, 
Edinburgh University, UK 
S683 
(NA) 
NA rabbit Goat anti-rabbit AS (1:200 ) 
 FS ( 1:200 ) 
H ( 1:200 ) 
 Reduced antigen 
retrieval time 
(10min in 
microwave) 
17αOH/17,20 
lyase 
M Gift from Dr C Richard 
Parker Jr., Univeristy of 
Alabama at Birmingham, 
USA 
M  anti -17OH 
clone 2C2 
(NA) 
NA mouse Goat anti-
mouse 
AS ( 1:40 ) 
H ( 1:40 ) 
IF (1:200 ) for 
bovine theca cells 
Androgen 
Receptor 
P RDI, Fitzgerald 
Industries, Concord,USA 
RDI-
ANDRECPTabr  
(1mg/ml) 
Synthetic 
peptide 
human and rat  
AR (N terminal 
1-21 AA) 
rabbit Goat anti-rabbit; 
swine anti-
rabbit 
AS 1.6 µg/ml 
 FS 1.8 µg/ml 
 
 
ADIPOR1 P Phoenix  
Pharmaceuticals, Inc, 
Burlingame, USA 
H-001-45 
(NA) 
ADIPOR1 
human  
(41-65) 
rabbit Goat anti-rabbit AS ( 1:150 ) 
 FS (1:100) 
H ( 1:100 ) 
 
ADIPOR2 P Phoenix  
Pharmaceuticals, Inc, 
Burlingame, USA 
H-001-23 
(NA) 
ADIPOR2 
human (374-
386) 
rabbit Goat anti-rabbit AS ( 1:200 ) 
 FS ( 1:150 ) 
H ( 1:100 ) 
 
LHR M Gift from Prof Katja 
Teerds (Dr Wimalasema) 
 Wagenigen University 
The Netherlands 
P1B4 
(NA) 
Rat LHR 
(NA) 
mouse Goat anti-
mouse 
AS (1:4000 ) 
H ( 1:4000 ) 
No antigen 
retrieval  
17βHSD type 5 P Abcam, UK Ab 84327 
(0.5 mg/ml) 
human  
AKR1C3 
rabbit Goat anti-rabbit AS  2.5 µg/ml 
H 2.5  µg/ml 
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7.2.3. Immunofluorescence 
Bovine theca cells 
Cells were plated at variable densities in media supplemented with 10% fetal bovine 
serum (FBS), transferrin, selenium, linoleic acid and antibiotic-antimycotic on round 
glass coverslips (16mm diameter) on the bottom of 6-well plates and incubated at 38.5 
0C and 5%CO2 for 24h. After overnight incubation, cells were washed twice in PBS 5 
min and fixed for 15min in ice-cold paraformaldehyde 4% (w/v). In the next step, cells 
were further washed with PBS for 5min three times, and then incubated 5 min in 
permeabilization solution, 0.1% Triton in PBS (v/v). Subsequently, cells were washed 
three times for 5min in PBS and then incubated for 20 minutes in blocking solution, 
10% goat serum in PBS (v/v), employed to reduce non-specific binding of proteins. The 
primary antibody against P450c17 antigen  (gift from Dr Richard Parker from the 
University of Alabama at Birmingham) was incubated at a dilution of 1:200 for 1 hour at 
room temperature. In the next stage, sections were washed three times in PBS and the 
secondary fluorescent antibody goat anti-mouse (Alexa-Fluor goat anti-mouse 555, 
Invitrogen, Oregon, USA) was added in dark for 1 hour. Sections were washed twice 
for 5min in PBS, immersed three minutes in DAPI (1µg/ml) and mounted in Prolong 
Gold Antifade (Invitrogen, Oregon, USA). 
7.3. IMAGE ANALYSIS (HUMAN AND SHEEP SECTIONS) 
7.3.1. Analysis 
Sections were coded, kept anonymised and examined on a microscope E600 (Nikon 
UK Ltd, Kingston-upon-Thames, UK) and images captured with DXM 1200 digital 
camera (Nikkon) with the assistance of the softwares Lucia (Image analysis program, 
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Nikkon, Japan) or NIS-Elements-Ar (Nikkon, Japan). Pictures were taken at the same 
microscope settings for each experiment. All images were saved in TIFF format. In the 
immunohistochemistry experiments, the area for analysis in human and adult antral 
follicles was chosen using a random number sequence (1 to 8) corresponding to 8 
different zones which were arbitrarily established (Fig. 7.2A).  The Graphpad software 
was used to obtain the random sequence number. To merge pictures and compose a 
full image of one section, another software (Double take 2.1, Worcester, UK) was used. 
The presence of staining for a specific protein was analyzed only in healthy follicles 
(unless otherwise mentioned) and classified as present (positive) or absent (negative).  
In 3βHSDII and P450c17 experiments, a semi-quantitative determination was used 
establishing categories for weak (+) or strong (++) staining. A quantitative 
measurement of the intensity of labeling was also performed in the 3βHSDII and 
P450c17 studies registering the density measurement obtained with the use of the 
software Nis-elements (Ar) (Nikkon, Japan). In order to obtain the mean density 
measurements for each follicle it was first necessary to define the area of staining 
using some of the software facilities (measurement box). The final mean was 
calculated based on the average mean density (per follicle) of all follicles in one section 
(Fig. 7.2B).  
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Fig 7.2:  Random selection of the follicular area in antral follicles and 
quantitative immunohistochemistry measurements.  
Ovary sections representing each patient or animal were arranged by an anonymous number 
code and the antral follicles (from the left to right) were individually numbered. To define the 
follicular area to be analysed, an aleatory zone employing a random number sequence from 1 
to 8 (pictured) was used. (B) quantification of the labeling was possible by measurement of the 
density using the resources available in the software (Nis-Elements Ar, Nikkon, Japan). To 
perform the measurement of the density (an estimate of absorbance) each theca cell was 
previously individualized, as shown in the picture. The final mean of these individual values (in 
arbitrary units) was the value used for comparison between groups. 
  
B 
A 
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7.3.2. Morphologic analysis of the follicles 
The classification of follicular stages was based on the exposed follicles in the following 
categories, as previously described (Webber et al, 2003):  
a) primordial follicle – one layer of flattened granulosa cells; 
b) transitional – a single layer in which, at least one (but not all) granulosa cells are 
clearly cuboidal. 
c) primary –one complete layer of cuboidal cells; 
d) secondary – between two to four layers of cuboidal cells and evidence of thecal 
layer; 
e) antral – presence of  antral cavity . 
Follicles were classified as healthy or atretic. In preantral follicles, atresia   was defined 
by the presence of 2 or more abnormalities: 1) nuclear pyknosis in granulosa cells or 
oocyte; 2) cytoplasm vacuolization; 3) condensation of nuclear or cytoplasmic material; 
4) irregular morphology “blebbing” or reduction of basement membrane of the oocyte . 
A modified classification of atresia in antral follicles based on the studies of Gougeon  
(Gougeon et al, 1996) was employed as showed below: 
a) ”Early” atretic (Stage A of Gougeon): up to 20% of the granulosa cells exhibiting 
pyknoses and fragmentation; 
 b) ”Mid” atretic (Stage B of Gougeon): a further stage, characterized by numerous 
pyknotic granulosa cells, partial disappearance of the GC layer but without alterations 
in theca cells (TCs); 
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c) “Late” atretic (Stage C and D of Gougeon): the follicle is shrunken and no GCs are 
visible (with exception of the cumulus oophorus- stage C); TCs assume a new 
organization changing into an interstitial gland; the basal lamina is thickened with a fine 
lamina of fibroblasts which later invade the antrum (Stage D). 
7.4. THECA CELL CULTURE 
7.4.1. Culture of primary bovine theca cells 
Ovaries from adult non-pregnant cattle were obtained from an UK slaughterhouse 
(Anglo Dutch farms, Kent, UK). They were collected locally and sequentially rinsed in 
saline solution (NaCl 0.9%), 70% ethanol, and immersed in saline solution before being 
transported in warm medium (380C) to the laboratory. The ovaries were then dissected 
and classified according with the presence and the size of the corpus luteum (Ireland et 
al, 1980; Tabandeh et al, 2010). Ovaries with a corpus luteum equal to or smaller than 
1 cm in diameter were selected and their follicles dissected.  The follicular size was 
estimated by the amount of fluid obtained by aspiration of the follicle.  Follicles were 
classified as large (if they had more than 0.8ml of follicular fluid aspirated) or small (if 
had less than 0.5 ml of follicular fluid aspirated). This decision was based on previous 
classification of follicles in the literature (Stewart et al, 1995; Spicer et al, 2000) (Fig. 
7.3).  
After isolation and aspiration of its contents, follicles were hemi-sectioned,  generating 
two hemispherical shells which were  immersed briefly in Hank’s Balanced Salt 
Solution (HBSS) (Invitrogen, Paisle, UK). Shells were inverted and rinsed vigorously 
with HBSS in order to remove any remaining granulosa cells. Subsequently, the 
internal face of shells were scraped and finely minced. This material was placed in a 
15ml tube containing a HBSS solution with two different collagenases (Sigma, 
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Gilingham, UK) at 1mg/ml and DNAse (Sigma, Gilingham, UK) at 0.01 mg/ml was 
digested for one hour in a shaker at 37.5 0C. Cells were centrifuged at 50 x g for 5 min, 
the supernatant discarded and then passed through a 100 µm filter (Steriflip, Milipore, 
UK) before the filtered content was re-suspended in fresh medium (Fig 7.3) with serum. 
Finally, theca cells were plated in 10 cm dishes at 38.5 0C and 5% CO2.  Medium was 
changed in a daily basis (about 50% each time). To transfer theca cells to other plates, 
an EDTA-collagenase solution (Accutase, Sigma, Gilingham, UK) was employed. 
Briefly, medium was aspirated and 5-7 ml of Accutase were added to cells in a 10cm 
dish for 5 to 8 minutes. After this time, solution was removed and plate rinsed with 5 ml 
of fresh medium plus serum. Theca cells were detached with a cell scraper (VWR 
International Ltd, UK). All this content was centrifuged (50 x g for 4 minutes) and the 
supernatant discarded. Theca cells were then re-suspended in medium, and the 
number of viable cells estimated by Trypan Blue exclusion test. In this method, cells 
are diluted at 1:2 in Trypan Blue (Sigma, Gilingham, UK) and the unstained cells in 5 
grids of a glass slide (Fisher Scientific, Lougborough, UK) were counted by 
microscopy. Theca cells were plated at a density according to the optimization 
protocols. 
 Optimization of the cell culture 
To establish optimum conditions for the culture of isolated bovine theca cells, the 
effects of cell plating density, temperature, purity of cells, viability of cells and the 
presence and amount of steroids and other components in culture medium were 
determined. To facilitate the comparison among samples, a luminescent cell viability 
assay (Cell-Titer Glo Promega, USA) was employed to give an estimate of the 
number of viable cells per well.   
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The effects of different treatments in the number of viable cells were evaluated by the 
use of CellTitter-Glo® Luminescent Cell Viability Assay (Promega, Fitchburg, USA). 
This assay is based on the indirect estimate of viable cells through the determination of 
available ATP, indicating the presence of metabolically active cells. Previously 
prepared CellTitter-Glo reagents were kept at room temperature before use according 
the manufacter’s instructions. A similar volume of this reagent was added to the 
volume of medium in each well plate and mixed for 2 min using a shaker. The plate 
was then incubated at room temperature for 10 min to stabilize the luminescence 
signal. After this, measurements of luminescence using the Wallac Victor 2 counter 
(Perking Elmer Life Sciences, Boston, USA) were performed.  
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Fig 7.3:  Primary culture from bovine theca cells (details in the text). 
* Bovine theca cells medium (with serum) 
 
D-MEM/F-12 (Invitrogen 31330038) 
(glucose 17.5 mM; bicarbonate 14.3; calcium 116 ng/ml; L-glut 2.5 mM; HEPES 15 m M )  
500ml 
FBS  (Invitrogen  1 0 %  
Transferrin (Sigma T 0665 )  1 g/ml 
Selenium   (Sigma 84920 )  1 ng/ml 
Linoleic acid ( Sigma L101 2 )  1 g/ml 
Penicilin (Invitrogen 1514 0 )  100 U/ml 
Streptomycin (Invitrogen 15140)  100 g/ml 
Gentamicin  (Sigma  G 1272)  0.5 g/ml 
Amphotericin (Sigma A 2942 )  2.5 g/ml 
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7.5. MOLECULAR BIOLOGY TECHNIQUES 
7.5.1. RNA extraction  
Total RNA was obtained from tissues (sheep ovaries) and cell culture monolayers 
employing different techniques. For tissues, and cells grown in surfaces larger than 1.9 
cm2 (24 well-plate chamber), the isolation of total RNA was performed using Trizol 
Reagent (Invitrogen, Life Technologies Co, Paisley, UK) using the manufacture’s 
recommendations. For smaller samples developing in growing surfaces less than 0.14 
cm2 (96 well-plate chamber), a cell lysis buffer (RLT) from RNeasy Mini Kit (Qiagen, 
Texas, USA) was employed. In some studies using 96 well plates, an additional step 
(Qiashredder, Qiagen, Texas, USA) was included in order to improve cell lysis. After 
the isolation, the total RNA was quantified using a spectrophotomer (Nanodrop ND-
1000, Thermo Scientific, Epsom, UK). Samples with 260/280nm ratio absorbance 
equal or superior to 2 were considered satisfactory to proceed to cDNA synthesis. 
7.5.2. Complementary DNA (cDNA) Synthesis 
Total RNA was treated with DNAse I (Invitrogen, Life Technologies Co, Paisley, UK). 
For a single reaction, DNAse I (1 U), was added to specific reagents (DW up to 10 µl, 
10X DNAse I reaction buffer 1µl) and 1 µg of RNA sample. This mix was incubated at 
RT for 15 min. Subsequently, 2 µl of 25 mM EDTA (pH 8.0) solution was added to each 
Eppendorf tube to stop DNAse reaction. This mixture was then heated for 10 min at 65 
0C.  The first-strand cDNA synthesis was initiated in a single sample by the addition of 
3 µl of a mix solution (1µl of dNTP (10 mM), 1µl of random hexamers (50 ng/µl), and up 
to 12 µl of DW) to 7 µl of RNA previously treated with DNAse I. This preparation was 
incubated at 650C for 5 min and cooled on ice for at least 1 min. The next step 
employed a SuperScript II reverse transcriptase (from Invitrogen, Life Technologies Co, 
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Texas, USA). In a separated tube, a mix solution of (4 µl of 5X First-strand Buffer, 4 µl 
of MgCl2 (25mM), 2 µl of DTT (0.1 M), 1 µl of RNAse OUT (40 U/µl)) was prepared and 
9µl of this mix added to each 10 µl of the RNA + dNTP/random hexamers, as specified 
by the manufacture.  Samples intended to generate cDNA were treated with 1 µl of 
Superscript II (200 units). The omission of reverse transcriptase (Superscript II) was 
intended to create reverse-transcriptase negative controls. After an incubation of 10 
minutes at room temperature, samples were inserted in a thermal cycler (TC 3000, 
Barloworld Scientific Ltd, Staffordshire, UK) and heated at 42 0C for 50 min followed by 
70 0C for 15 min.  
7.5.3. Primer design  
The design of primer pairs was intended to target functional gene transcripts. Details 
about the oligonucleotides employed are in Table 7.3.   Oligonucleotide primer pairs 
designed to work in optimal conditions were defined with help of the software Primer 3  
(Whitehead Institute for Biomedical Research, 2007, 
http://frodo.wi.mit.edu/primer3/input.htm). Products larger than 300bps were avoided 
because these were less efficient to amplify and perform qPCR assays. All oligo 
sequences were blasted to determine their specificity 
(http//www.ncbi.nml.nih.gov/BLAST). The ability to the oligo sequences to form 
heterodimers was accessed by the use of the software Amplify 3 (v 3.14, 2005, Bill 
Engels, University of Wisconsin). Only those sequences considered specific for their 
target and which did not produce heterodimers were employed in RT-PCR and qPCR 
experiments. 
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7.5.4. Conventional PCR 
Conventional PCR   was performed using Platinum® Blue PCR Supermix (Invitrogen, 
Life Technologies Corporation, USA).  Briefly, 1.0 µl of cDNA  (corresponding to 10-75 
ng of RNA present in the initial RT reaction) was added to a Mastermix solution 
composed of: 22.5µl of Platinum® PCR Supermix, (Invitrogen) plus 0.5 µl of Primers 
(20 µM of  forward plus reverse). The final 25 µl of this mixture in an Eppendorf tube 
was inserted in a thermal cycler (TC 3000, Barloworld Scientific Ltd, Staffordshire, UK) 
following this specific sequence: 1) denaturation 95 0C for 2 min; 2) 35-37 cycles 
consisting on 95 0C for 30 sec, annealing temperature (variable according the primers) 
for 30 sec, 720C for 20 sec; 3) 720C for final extension for 5 min.  
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Target Acession 
number 
Forward sequence  
(5’-3’) 
Reward sequence 
 (3’-5’) 
Species 
ADIPOR1 NM_015999 ACATCTGGACCCATCTGCT
T 
TGAATGACAATAGACGGTG
TGA 
Homo 
sapiens 
ADIPOR2 NM_024551 ACACAGAAACAGGCAACAT
TT 
TTTAGAGAAGAGCCGAGAG
ACC 
Homo 
sapiens 
AR AF105713 TATTGAAGGCTATGAGTGT
CAGC 
GAAAGGAGTCAGGTTGGTT
GTTGT 
Ovis aries 
CYP17A1 NM_001009483 GGAGGTTCTGAGCAAGGA
AGT 
CAGCAAGTTAGTGATGGAG
TCG 
Ovis aries 
HSD3B2 NM_001135932 CTGCTGGAAGGAGACATTC
TG 
CTCTATGGTGCTGGTGTGG
ATA 
Ovis aries 
RPL19 NM_001112820 AATGCCAATGCCAACTC CCCTTTCGCTACCTATACC Ovis aries 
 
ADIPOR1 NM_001034055 GCTGAAGTGAGAGGAAGA
GTC 
GAGGGAATGGAGTTTATTG
CC 
Ovis aries 
ADIPOR2 NM_001040499 GGCAACATCTGGACACATC CTGGAGACCCCTTCTGAG Ovis aries 
APPL1 NM_001099003 AGCTGCTTCCAGTAGACCA
AAC 
TGCCATTCTACCACAGAAAT
TG 
Bos taurus 
CYP11A1 NM_176644 TGATGCCGTCTACAAGATG
TTC 
CAGTAGAGGATGCCTGGGT
AAT 
Bos taurus 
STAR NM_174189 CTTGAGGAGGTCAAGAGG
TCTG 
TGGAAGAAGTACGGGAATC
AGT 
Bos taurus 
ADIPOR1 NM_001034055 CCTGCTCGGTTTCGTGCTG
TTT 
GGCGATCCCTGAATAGTCC
AGC 
Bos taurus 
ADIPOR2 NM_001040499 GGGAAGGTCGATGGCGAG
TGAT 
GCACAGGAAGAACACACAA
CCCAA 
Bos taurus 
CYP17A1 NM_174304 GTTGTGTTCAAACGCGAAA
T 
GCCCACGATCCACTTTATC
AC 
Bos taurus 
LHR NM_174381 CAATGTTGAAAGCACAGCA
AG 
CACAGGGATTGAAAGCATC
T 
Bos taurus 
FSHR NM_174061 GCGGCAAACCTCTGACCTT
C 
GGGAGCAAGTCACATCAAC
CA 
Bos taurus 
RPL19 NW_001495013 CCTGGATGAGGAGGATGA
GA 
TTGTCTGCCTTCAGCTTGT
G 
Bos taurus 
 
Table 7.3: Primers employed in RT-PCR and qPCR reactions. 
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7.5.5  Quantitative PCR (qPCR) 
Quantitative real time PCR (qPCR) is perhaps the optimal method to quantify gene 
expression. This method is based in the detection of a fluorescent signal which is 
proportional to the amount of dsDNA created during a PCR reaction.  
The qPCR reactions were performed using KAPA™SYBR FAST Master Mix (2X) ABI 
Prism (KAPABIOSYSTEMS, USA), according manufactures’ recommendations. For 
example, in a 20 µl reaction, 10 µl KAPA™SYBR FAST Master Mix (1X), 0.5 µl of 
primers (final concentration 400nM) was added to variable amounts of cDNA.  
The analysis of relative gene expression employing qPCR used the 2-ΔΔCT method as 
previously described in the literature (Livak K, 2001; Huggett J et al, 2005). This 
normalization strategy involves the use of internal control (housekeeping gene) 
allowing adjustment for the efficiency for each  PCR reaction.   
7.5.6  Gene silencing  
The Dharmacon® Accell® siRNA Delivery developed by Thermo Scientific Dharmacon 
(Thermo Scientific, Epsom, UK) was applied to “knock down” genes targeting AdipoR1, 
AdipoR2, and APPL-1. One advantage of this protocol is that it does not use 
transfection reagents (e.g lipofectamine) usually employed for disruptions in other 
genes.  Overall, 6 different sequences of siRNA   were employed as shown below 
(Table 7.4): 
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Table 7.4: Sequences of siRNA employed to knockdown ADIPOR1, 
ADIPOR2  and APPL1 in bovine theca cells.  
 
Briefly, cells were plated in 96 well plates at 50% confluence and allowed to grow 
overnight in 100 µl of medium containing D-MEM/F12, FBS 10%, 1µg/ml Transferrin, 1 
ng/ml Selenium, 1 µg/ml Linoleic acid, 100 UI/ml Penicilin, 100 µg/ml Streptomycin, 0.5 
µg/ml Gentamicin. The next day, wells were washed and then incubated for 72 hours in 
serum-free media (D-MEM/F12, 1µg/ml Transferrin, 1 ng/ml Selenium, 1 µg/ml Linoleic 
acid, 100 UI/ml Penicilin, 100 µg/ml Streptomycin, 0.5 µg/ml Gentamicin) with 10 ng/ml 
of LH plus specific siRNAs.  Control groups (non-siRNA) were created for each 
treatment, as well a scrambled siRNA group. The efficiency of transfection was 
estimated by the amount of cells expressing a fluorescent marker (fluorescent 
scrambled siRNA), after 24/48 h of the initial treatment. Assay for the effect of 
knockdown were taken at the end of the experiment (Fig 7.4A).  A variation of this 
protocol included a medium change after 72 h when a new different treatment 
(adiponectin 3µg/ml) was carried on for a further 24 h (Fig 7.4B). 
Duplex Sense Antisense Length Nanomoles 
1) ADIPOR1 CGGACUGGCUGAAG
GACAAUU 
UUGUCCUUCAGCCA
GUCCGUU 
21 20 
2) ADIPOR1 UGGAGAAGAUGGAG
GAGUUUU 
AACUCCUCCAUCUU
CUCCAUU 
21 20 
3) ADIPOR2 UGGAAGAGUUUGUU
UGUAAUU 
UUACAAACAAACUCU
UCCAUU 
21 20 
4) ADIPOR2 GGAGAGGAUGGAAG
AGUUUUU 
AAACUCUUCCAUCC
UCUCCUU 
21 20 
5) APPL1 GGAAAUGGACAGUG
AUGUAUU 
UACAUCACUGUCCA
UUUCCUU 
21 20 
6) APPL1 GGAAAUUGCUGCAC
GAGUAUU 
UACUCGUCCAGCAA
UUUCCUU 
21 20 
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Fig 7.4: Standard Accell delivery protocol employed.  
Shown in the top panel are results using the conventional protocol (A) in which cells are 
incubated for 72h with SiRNA before the assay for knockdowns; shown in the bottom panel is 
an additional step (B), where cells are treated for more 24 hours with a different mediium and 
then accessed for knockdown.  
7.6. ELISA 
An enzyme-linked immunosorbent assay (ELISA) was performed to estimate the levels 
of androstenedione and progesterone in cell culture medium. Kits for androstenedione 
(Active® Androstenedione (human) EIA, DSL-10-3800, Texas, USA) and for 
progesterone (progesterone (human) ELISA kit, KA0235, Abnova, Taiwan) were based 
on competitive binding and performed according the manufacturer’s instructions. As a 
rule, a 6-point curve using standard controls provided in the kit was established (iower 
limit of detection of androstenedione 0.03 ng/ml and intra-assay coefficient of variation 
of 8.7%). The absorbance was measured by microplate reader (Tecan Sunrise, Tecan 
Switzerland) and results were transformed for ng/ml.  
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7.7.  STATISTICAL ANALYSIS 
Where appropriate, data collected were stored in Excel (.xls) files. Statistical analysis 
was performed using the software Instat 3 and the graphs were elaborated with an 
auxiliary of the software Prism (both from Graphpad Software Inc, San Diego, USA).  
Differences between groups of sections were tested using Student t-test (if normal 
distribution) or Mann-Whitney test (if asymmetrically distributed). For the comparison of 
more than two groups normally distributed, an one-way analysis of variance (ANOVA) 
and additional post-test (Tukey’s or Dunnet’s test) was chosen; for data asymmetrically 
distributed, the Kruskal–Wallis test and additional (Dunn’s multiple comparison test) 
were performed.  In all cases, a probability value (P)  inferior to 0.05 was considered as 
statistically significant.  Normal distributed data were represented by mean plus SEM or 
SD. Clearly skewed data were represented by median plus interquartile range. For 
data with a normal trend but small n, the mean plus 95% of confidence interval was 
selected (Gougeon, 1996; Webber et al., 2003).  
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